e424b3
Filed Pursuant to Rule 424(b)(3) and Rule 424(c)
Registration No. 333-169385
PROSPECTUS SUPPLEMENT NO. 2
8,140,496 Shares of Common Stock
This Prospectus Supplement No. 2 (the Prospectus Supplement) amends our Prospectus dated May 6,
2011 (the Prospectus). The Prospectus relates to the offer for sale by the existing holders of
our common stock, par value $0.01 per share, named in the Prospectus of 8,140,496 shares of our
common stock, including 3,488,784 shares of our common stock issuable upon exercise of the warrants
held by the selling security holders. These existing holders of our common stock are referred to as
selling security holders throughout this Prospectus Supplement.
All of the shares of common stock offered by this Prospectus Supplement are being sold by the
selling security holders. It is anticipated that the selling security holders will sell these
shares of common stock from time to time in one or more transactions, in negotiated transactions or
otherwise, at prevailing market prices or at prices otherwise negotiated. We will not receive any
proceeds from the sales of shares of common stock by the selling security holders.
On June 30, 2011, Emisphere Technologies, Inc. (the Company) filed with the Securities and
Exchange Commission (SEC) a Current Report on Form 8-K (the Form 8-K) announcing that the
Company entered into a Securities Purchase Agreement (the Purchase Agreement) with certain
institutional investors (collectively, the Buyers) to sell an aggregate of approximately 4.3
million shares of its common stock and warrants (the Warrants) to purchase a total of
approximately 3.0 million shares of its common stock (the Warrant Shares) to the Buyers for gross
proceeds, before deducting fees and expenses and excluding the proceeds, if any, from the exercise
of the Warrants of approximately $3.75 million (the Private Placement). Each unit, consisting of
one share of common stock and a warrant to purchase 0.7 shares of common stock, will be sold at a
purchase price of $0.872. In connection with the Purchase Agreement, on or about July 6, 2011, the
Company and the Buyers will enter into a Registration Rights Agreement, pursuant to which the
Company will provide certain registration rights to the Buyers, including an obligation of the
Company to file a registration statement with the SEC within 20 days.
The Company further announced in the Form 8-K that, simultaneously with entering into the Purchase
Agreement, it entered into a Securities Purchase Agreement (the MHR Purchase Agreement) with MHR
Fund Management LLC (the MHR Buyer) to sell an aggregate of approximately 4.3 million shares of
its common stock and warrants (the MHR Warrants) to purchase a total of approximately 3.0 million
shares of its common stock (the MHR Warrant Shares) for gross proceeds, before deducting fees and
expenses and excluding the proceeds, if any, from the exercise of the MHR Warrants of approximately
$3.75 million (the MHR Private Placement). Each unit, consisting of one share of common stock and
a warrant to purchase 0.7 shares of common stock, will be sold at a purchase price of $0.872.
A complete copy of the Form 8-K is attached hereto.
This Prospectus Supplement should be read in conjunction with the Prospectus, as previously
supplemented, and is qualified by reference to the Prospectus except to the extent that the
information in this Prospectus Supplement supersedes the information contained therein.
Our common stock is currently traded on the Over-The-Counter Bulletin Board, commonly known as the
OTC Bulletin Board (OTCBB), under the symbol EMIS.QB As of June 30, 2011, the closing sale
price of our common stock was $0.90 per share.
Investing in our securities involves substantial risks. You should carefully consider the matters
discussed under the section entitled Risk Factors beginning on page 6 of the Prospectus, as
previously supplemented .
Neither the SEC nor any state securities commission has approved or disapproved of these securities
or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a
criminal offense.
The date of this prospectus supplement is July 1, 2011.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): June 30, 2011
Emisphere Technologies, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-17758
|
|
13-3306985 |
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer |
of incorporation)
|
|
File Number)
|
|
Identification No.) |
|
|
|
240 Cedar Knolls Road, Suite 200
Cedar Knolls, NJ
|
|
07927 |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: 973-532-8000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 1.01. Entry into a Material Definitive Agreement.
Private Placement
On June 29, 2011, Emisphere Technologies, Inc. (the Company) entered into a Securities Purchase
Agreement (the Purchase Agreement) with certain institutional investors (collectively, the
Buyers) to sell an aggregate of approximately 4.3
million shares of its common stock and warrants (the Warrants) to
purchase a total of approximately 3.0 million shares of its common stock (the Warrant Shares) to
the Buyers for gross proceeds, before deducting fees and expenses and excluding the proceeds, if
any, from the exercise of the Warrants of approximately $3.75 million (the Private Placement). Each unit,
consisting of one share of common stock and a warrant to purchase 0.7 shares of common stock, will
be sold at a purchase price of $0.872.
The Warrants will be exercisable at an exercise price of $1.09 per share beginning immediately
after issuance and will expire 5 years from the date of issuance. The exercise price of the
Warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of
shares and similar recapitalization transactions.
A copy of the Purchase Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by
reference. A copy of the form of Warrants is also attached hereto as Exhibit 4.1 and is
incorporated herein by reference.
In
connection with the Purchase Agreement, on or about July 6, 2011, the Company and the Buyers will enter
into a Registration Rights Agreement (the Registration Rights Agreement). Pursuant to the
Registration Rights Agreement, the Company will provide certain registration rights under the
Securities Act of 1933, as amended (the Securities Act), and applicable state securities laws.
The Company will be required to file a registration statement (the Registration Statement) with
the Securities and Exchange Commission (the SEC) within 20 days of the closing date and use its
reasonable best efforts to have such Registration Statement declared effective as soon as
practicable, but in no event later than 60 days of the closing date of the Private Placement (90
days in the event the SEC reviews the Registration Statement).
A copy of the form of Registration Rights Agreement to be entered into by the Company and the
Buyers is attached hereto as Exhibit 4.2 and is incorporated herein by reference.
MHR Private Placement
In connection with the Companys entry into the Securities Purchase Agreement, the Company entered
into a Securities Purchase Agreement (the MHR Purchase Agreement) on the same date with MHR
Fund Management LLC (the MHR Buyer) to sell an
aggregate of approximately 4.3 million shares of its common
stock and warrants (the MHR Warrants) to purchase
a total of approximately 3.0 million shares of its common
stock (the MHR Warrant Shares) for gross proceeds, before deducting fees and expenses and
excluding the proceeds, if any, from the exercise of the MHR Warrants of approximately $3.75 million (the MHR
Private Placement). Each unit, consisting of one share of common stock and a warrant to purchase
0.7 shares of common stock, will be sold at a purchase price of $0.872. MHR Buyer, together with
certain of its affiliated investment funds (collectively, MHR), is the holder of the Companys
11% Senior Secured Convertible Notes (the MHR Senior Secured Notes) and, after giving effect to
the MHR Private Placement, will beneficially own approximately 47.6% of the Companys common
stock, assuming conversion and exercise by MHR of all convertible securities, warrants and options
held, including the MHR Warrants and the MHR Waiver Warrants (as defined below).
The Buyers required, as a condition to the Purchase Agreement, that MHR enter into the MHR Purchase
Agreement.
The MHR Warrants will be exercisable at an exercise price of $1.09 per share beginning immediately
after issuance and will expire 5 years from the date of issuance. The exercise price of the MHR
Warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of
shares and similar recapitalization transactions.
MHR has existing registration rights under that certain Registration Rights Agreement, dated as of
September 26, 2005, by and between the Company and MHR under which the MHR Private Placement
Securities (as defined below) shall constitute Registrable Securities.
A copy of the MHR Purchase Agreement entered into by the Company and the MHR Buyer is attached
hereto as Exhibit 10.2 and is incorporated herein by reference. A copy of the form of MHR Warrant
is attached hereto as Exhibit 4.3 and is incorporated herein by reference.
The collective net proceeds to the Company from the Private Placement and the MHR Private
Placement, after deducting fees and expenses and excluding the proceeds, if any, from the exercise
of the Warrants and the MHR Warrants, are expected to be approximately $7.25 million. The
Private Placement and the MHR Private Placement are expected to close
on or about July 6, 2011,
subject to the satisfaction of customary closing conditions.
MHR Waiver Agreement
In connection with the Private Placement and the MHR Private Placement, the Company entered into a
Waiver Agreement with MHR (Waiver Agreement), pursuant to which MHR waived certain anti-dilution
adjustment rights under the MHR Senior Secured Notes and certain warrants issued by the Company to
MHR that would otherwise have been triggered by the Private Placement described above. As
consideration for such waiver, the Company will issue to MHR a warrant (the MHR Waiver Warrant)
to purchase 795,000 shares of its common stock (the MHR Waiver Warrant Shares) and agreed to
reimburse MHR for up to $25,000 of its legal fees. The MHR Waiver Warrant shall be in the same form
of warrant as the MHR Warrants described above.
A copy of the Waiver Agreement is attached hereto as Exhibit 10.3 and is incorporated herein by
reference.
The foregoing descriptions of the Purchase Agreement, MHR Purchase Agreement, Waiver Agreement,
Registration Rights Agreement and the form of Warrants and MHR Warrants do not purport to be
complete and are qualified in their entirety by reference to Exhibits 10.1, 10.2, 10.3, 4.2, 4.1,
and 4.3, respectively.
Item 3.02. Unregistered Sales of Equity Securities.
The disclosures related to the Private Placement and the MHR Private Placement set forth in Item
1.01 of this Current Report on Form 8-K are hereby incorporated by reference into this Item 3.02.
The shares of common stock, the Warrants and the Warrant Shares to be sold and issued in connection
with the Private Placement (collectively, the Private Placement Securities), the shares of
common stock, the MHR Warrants and the MHR Warrant Shares to be sold and issued in connection with
the MHR Private Placement (collectively, the MHR Private Placement Securities) and the MHR
Waiver Warrant and MHR Waiver Warrant Shares to be issued in connection with the Waiver Agreement
will not be registered under the Securities Act at the time of sale, and therefore, may not be
offered or sold in the United States absent registration or an applicable exemption from
registration requirements. For these issuances, the Company will rely on the exemption from federal
registration under Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder, based
on the Companys belief that the offer and sale of the Private Placement Securities, the MHR
Private Placement Securities, the MHR Waiver Warrant and the MHR Waiver Warrant Shares have and
will not involve a public offering, as each purchaser of such securities is an accredited
investor (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities
Act) and/or a qualified institutional buyer (as such term is defined in Rule 144A of the
Securities Act), and no general solicitation has been involved in connection with the Private
Placement, the MHR Private Placement or the Waiver Agreement.
Item 8.01. Other Events.
On June 30, 2011, the Company announced that it entered into the Private Placement and the MHR
Private Placement. The Companys press release announcing such transactions is filed as Exhibit
99.1 and is incorporated herein by reference.
Safe Harbor Statement Regarding Forward-Looking Statements. The press release attached as an
exhibit hereto contains forward-looking statements which involve certain risks and uncertainties
that could cause actual results to differ materially from those expressed or implied by these
statements. Please refer to the Safe Harbor Statement in the press release regarding these
forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
|
Exhibit |
|
|
No. |
|
Description |
|
4.1 |
|
|
Form of Warrant |
|
|
|
|
|
|
4.2 |
|
|
Form of Registration Rights Agreement by and among Emisphere Technologies, Inc. and the Buyers named therein. |
|
|
|
|
|
|
4.3 |
|
|
Form of MHR Warrant |
|
|
|
|
|
|
10.1 |
|
|
Securities
Purchase Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and the Buyers
named therein. |
|
|
|
|
|
|
10.2 |
|
|
Securities
Purchase Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and the MHR Buyer. |
|
|
|
|
|
|
10.3 |
|
|
Waiver
Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and MHR. |
|
|
|
|
|
|
99.1 |
|
|
Press Release of Emisphere Technologies, Inc., dated June 30, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Emisphere Technologies, Inc.
|
|
June 30, 2011 |
By: |
/s/ Michael R. Garone
|
|
|
|
Name: |
Michael R. Garone |
|
|
|
Title: |
Interim Chief Executive Officer and
Chief Financial Officer |
|
|
Exhibit Index
|
|
|
|
|
Exhibit |
|
|
No. |
|
Description |
|
4.1 |
|
|
Form of Warrant |
|
|
|
|
|
|
4.2 |
|
|
Form of Registration Rights Agreement by and among Emisphere Technologies, Inc. and the Buyers named therein. |
|
|
|
|
|
|
4.3 |
|
|
Form of MHR Warrant |
|
|
|
|
|
|
10.1 |
|
|
Securities
Purchase Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and the Buyers
named therein. |
|
|
|
|
|
|
10.2 |
|
|
Securities
Purchase Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and the MHR Buyer. |
|
|
|
|
|
|
10.3 |
|
|
Waiver
Agreement, dated June 30, 2011, by and among Emisphere Technologies, Inc. and MHR. |
|
|
|
|
|
|
99.1 |
|
|
Press
Release of Emisphere Technologies, Inc., dated June 30, 2011. |
Exhibit 4.1
FORM OF WARRANT
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES
INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER
(IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS
NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
EMISPHERE TECHNOLOGIES, INC.
WARRANT
|
|
|
|
|
|
Warrant No. A-[XX]
|
|
Original Issue Date: ______, 2011 |
EMISPHERE TECHNOLOGIES, INC., a Delaware corporation (the Company), hereby certifies
that, for value received, [NAME OF HOLDER] or its permitted registered assigns (the
Holder), is entitled to purchase from the Company up to a total of [NUMBER] shares of
Common Stock (as defined below) of the Company (each such share, a Warrant Share and all
such shares, the Warrant Shares) at an
exercise price equal to $1.09 per share (as
adjusted from time to time as provided herein, the Exercise Price), at any time and from
time to time on or after the Original Issue Date and through and including the Expiration Date (as
defined below), and subject to the following terms and conditions:
This Warrant is one of a series of warrants issued pursuant to that certain Securities
Purchase Agreement dated June 30, 2011 (the Subscription Date"), by and between the
Company and each of the purchasers identified therein (the Purchase Agreement). All such
warrants are referred to herein, collectively, as the Warrants.
1. Definitions. In addition to the terms defined elsewhere in this Warrant,
capitalized terms that are not otherwise defined herein have the meanings given to such terms in
Section 19.
2. List of Warrant Holders. The Company shall register this Warrant, upon records to
be maintained by the Company for that purpose (the Warrant Register), in the name of the
record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder from time to time). The
Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.
3. List of Transfers; Restrictions on Transfer.
(a) This Warrant may be offered for sale, sold, transferred or assigned without the consent of
the Company, except as may otherwise be required by Section 2(g) of the Purchase Agreement.
(b) The Company shall register any such transfer of all or any portion of this Warrant in the
Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto duly
completed and signed, to the Company at its address specified herein. Upon any such registration
or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (in
accordance with Section 3(e)), evidencing the portion of this Warrant so transferred shall be
issued to the transferee and a new Warrant evidencing the remaining portion of this Warrant not so
transferred, if any, shall be issued to the transferring Holder. The acceptance of the new Warrant
by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights
and obligations in respect of the new Warrant that the Holder has in respect of this Warrant.
(c) This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Warrant or Warrants (in accordance with Section 3(e)) representing
in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant,
and each such new Warrant will represent the right to purchase such portion of such Warrant Shares
as is designated by the Holder at the time of such surrender; provided, however, no warrants for
fractional shares of Common Stock shall be given.
(d) If, at the time of the surrender of this Warrant in connection with any transfer of this
Warrant, transfer of this Warrant shall not be registered pursuant to an effective registration
statement under the Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the Holder or transferee of
this Warrant, as the case may be, furnish to the Company a written opinion of counsel (which
opinion shall be in form, substance and scope customary for opinions of counsel in comparable
transactions) to the effect that such transfer may be made without registration under the
Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or
transferee execute and deliver to the Company an investment letter in form and substance acceptable
to the Company and (iii) that the transferee be an accredited investor as defined in Rule 501(a)
promulgated under the Securities Act.
(e) Whenever the Company is required to issue a new Warrant pursuant to the terms of this
Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as
indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying
this Warrant (or in the case of a new Warrant being issued pursuant to this Section 3 or Section 7,
the Warrant Shares designated by the Holder which, when added to the number of shares of Common
Stock underlying the other new Warrants issued in connection with such issuance, does not exceed
the number of Warrant Shares then underlying this Warrant), (iii) shall
2
have an issuance date, as indicated on the face of such new Warrant which is the same as the
Original Issue Date, and (iv) shall have the same rights and conditions as this Warrant.
4. Exercise and Duration of Warrants.
(a) All or any part of this Warrant shall be exercisable by the registered Holder in any
manner permitted by Section 4 of this Warrant at any time and from time to time on or after the
Original Issue Date and through and including the Expiration Date. Subject to Section 11 hereof,
at 5:00 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised
prior thereto shall be and become void and of no value and this Warrant shall be terminated and no
longer outstanding. In addition, if cashless exercise would be permitted under Section 4(c) of
this Warrant, then all or part of this Warrant may be exercised by the registered Holder utilizing
such cashless exercise provisions at any time, or from time to time, on or after the Original Issue
Date and through and including the Expiration Date.
(b) The Holder may exercise this Warrant by delivering to the Company an exercise notice, in
the form attached hereto (the Exercise Notice), completed and duly signed. If such
Holder is not utilizing the cashless exercise provisions set forth in this Warrant, within one (1)
Trading Day following an exercise of this Warrant as aforesaid, the Holder shall deliver payment to
the Company of an amount equal to the Exercise Price for the number of Warrant Shares as to which
this Warrant is being exercised (the Aggregate Exercise Price). The date the Exercise
Notice is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an Exercise Date. The Holder shall not be required to deliver the original Warrant in
order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing
the right to purchase the remaining number of Warrant Shares. Additionally, at the request of the
Holder, if this Warrant shall have been exercised in part and the Holder shall have surrendered
this Warrant certificate, the Company shall, at the time of delivery of the certificate or
certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of
Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.
(c) Notwithstanding anything contained herein to the contrary (other than Section 11 below),
if at the time of exercise hereof, but not prior to six months after the Original Issue Date, a
Registration Statement (as defined in the Registration Rights Agreement (as defined in the Purchase
Agreement)) is not effective (or the prospectus contained therein is not available for use) for the
resale by the Holder of all of the Warrant Shares, then the Holder may, in its sole discretion,
exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise
contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise
Price, elect instead to receive upon such exercise the Net Number of shares of Common Stock
determined according to the following formula (a Cashless Exercise):
|
|
|
|
|
Net Number =
|
|
(A x B) - (A x C)
|
|
|
|
|
|
|
|
|
|
B |
|
|
3
For purposes of the foregoing formula:
|
A= |
|
the total number of shares with respect to which this Warrant
is then being exercised. |
|
|
B= |
|
as applicable: (i) the Closing Sale Price of the Common Stock
on the Trading Day immediately preceding the date of the applicable Exercise
Notice if such Exercise Notice is (1) both executed and delivered pursuant to
Section 4 hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 4 hereof on a Trading Day prior to the opening of
regular trading hours (as defined in Rule 600(b)(64) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii) the
Bid Price of the Common Stock as of the time of the Holders execution of the
applicable Exercise Notice if such Exercise Notice is executed during regular
trading hours on a Trading Day and is delivered within two (2) hours
thereafter pursuant to Section 4 hereof and (iii) the Closing Sale Price of the
Common Stock on the date of the applicable Exercise Notice if the date of such
Exercise Notice is a Trading Day and such Exercise Notice is both executed and
delivered pursuant to Section 4 hereof after the close of regular trading
hours on such Trading Day. |
|
|
C= |
|
the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise. |
(d) In the case of a dispute as to the determination of the Exercise Price or the arithmetic
calculation of the number of Warrant Shares to be issued pursuant to the terms hereof, the Company
shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve
such dispute in accordance with Section 16.
5. Delivery of Warrant Shares.
(a) On or before the first (1st) Trading Day following the date on which the
Company has received an Exercise Notice, the Company shall transmit by facsimile or electronic mail
an acknowledgment of confirmation of receipt of such Exercise Notice, to the Holder and the
Companys transfer agent (the Transfer Agent). On or before the third (3rd)
Trading Day following the date on which the Company has received such Exercise Notice, the Company
shall (X) provided that the Transfer Agent is participating in The Depository Trust Company
(DTC) Fast Automated Securities Transfer Program and the Warrant Shares can be issued
without restrictive legends, upon the request of the Holder, credit such aggregate number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise to the Holders or its
designees balance account with DTC through its Deposit/Withdrawal at Custodian system, or (Y) if
the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or
the Warrant Shares cannot be issued without restrictive legends, issue and deliver to the Holder
or, at the Holders instruction pursuant to the Exercise Notice, the Holders agent or designee, in
each case, sent by reputable overnight courier to the address as specified in the applicable
Exercise Notice, a certificate, registered in the Companys share register in the name
4
of the Holder or its designee (as indicated in the applicable Exercise Notice), for the number
of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery
of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date such Warrant Shares are credited to the Holders DTC account or the date
of delivery of the certificates evidencing such Warrant Shares (as the case may be). The Holder,
or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to
have become the holder of record of such Warrant Shares as of the Exercise Date. Notwithstanding
the foregoing, except in the case where an exercise of this Warrant is validly made pursuant to a
cashless exercise, the Companys failure to deliver Warrant Shares to the Holder on or prior to the
later of (x) the close of the third Trading Day after delivery of an Exercise Notice and (y) the
Trading Day in which the Companys receives the Aggregate Exercise Price (such later date, the
Share Delivery Deadline) shall not be deemed to be a breach of this Warrant.
(b) If by the Share Delivery Deadline, the Company fails to deliver to the Holder a
certificate representing the required number of Warrant Shares in the manner required pursuant to
Section 5(a), and if after such third Trading Day and prior to the receipt of such Warrant Shares,
the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a Buy-In), then the Company shall, within three Trading
Days after the Holders request and in the Holders sole discretion, either (i) pay in cash to the
Holder an amount equal to the Holders total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased (the Buy-In Price), at which point the
Companys obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate
or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such shares of Common Stock or credit the Holders balance account with DTC for the
number of shares of Common Stock to which the Holder is entitled upon the Holders exercise
hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any)
of the Buy-In Price over the product of (A) such number of shares of Common Stock times (B) the
Closing Sale Price of the Common Stock on the Trading Day immediately preceding the date of the
applicable Exercise Notice.
(c) To the extent permitted by law, the Companys obligations to issue and deliver Warrant
Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any
provision hereof, the recovery of any judgment against any Person or any action to enforce the
same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other
circumstance that might otherwise limit such obligation of the Company to the Holder in connection
with the issuance of Warrant Shares. Nothing herein shall limit a Holders right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the Companys failure to
timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.
5
6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of
Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue
or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
provided, however, that the Company shall not be required to pay any tax that may be payable in
respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other
tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.
7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant (in accordance
with Section 3(e)), but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction and customary and reasonable indemnity (which shall not include a
surety bond), if requested. Applicants for a new Warrant under such circumstances shall also
comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a new Warrant is requested as a result of a
mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as
a condition precedent to the Companys obligation to issue the new Warrant.
8. Reservation of Warrant Shares. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable
and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other
contingent purchase rights of persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and
deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. If,
notwithstanding the foregoing, and not in limitation thereof, at any time while any of the Warrants
remain outstanding the Company does not have a sufficient number of authorized and unreserved
shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of the
Warrants at least a number of shares of Common Stock equal to the number of shares of Common Stock
as shall from time to time be necessary to effect the exercise of all of the Warrants then
outstanding (the Required Reserve Amount, and such reservation failure, an
Authorized Share Failure), then the Company shall promptly take all action necessary to
increase the Companys authorized shares of Common Stock to an amount sufficient to allow the
Company to reserve the Required Reserve Amount for all the Warrants then outstanding. Without
limiting the generality of the foregoing sentence, as soon as practicable after the date of the
occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the
occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders
for the approval of an increase in the number of authorized shares of Common Stock. In connection
with such meeting, the Company shall provide each stockholder with a proxy statement and shall use
its best efforts to solicit its stockholders approval of such increase in authorized shares of
Common Stock and to cause its board of directors to recommend to the stockholders that they approve
such proposal.
6
9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon
exercise of this Warrant are subject to adjustment from time to time as set forth in this Section
9.
(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any
class of capital stock that is payable in shares of Common Stock, (ii) subdivides (by any stock
split, stock dividend, recapitalization or otherwise) outstanding shares of Common Stock into a
larger number of shares, or (iii) combines (by combination, reverse stock split or otherwise)
outstanding shares of Common Stock into a smaller number of shares, then in each such case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment
made pursuant to clause (i) of this paragraph shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution, and
any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this paragraph occurs during the period that an Exercise Price is calculated
hereunder, then the calculation of such Exercise Price shall be adjusted appropriately to reflect
such event.
(b) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its
indebtedness, (ii) any security (other than a distribution of Common Stock covered by Section
9(a)), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset
(in each case, Distributed Property), then, upon any exercise of this Warrant that occurs
after the record date fixed for determination of stockholders entitled to receive such
distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise
issuable upon such exercise (if applicable) (without regard to any limitations on exercise hereof,
including without limitation, the Maximum Percentage), the Distributed Property that such Holder
would have been entitled to receive in respect of such number of Warrant Shares had the Holder been
the record holder of such Warrant Shares immediately prior to such record date (provided, however,
to the extent that the issuance of any Distributed Property would result in the Holder exceeding
the Maximum Percentage, then the Holder shall not be entitled to receive such Distributed Property
to such extent (or the beneficial ownership of any such shares of Common Stock as a result of
issuance of Distributed Property to such extent) and the Holders right to receive such Distributed
Property to such extent shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).
(c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i)
the Company effects any merger or consolidation of the Company with or into another Person, in
which the shareholders of the Company as of immediately prior to the transaction own less than a
majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for other securities,
7
cash or property, or (iv) the Company effects any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or
exchanged for other securities, cash or property (each, a Fundamental Transaction), then
the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same
amount and kind of securities, cash or property as it would have been entitled to receive upon the
occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this
Warrant (the Alternate Consideration). The Company shall not effect any such Fundamental
Transaction unless prior to or simultaneously with the consummation thereof, any successor to the
Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other
appropriate corporation or entity shall assume the obligation to deliver to the Holder, such
Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled
to purchase, and the other obligations under this Warrant. The provisions of this paragraph (c)
shall similarly apply to subsequent transactions analogous to a Fundamental Transaction.
(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise
Price pursuant to paragraphs (a) and (b) of this Section 9, the number of Warrant Shares that may
be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that
after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of
Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to
such adjustment.
(e) Calculations. All calculations under this Section 9 shall be made to the nearest
cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for the account of the
Company, and the disposition of any such shares shall be considered an issue or sale of Common
Stock.
(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this
Section 9, the Company at its expense will, at the written request of the Holder, promptly compute
such adjustment in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or
type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon
which such adjustment is based. Upon written request, the Company will promptly deliver a copy of
each such certificate to the Holder and to the Companys Transfer Agent.
(g) Notice of Events. The Company will give written notice to the Holder at least two
(2) days prior to the date on which the Company closes its books or takes a record (A) with respect
to any dividend or distribution upon the shares of Common Stock, or (B) for determining rights to
vote with respect to any Fundamental Transaction, dissolution or liquidation. Notwithstanding the
foregoing, the failure deliver such notice or any defect therein shall not affect the validity of
the corporate action required to be described in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company
(including its subsidiaries), the Company shall simultaneously file such notice with the SEC (as
defined in the Purchase Agreement) pursuant to a Current Report on
8
Form 8-K. It is expressly understood and agreed that the time of execution specified by the
Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the
Company.
10. Payment of Exercise Price. The Holder shall pay the Exercise Price by delivering
immediately available funds to the Company unless the Holder has specified a Cashless Exercise in
the applicable Exercise Notice.
11. Limitations on Exercise. Notwithstanding anything to the contrary contained in
this Warrant, this Warrant shall not be exercisable by the Holder (other than Bai Feng) hereof to
the extent (but only to the extent) that such Holder or any of its affiliates would beneficially
own in excess of 4.9% (the Maximum Percentage) of the Common Stock. To the extent the above
limitation applies, the determination of whether this Warrant shall be exercisable (vis-à-vis other
convertible, exercisable or exchangeable securities owned by the Holder or any of its affiliates)
and of which such securities shall be exercisable (as among all such securities owned by the
Holder) shall, subject to such Maximum Percentage limitation, be determined on the basis of the
first submission to the Company for conversion, exercise or exchange (as the case may be). No prior
inability to exercise this Warrant pursuant to this paragraph shall have any effect on the
applicability of the provisions of this paragraph with respect to any subsequent determination of
exercisability. For the purposes of this paragraph, beneficial ownership and all determinations and
calculations (including, without limitation, with respect to calculations of percentage ownership)
shall be determined in accordance with Section 13(d) of the 1934 Act (as defined in the Purchase
Agreement) and the rules and regulations promulgated thereunder. The provisions of this paragraph
shall be implemented in a manner otherwise than in strict conformity with the terms of this
paragraph to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Maximum Percentage beneficial ownership limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such Maximum Percentage
limitation. The limitations contained in this paragraph shall apply to a successor Holder of this
Warrant. The holders of Common Stock shall be third party beneficiaries of this paragraph and the
Company may not waive this paragraph without the consent of holders of a majority of its Common
Stock. For any reason at any time, upon the written or oral request of the Holder, the Company
shall within one (1) Business Day confirm orally and in writing to the Holder the number of shares
of Common Stock then outstanding, including by virtue of any prior conversion or exercise of
convertible or exercisable securities into Common Stock, including, without limitation, pursuant to
this Warrant or securities issued pursuant to the Purchase Agreement. For any reason at any time,
upon the written or oral request of the Holder, the Company shall within one (1) Business Day
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding,
including by virtue of any prior conversion or exercise of convertible or exercisable securities
into Common Stock, including, without limitation, pursuant to this Warrant or securities issued
pursuant to the Purchase Agreement.
12. No Fractional Shares. No fractional Warrant Shares will be issued in connection
with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be
issuable, the Company shall pay cash equal to the product of such fraction multiplied by the
Closing Bid Price of one Warrant Share on the applicable Exercise Date.
9
13. Notices. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given
and effective on the earliest of (i) upon confirmation of receipt, if such notice or communication
is delivered via facsimile or electronic mail at the facsimile number or e-mail address specified
in this Section at or prior to 5:00 p.m. (New York City time) on a Trading Day (provided
confirmation of transmission is mechanically or electronically generated and kept on file by the
sending party), (ii) the next Trading Day after the date of confirmation of receipt, if such notice
or communication is delivered via facsimile or electronic mail at the facsimile number or e-mail
address specified in this Section on a day that is not a Trading Day or later than 5:00 p.m. (New
York City time) on any Trading Day (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party), (iii) the Trading Day following
the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon
actual receipt by the party to whom such notice is required to be given. The addresses for such
notices or communications shall be: if to the Company, to Emisphere Technologies, Inc., 240 Cedar
Knolls Road, Suite 200, Cedar Knolls, New Jersey 07927. Attention: Chief Financial Officer,
Facsimile No.: (973) 532-8121, e-mail address: mgarone@emisphere.com (or such other address as the
Company shall indicate in writing in accordance with this Section) or (ii) if to the Holder, to the
address, facsimile number or e-mail address appearing on the Warrant Register (or such other
address as the Company shall indicate in writing in accordance with this Section).
14. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon
30 days notice to the Holder, the Company may appoint a new warrant agent. Any corporation into
which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to
which the Company or any new warrant agent transfers substantially all of its corporate trust or
shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as
warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holders
last address as shown on the Warrant Register.
15. Noncircumvention. The Company hereby covenants and agrees that the Company will
not, by amendment of its Articles of Incorporation, as amended, its Bylaws as amended or through
any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, and will at all times in good faith carry out
all the provisions of this Warrant and take all action as may be required to protect the rights of
the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase
the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the
Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Warrants are
outstanding, take all action necessary to reserve and keep available out of its authorized and
unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Warrants,
the maximum number of shares of Common Stock as shall from time to time be necessary to effect the
exercise of the Warrants then outstanding (without regard to any limitations on exercise).
10
16. Dispute Resolution. In the case of a dispute as to the determination of the
Exercise Price, the Closing Bid Price, the Closing Sale Price, the Bid Price or fair market value
or the arithmetic calculation of the number of Warrant Shares (as the case may be), the Company or
the Holder (as the case may be) shall submit the disputed determinations or arithmetic calculations
(as the case may be) via facsimile (i) within two (2) Business Days after receipt of the applicable
notice giving rise to such dispute to the Company or the Holder (as the case may be) or (ii) if no
notice gave rise to such dispute, at any time after the Holder learned of the circumstances giving
rise to such dispute. If the Holder and the Company are unable to agree upon such determination or
calculation (as the case may be) of the Exercise Price, the Closing Bid Price, the Closing Sale
Price, the Bid Price or fair market value or the number of Warrant Shares (as the case may be)
within three (3) Business Days of such disputed determination or arithmetic calculation being
submitted to the Company or the Holder (as the case may be), then the Company shall, within two (2)
Business Days submit via facsimile (a) the disputed determination of the Exercise Price, the
Closing Bid Price, the Closing Sale Price, the Bid Price or fair market value (as the case may be)
to an independent, reputable investment bank selected by the Company and approved by the Holder or
(b) the disputed arithmetic calculation of the number of Warrant Shares to the Companys
independent, outside accountant. The Company shall cause the investment bank or the accountant (as
the case may be) to perform the determinations or calculations (as the case may be) and notify the
Company and the Holder of the results no later than ten (10) Business Days from the time it
receives such disputed determinations or calculations (as the case may be). Such investment banks
or accountants determination or calculation (as the case may be) shall be binding upon all parties
absent demonstrable error. If a disputed determination or arithmetic calculation is submitted to
the investment bank or the accountant (as the case may be) pursuant to this Section 16, then the
prevailing party in such determination or calculation shall be reimbursed by the other party for
its costs and expenses (including any and all fees and expenses charged by the investment back or
accountant) incurred in connection with the determination or calculation (as the case may be).
17. Remedies, Characterization, Other Obligations, Breaches and Injunctive Relief. The
remedies provided in this Warrant shall be cumulative and in addition to all other remedies
available under this Warrant and the other Transaction Documents, at law or in equity (including a
decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
right of the Holder to pursue actual damages for any failure by the Company to comply with the
terms of this Warrant. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. Amounts set forth or provided
for herein with respect to payments, exercises and the like (and the computation thereof) shall be
the amounts to be received by the Holder and shall not, except as expressly provided herein, be
subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Holder and that the remedy at law for any such breach may be inadequate. The Company therefore
agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall
be entitled, in addition to all other available remedies, to an injunction restraining any breach,
without the necessity of showing economic loss and without any bond or other security being
required. The Company shall provide all information and documentation to the Holder that is
requested by the Holder that is reasonably necessary to enable the Holder to confirm the Companys
compliance with the terms and conditions of this Warrant. The issuance of shares and certificates
for shares as contemplated
11
hereby upon the exercise of this Warrant shall be made without charge to the Holder or such
shares for any issuance tax or other costs in respect thereof, provided that the Company shall not
be required to pay any tax which may be payable in respect of any transfer involved in the issuance
and delivery of any certificate in a name other than the Holder or its agent on its behalf.
18. Miscellaneous.
(a) This Warrant shall be binding on and inure to the benefit of the parties hereto and their
respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant
shall be construed to give to any Person other than the Company and the Holder any legal or
equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in
writing signed by the Company and the Holder, or their successors and assigns. No waiver shall be
effective unless it is in writing and signed by an authorized representative of the waiving party.
(b) This Warrant shall be governed by and construed and enforced in accordance with, and all
questions concerning the construction, validity, interpretation and performance of this Warrant
shall be governed by, the internal laws of the State of New York, without giving effect to any
choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York. The parties hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. THE PARTIES HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY
TRANSACTION CONTEMPLATED HEREBY.
(c) If any provision of this Warrant is prohibited by law or otherwise determined to be
invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise
be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent
that it would be valid and enforceable, and the invalidity or unenforceability of such provision
shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant
as so modified continues to express, without material change, the original intentions of the
parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or
reciprocal obligations of the parties or the practical realization of the benefits that would
otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to
replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect
of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).
12
(d) The headings herein are for convenience only, do not constitute a part of this Warrant and
shall not be deemed to limit or affect any of the provisions hereof.
(e) In case any one or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision
in this Warrant.
(f) Prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a
Holder, be entitled to any rights of a stockholder with respect to the Warrant Shares.
19. Certain Definitions. For purposes of this Warrant, the following terms shall have
the following meanings:
(a) Bid Price means, for any security as of the particular time of determination, the bid
price for such security on the Principal Market as reported by Bloomberg as of such time of
determination, or, if the Principal Market is not the principal securities exchange or trading
market for such security, the bid price of such security on the principal securities exchange or
trading market where such security is listed or traded as reported by Bloomberg as of such time of
determination, or if the foregoing does not apply, the bid price of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg
as of such time of determination, or, if no bid price is reported for such security by Bloomberg as
of such time of determination, the average of the bid prices of any market makers for such security
as reported in the pink sheets by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.)
as of such time of determination. If the Bid Price cannot be calculated for a security as of the
particular time of determination on any of the foregoing bases, the Bid Price of such security as
of such time of determination shall be the fair market value as mutually determined by the Company
and the Holder. If the Company and the Holder are unable to agree upon the fair market value of
such security, then such dispute shall be resolved in accordance with the procedures in Section 16.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during such period.
(b) Bloomberg means Bloomberg, L.P.
(c) Business Day means any day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to remain closed.
(d) Closing Bid Price and Closing Sale Price means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the
Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an
extended hours basis and does not designate the closing bid price or the closing trade price (as
the case may be) then the last bid price or last trade price, respectively, of such security prior
to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or
last
13
trade price, respectively, of such security on the principal securities exchange or trading
market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not
apply, the last closing bid price or last trade price, respectively, of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by
Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such
security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any
market makers for such security as reported in the pink sheets by Pink Sheets LLC (formerly the
National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be
calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price
or the Closing Sale Price (as the case may be) of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder
are unable to agree upon the fair market value of such security, then such dispute shall be
resolved in accordance with the procedures in Section 16. All such determinations shall be
appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during such period.
(e) Common Stock means (i) the Companys shares of common stock, $0.01 par value per share,
and (ii) any capital stock into which such common stock shall have been changed or any share
capital resulting from a reclassification of such common stock.
(f) Eligible Market means The New York Stock Exchange, the NYSE Amex, the Nasdaq Global
Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the Principal Market.
(g) Expiration Date means the date that is the fifth (5th) anniversary of the
Original Issue Date or, if such date falls on a day other than a Business Day or on which trading
does not take place on the Principal Market (a Holiday), the next date that is not a Holiday.
(h) Parent Entity of a Person means an entity that, directly or indirectly, controls the
applicable Person and whose common stock or equivalent equity security is quoted or listed on an
Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent
Entity with the largest public market capitalization as of the date of consummation of the
Fundamental Transaction.
(i) Person means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization, any other entity or a government or any
department or agency thereof.
(j) Principal Market means the OTC Bulletin Board.
(k) Successor Entity means the Person (or, if so elected by the Holder, the Parent Entity)
formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected
by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered
into.
(l) Trading Day means any day on which the Common Stock is traded on the Principal Market,
or, if the Principal Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common
14
Stock is then traded, provided that Trading Day shall not include any day on which the
Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day
that the Common Stock is suspended from trading during the final hour of trading on such exchange
or market (or if such exchange or market does not designate in advance the closing time of trading
on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such
day is otherwise designated as a Trading Day in writing by the Holder and the Company.
(m) Voting Stock of a Person means capital stock of such Person of the class or classes
pursuant to which the holders thereof have the general voting power to elect, or the general power
to appoint, at least a majority of the board of directors, managers or trustees of such Person
(irrespective of whether or not at the time capital stock of any other class or classes shall have
or might have voting power by reason of the happening of any contingency).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
SIGNATURE PAGE FOLLOWS]
15
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.
|
|
|
|
|
|
|
|
|
EMISPHERE TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
|
|
|
By:
Name:
|
|
Michael
R. Garone
|
|
|
|
|
Title:
|
|
Chief Financial Officer |
|
|
16
EXERCISE NOTICE
EMISPHERE TECHNOLOGIES, INC.
WARRANT NO. A-[XX] DATED , 2011
Ladies and Gentlemen:
(1) Form of Exercise Price. The Holder intends that payment of the Exercise Price
shall be made as:
|
|
|
|
|
|
|
|
|
|
|
a Cash
Exercise with respect to
Warrant Shares; and/or
|
|
|
|
|
|
|
|
|
|
|
|
|
|
a Cashless
Exercise with respect to
Warrant Shares.
|
|
|
In the event that the Holder has elected a Cashless Exercise with respect to some or all of
the Warrant Shares to be issued pursuant hereto, the Holder hereby represents and warrants that (i)
this Exercise Notice was executed by the Holder at [a.m.][p.m.] on the date set forth
below and (ii) if applicable, the Bid Price as of such time of execution of this Exercise Notice
was $ .
(2) Payment of Exercise Price. In the event that the Holder has elected a Cash
Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder
shall pay the Aggregate Exercise Price in the sum of $ to the Company in
accordance with the terms of the Warrant.
(3) Delivery of Warrant Shares. The Company shall deliver to Holder, or its designee
or agent as specified below, Warrant Shares in accordance with the terms of the Warrant.
Delivery shall be made to Holder, or for its benefit, to the following address:
(4) Limitations on Exercise. By its delivery of this Exercise Notice, the undersigned
represents and warrants to the Company that in giving effect to the exercise evidenced hereby the
Holder will not beneficially own in excess of the number of shares of Common Stock (as determined
in accordance with Section 13(d) of the Securities Exchange Act of 1934) permitted to be owned
under Section 11 of this Warrant to which this notice relates.
|
|
|
|
|
|
|
|
|
HOLDER |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
17
WARRANT ORIGINALLY ISSUED , 2011
WARRANT NO. A-[XX]
FORM OF ASSIGNMENT
To be completed and signed only upon transfer of Warrant
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
the right represented by the within Warrant to purchase
shares of Common
Stock to which the within Warrant relates and appoints
attorney to transfer said
right on the books of the Company with full power of substitution in the premises.
|
|
|
|
|
|
|
|
|
|
|
Dated: |
|
|
|
|
|
TRANSFEROR: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TRANSFEREE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Address of Transferee) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the presence of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18
Exhibit
4.2
REGISTRATION RIGHTS AGREEMENT
This REGISTRATION RIGHTS AGREEMENT (this Agreement), dated as of ___________, 2011, is by
and among Emisphere Technologies, Inc., a Delaware corporation with headquarters located at 240
Cedar Knolls Rd, Suite 200, Cedar Knolls, New Jersey 07927 (the Company), and each of the
undersigned buyers (each, a Buyer, and collectively, the Buyers).
RECITALS
A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated
as of June 30, 2011 (the Securities Purchase Agreement), the Company has agreed, upon the terms
and subject to the conditions of the Securities Purchase Agreement, to issue and sell to each Buyer
(i) shares (the Common Shares) of the Companys common stock, $0.01 par value (the Common
Stock) and (ii) the Warrants (as defined in the Securities Purchase Agreement) which will be
exercisable to purchase Warrant Shares (as defined in the Securities Purchase Agreement) in
accordance with the terms of the Warrants.
B. To induce the Buyers to consummate the transactions contemplated by the Securities Purchase
Agreement, the Company has agreed to provide certain registration rights under the Securities Act
of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
(collectively, the 1933 Act), and applicable state securities laws.
AGREEMENT
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each of the Buyers hereby agree as follows:
1. Definitions.
Capitalized terms used herein and not otherwise defined herein shall have the respective
meanings set forth in the Securities Purchase Agreement. As used in this Agreement, the following
terms shall have the following meanings:
(a) Business Day means any day other than Saturday, Sunday or any other day on which
commercial banks in New York, New York are authorized or required by law to remain closed.
(b) Closing Date shall have the meaning set forth in the Securities Purchase Agreement.
(c) Effective Date means the date that the applicable Registration Statement has been
declared effective by the SEC.
(d) Effectiveness Deadline means (i) with respect to the initial Registration Statement
required to be filed pursuant to Section 2(a), the earlier of the (A) 60th calendar day
after the Closing Date (or the 90th calendar day after the Closing Date in the event
that such
Registration Statement is subject to review by the SEC) and (B) 2nd Business Day
after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that
such Registration Statement will not be reviewed or will not be subject to further review and (ii)
with respect to any additional Registration Statements that may be required to be filed by the
Company pursuant to this Agreement, the earlier of the (A) 40th calendar day following
the date on which the Company was required to file such additional Registration Statement (or the
90th calendar day after such date in the event that such Registration Statement is
subject to review by the SEC) and (B) 2nd Business Day after the date the Company is
notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement
will not be reviewed or will not be subject to further review.
(e) Filing Deadline means (i) with respect to the initial Registration Statement required to
be filed pursuant to Section 2(a), the 20th calendar day after the Closing Date and (ii)
with respect to any additional Registration Statements that may be required to be filed by the
Company pursuant to this Agreement, the date on which the Company was required to file such
additional Registration Statement pursuant to the terms of this Agreement.
(f) Investor means a Buyer or any transferee or assignee of any Registrable Securities or
Warrants, as applicable, to whom a Buyer assigns its rights under this Agreement and who agrees to
become bound by the provisions of this Agreement in accordance with Section 9 and any transferee or
assignee thereof to whom a transferee or assignee of any Registrable Securities or Warrants, as
applicable, assigns its rights under this Agreement and who agrees to become bound by the
provisions of this Agreement in accordance with Section 9.
(g) Person means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization or a government or any department or agency
thereof.
(h) Register, Registered, and Registration refer to a registration effected by preparing
and filing one or more Registration Statements in compliance with the 1933 Act and pursuant to Rule
415 and the declaration of effectiveness of such Registration Statement(s) by the SEC.
(i) Registrable Securities means (i) the Common Shares, (ii) the Warrant Shares and (iii)
any capital stock of the Company issued or issuable with respect to the Common Shares, the Warrant
Shares or the Warrants, including, without limitation, (1) as a result of any stock split, stock
dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock
of the Company into which the shares of Common Stock are converted or exchanged and shares of
capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common
Stock are converted or exchanged, in each case, without regard to any limitations on exercise of
the Warrants.
(j) Registration Statement means a registration statement or registration statements of the
Company filed under the 1933 Act covering Registrable Securities.
(k) Required Holders means the holders of at least a majority of the Registrable Securities.
2
(l) Required Registration Amount means the sum of (i) the Common Shares issued and (ii) the
maximum number of Warrant Shares issued and issuable pursuant to the Warrants as of the Trading Day
(as defined in the Warrants) immediately preceding the applicable date of determination (without
taking into account any limitations on the exercise of the Warrants set forth therein), all subject
to adjustment as provided in Section 2(d).
(m) Rule 144 means Rule 144 promulgated by the SEC under the 1933 Act, as such rule may be
amended from time to time, or any other similar or successor rule or regulation of the SEC that may
at any time permit the Investors to sell securities of the Company to the public without
registration.
(n) Rule 415 means Rule 415 promulgated by the SEC under the 1933 Act, as such rule may be
amended from time to time, or any other similar or successor rule or regulation of the SEC
providing for offering securities on a continuous or delayed basis.
(o) SEC means the United States Securities and Exchange Commission or any successor thereto.
2. Registration.
(a) Mandatory Registration. The Company shall prepare and, as soon as practicable,
but in no event later than the Filing Deadline, file with the SEC an initial Registration Statement
on Form S-3 covering the resale of all of the Registrable Securities, provided that such initial
Registration Statement shall register for resale at least the number of shares of Common Stock
equal to the Required Registration Amount as of the date such Registration Statement is initially
filed with the SEC, provided further that if Form S-3 is unavailable for such a registration, the
Company shall use such other form as is required by Section 2(c). Such initial Registration
Statement, and each other Registration Statement required to filed pursuant to the terms of this
Agreement, shall contain (except if otherwise directed by the Required Holders) the Selling
Stockholders and Plan of Distribution sections in substantially the form attached
hereto as Exhibit A. The Company shall use its reasonable best efforts to have such initial
Registration Statement, and each other Registration Statement required to filed pursuant to the
terms of this Agreement, declared effective by the SEC as soon as practicable, but in no event
later than the applicable Effectiveness Deadline for such Registration Statement.
(b) Legal Counsel. Subject to Section 5 hereof, the Investor holding the largest
amount of Registrable Securities to be registered on the applicable Registration Statement (the
Lead Investor) shall have the right to select one (1) legal counsel to review and oversee, solely
on its behalf, any registration pursuant to this Section 2 (the Legal Counsel).
(c) Ineligibility to Use Form S-3. In the event that Form S-3 is not available for the
registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form reasonably acceptable to the
Required Holders and (ii) undertake to register the resale of the Registrable Securities on Form
S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness
of all Registration Statements then in effect until such time as a Registration Statement on Form
S-3 covering the resale of all the Registrable Securities has been declared effective by the SEC.
3
(d) Sufficient Number of Shares Registered. In the event the number of shares
available under any Registration Statement is insufficient to cover all of the Registrable
Securities required to be covered by such Registration Statement, the Company shall amend such
Registration Statement (if permissible), or file with the SEC a new Registration Statement (on the
short form available therefor, if applicable), or both, so as to cover at least the Required
Registration Amount as of the Trading Day immediately preceding the date of the filing of such
amendment or new Registration Statement, in each case, as soon as practicable, but in any event not
later than fifteen (15) days after the necessity therefor arises (but taking account of any
position of the staff of the SEC (the Staff) with respect to the date on which the Staff will
permit such amendment to the Registration Statement and/or such new Registration Statement (as the
case may be) to be filed with the SEC). The Company shall use its reasonable best efforts to cause
such amendment to such Registration Statement and/or such new Registration Statement (as the case
may be) to become effective as soon as practicable following the filing thereof with the SEC, but
in no event later than the applicable Effectiveness Deadline for such Registration Statement. For
purposes of the foregoing provision, the number of shares available under a Registration Statement
shall be deemed insufficient to cover all of the Registrable Securities if at any time the number
of shares of Common Stock available for resale under the applicable Registration Statement is less
than the product determined by multiplying (i) the Required Registration Amount as of such time by
(ii) 0.90. The calculation set forth in the foregoing sentence shall be made without regard to any
limitations on exercise of the Warrants (and such calculation shall assume that the Warrants are
then fully exercisable for shares of Common Stock at the then-prevailing applicable Exercise
Price).
(e) Registrable Securities. Any security issued by the Company that constitutes a
Registrable Security shall cease to be a Registrable Security upon the earlier to occur of (i) the
sale of such security pursuant to a Registration Statement or (ii) the first date on which such
security may be sold without restriction pursuant to Rule 144 (including, without limitation,
volume restrictions) and without the need for current public information required by Rule 144(c)(1)
(or Rule 144(i)(2), if applicable) (assuming, for purposes of the foregoing determination,
cashless exercise of all Warrants).
(f) Offering. Notwithstanding anything to the contrary contained in this Agreement, in
the event the Staff or the SEC seeks to characterize any offering pursuant to a Registration
Statement filed pursuant to this Agreement as constituting an offering of securities by, or on
behalf of, the Company, or in any other manner, such that the Staff or the SEC do not permit such
Registration Statement to become effective and used for resales in a manner that does not
constitute such an offering and that permits the continuous resale at the market by the Investors
participating therein (or as otherwise may be acceptable to each Investor) without being named
therein as an underwriter, then the Company shall reduce the number of shares to be included in
such Registration Statement by all Investors until such time as the Staff and the SEC shall so
permit such Registration Statement to become effective as aforesaid. In making such reduction, the
Company shall reduce the number of shares to be included by all Investors on a pro rata basis
(based upon the number of Registrable Securities otherwise required to be included for each
Investor) unless the inclusion of shares by a particular Investor or a particular set of Investors
are resulting in the Staff or the SECs by or on behalf of the Company offering position, in
which event the shares held by such Investor or set of Investors shall be the only shares subject
to reduction (and if by a set of Investors on a pro rata basis by such Investors or on such other
basis
4
as would result in the exclusion of the least number of shares by all such Investors). In
addition, in the event that the Staff or the SEC requires any Investor seeking to sell securities
under a Registration Statement filed pursuant to this Agreement to be specifically identified as
an underwriter in order to permit such Registration Statement to become effective, and such
Investor does not consent to being so named as an underwriter in such Registration Statement, then,
in each such case, the Company shall reduce the total number of Registrable Securities to be
registered on behalf of such Investor, until such time as the Staff or the SEC does not require
such identification or until such Investor accepts such identification and the manner thereof. Any
reduction pursuant to this paragraph will first reduce all Registrable Securities other than those
issued pursuant to the Securities Purchase Agreement. In the event of any reduction in Registrable
Securities pursuant to this paragraph, an affected Investor shall have the right to require, upon
delivery of a written request to the Company signed by such Investor, the Company to file a
registration statement within thirty (30) days of such request (subject to any restrictions imposed
by Rule 415 or required by the Staff or the SEC) for resale by such Investor in a manner acceptable
to such Investor, and the Company shall following such request cause to be and keep effective such
registration statement in the same manner as otherwise contemplated in this Agreement
for registration statements hereunder, in each case until such time as: (i) all Registrable
Securities held by such Investor have been registered and sold pursuant to an effective
Registration Statement in a manner acceptable to such Investor or (ii) all Registrable Securities
may be resold by such Investor without restriction (including, without limitation, volume
limitations) pursuant to Rule 144 (taking account of any Staff position with respect to affiliate
status) and without the need for current public information required by Rule 144(c)(1) (or Rule
144(i)(2), if applicable) (assuming, for purposes of the foregoing determination, cashless
exercise of all Warrants), or (iii) such Investor agrees to be named as an underwriter in any such
Registration Statement in a manner acceptable to such Investor as to all Registrable Securities
held by such Investor and that have not theretofore been included in a Registration Statement under
this Agreement (it being understood that the special demand right under this sentence may be
exercised by an Investor multiple times and with respect to limited amounts of Registrable
Securities in order to permit the resale thereof by such Investor as contemplated above).
(g) [Intentionally Omitted]
(h) Allocation of Registrable Securities. The initial number of Registrable Securities
included in any Registration Statement and any increase in the number of Registrable Securities
included therein shall be allocated pro rata among the Investors based on the number of Registrable
Securities held by each Investor at the time such Registration Statement covering such initial
number of Registrable Securities or increase thereof is declared effective by the SEC. In the event
that an Investor sells or otherwise transfers any of such Investors Registrable Securities, each
transferee or assignee (as the case may be) that becomes an Investor shall be allocated a pro rata
portion of the then-remaining number of Registrable Securities included in such Registration
Statement for such transferor or assignee (as the case may be). Any shares of Common Stock included
in a Registration Statement and which remain allocated to any Person which ceases to hold any
Registrable Securities covered by such Registration Statement shall be allocated to the remaining
Investors, pro rata based on the number of Registrable Securities then held by such Investors which
are covered by such Registration Statement.
5
3. Related Obligations.
The Company shall use its reasonable best efforts to effect the registration of the
Registrable Securities in accordance with the intended method of disposition thereof, and, pursuant
thereto, the Company shall have the following obligations:
(a) The Company shall promptly prepare and file with the SEC a Registration Statement with
respect to all the Registrable Securities (but in no event later than the applicable Filing
Deadline) and use its reasonable best efforts to cause such Registration Statement to become
effective as soon as practicable after such filing (but in no event later than the Effectiveness
Deadline). Subject to Allowable Grace Periods (as defined below), the Company shall keep each
Registration Statement effective (and the prospectus contained therein available for use) pursuant
to Rule 415 for resales by the Investors on a delayed or continuous basis at then-prevailing market
prices (and not fixed prices) at all times until the earlier of (i) the date as of which all of the
Investors may sell all of the Registrable Securities required to be covered by such Registration
Statement (disregarding any reduction pursuant to Section 2(f)) without restriction pursuant to
Rule 144 (including, without limitation, volume restrictions) and without the need for current
public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) (assuming, for
purposes of the foregoing determination, cashless exercise of all Warrants) or (ii) the date on
which the Investors shall have sold all of the Registrable Securities covered by such Registration
Statement (the Registration Period). Notwithstanding anything to the contrary contained in this
Agreement, the Company shall ensure that, when filed and at all times while effective, each
Registration Statement (including, without limitation, all amendments and supplements thereto) and
the prospectus (including, without limitation, all amendments and supplements thereto) used in
connection with such Registration Statement (1) shall not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein, or necessary to make
the statements therein (in the case of prospectuses, in the light of the circumstances in which
they were made) not misleading and (2) will disclose (whether directly or through incorporation by
reference to other SEC filings to the extent permitted) all material information regarding the
Company and its securities. The Company shall submit to the SEC, within one (1) Business Day after
the later of the date that the Company learns that no review of a particular Registration Statement
will be made by the Staff or that the Staff has no further comments on a particular Registration
Statement (as the case may be) a request for acceleration of effectiveness of such Registration
Statement to a time and date not later than forty-eight (48) hours after the submission of such
request.
(b) Subject to Section 3(r) of this Agreement, the Company shall prepare and file with the SEC
such amendments (including, without limitation, post-effective amendments) and supplements to each
Registration Statement and the prospectus used in connection with each such Registration Statement,
which prospectus is to be filed pursuant to Rule 424 promulgated under the 1933 Act, as may be
necessary to keep each such Registration Statement effective at all times during the Registration
Period for such Registration Statement, and, during such period, comply with the provisions of the
1933 Act with respect to the disposition of all Registrable Securities of the Company required to
be covered by such Registration Statement until such time as all of such Registrable Securities
shall have been disposed of in accordance with the intended methods of disposition by the seller or
sellers thereof as set forth in such Registration Statement; provided, however, by 8:30 a.m. (New
York time) on the Business Day immediately following
6
each Effective Date, the Company shall file with the SEC in accordance with Rule 424(b) under
the 1933 Act the final prospectus to be used in connection with sales pursuant to the applicable
Registration Statement (whether or not such a prospectus is technically required by such rule). In
the case of amendments and supplements to any Registration Statement which are required to be filed
pursuant to this Agreement (including, without limitation, pursuant to this Section 3(b)) by reason
of the Company filing a report on Form 10-Q or Form 10-K or any analogous report under the
Securities Exchange Act of 1934, as amended (the 1934 Act), the Company shall have incorporated
such report by reference into such Registration Statement, if applicable, or shall file such
amendments or supplements with the SEC promptly after the 1934 Act report is filed which created
the requirement for the Company to amend or supplement such Registration Statement.
(c) The Company shall permit Legal Counsel to review and comment upon (i) each Registration
Statement at least three (3) calendar days prior to its filing with the SEC and (ii) all amendments
and supplements to each Registration Statement (including, without limitation, the prospectus
contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, and any similar or successor reports) within a reasonable number of days prior
to their filing with the SEC. The Company shall promptly furnish to Legal Counsel, without charge,
(i) copies of any correspondence from the SEC or the Staff to the Company or its representatives
relating to each Registration Statement, provided that such correspondence shall not contain any
material, non-public information regarding the Company, (ii) at the written request of any
Investor, after the same is prepared and filed with the SEC, one (1) copy of each Registration
Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial
statements and schedules, all documents incorporated therein by reference, if requested by such
Investor, and all exhibits and (iii) upon the effectiveness of each Registration Statement, one (1)
copy of the prospectus included in such Registration Statement and all amendments and supplements
thereto. The Company shall reasonably cooperate with Legal Counsel in performing the Companys
obligations pursuant to this Section 3.
(d) The Company shall promptly furnish to any Investor whose Registrable Securities are
included in any Registration Statement, without charge, upon the written request of such Investor,
(i) after the same is prepared and filed with the SEC, at least one (1) copy of each Registration
Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial
statements and schedules, all documents incorporated therein by reference, if requested by such
Investor, all exhibits and each preliminary prospectus, (ii) upon the effectiveness of each
Registration Statement, ten (10) copies of the prospectus included in such Registration Statement
and all amendments and supplements thereto (or such other number of copies as such Investor may
reasonably request from time to time) and (iii) such other documents, including, without
limitation, copies of any preliminary or final prospectus, as such Investor may reasonably request
from time to time in order to facilitate the disposition of the Registrable Securities owned by
such Investor.
(e) The Company shall use its reasonable best efforts to (i) register and qualify, unless an
exemption from registration and qualification applies, the resale by Investors of the Registrable
Securities covered by a Registration Statement under such other securities or blue sky laws of
all applicable jurisdictions in the United States, (ii) prepare and file in those
7
jurisdictions, such amendments (including, without limitation, post-effective amendments) and
supplements to such registrations and qualifications as may be necessary to maintain the
effectiveness thereof during the Registration Period, (iii) take such other actions as may be
necessary to maintain such registrations and qualifications in effect at all times during the
Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify
the Registrable Securities for sale in such jurisdictions; provided, however, the Company shall not
be required in connection therewith or as a condition thereto to (x) qualify to do business in any
jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (y)
subject itself to general taxation in any such jurisdiction, or (z) file a general consent to
service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and
each Investor who holds Registrable Securities of the receipt by the Company of any notification
with respect to the suspension of the registration or qualification of any of the Registrable
Securities for sale under the securities or blue sky laws of any jurisdiction in the United
States or its receipt of actual notice of the initiation or threatening of any proceeding for such
purpose.
(f) The Company shall notify Legal Counsel and each Investor in writing of the happening of
any event, as promptly as practicable after becoming aware of such event, as a result of which the
prospectus included in a Registration Statement, as then in effect, includes an untrue statement of
a material fact or omission to state a material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they were made, not
misleading (provided that in no event shall such notice contain any material, non-public
information regarding the Company), and, subject to Section 3(r), promptly prepare a supplement or
amendment to such Registration Statement and such prospectus contained therein to correct such
untrue statement or omission and deliver ten (10) copies of such supplement or amendment to Legal
Counsel and each Investor (or such other number of copies as Legal Counsel or such Investor may
reasonably request). The Company shall also promptly notify Legal Counsel and each Investor in
writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been
filed, when a Registration Statement or any post-effective amendment has become effective
(notification of such effectiveness shall be delivered to Legal Counsel and each Investor by
facsimile or e-mail on the same day of such effectiveness and by overnight mail), and when the
Company receives written notice from the SEC that a Registration Statement or any post-effective
amendment will be reviewed by the SEC, (ii) of any request by the SEC for amendments or supplements
to a Registration Statement or related prospectus or related information, (iii) of the Companys
reasonable determination that a post-effective amendment to a Registration Statement would be
appropriate; and (iv) of the receipt of any request by the SEC or any other federal or state
governmental authority for any additional information relating to the Registration Statement or any
amendment or supplement thereto or any related prospectus. The Company shall respond as promptly as
practicable to any comments received from the SEC with respect to each Registration Statement or
any amendment thereto.
(g) The Company shall (i) use its reasonable best efforts to prevent the issuance of any stop
order or other suspension of effectiveness of each Registration Statement or the use of any
prospectus contained therein, or the suspension of the qualification, or the loss of an exemption
from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such
an order or suspension is issued, to obtain the withdrawal of such order or suspension at the
earliest possible moment and (ii) notify Legal Counsel and each Investor who holds Registrable
Securities of the issuance of such order and the resolution thereof or its receipt of
8
actual notice of the initiation or threat of any proceeding for such purpose.
(h) If any Investor may be required under applicable securities law to be described in any
Registration Statement as an underwriter and such Investor consents to so being named an
underwriter, at the request of any Investor, the Company shall furnish to such Investor, on the
date of the effectiveness of such Registration Statement and thereafter from time to time on such
dates as an Investor may reasonably request (i) a letter, dated such date, from the Companys
independent certified public accountants in form and substance as is customarily given by
independent certified public accountants to underwriters in an underwritten public offering,
addressed to the Investors, and (ii) an opinion, dated as of such date, of counsel representing the
Company for purposes of such Registration Statement, in form, scope and substance as is customarily
given in an underwritten public offering, addressed to the Investors.
(i) If any Investor may be required under applicable securities law to be described in any
Registration Statement as an underwriter and such Investor consents to so being named an
underwriter, upon the written request of such Investor, the Company shall make available for
inspection by (i) such Investor, (ii) legal counsel for such Investor and (iii) one (1) firm of
accountants or other agents retained by such Investor (collectively, the Inspectors), all
pertinent financial and other records, and pertinent corporate documents and properties of the
Company (collectively, the Records), as shall be reasonably deemed necessary by each Inspector,
and cause the Companys officers, directors and employees to supply all information which any
Inspector may reasonably request; provided, however, each Inspector shall agree in writing to hold
in strict confidence and not to make any disclosure (except to such Investor) or use of any Record
or other information which the Companys board of directors determines in good faith to be
confidential, and of which determination the Inspectors are so notified, unless (1) the disclosure
of such Records is necessary to avoid or correct a misstatement or omission in any Registration
Statement or is otherwise required under the 1933 Act, (2) the release of such Records is ordered
pursuant to a final, non-appealable subpoena or order from a court or government body of competent
jurisdiction, or (3) the information in such Records has been made generally available to the
public other than by disclosure in violation of this Agreement or any other Transaction Document
(as defined in the Securities Purchase Agreement). Such Investor agrees that it shall, upon
learning that disclosure of such Records is sought in or by a court or governmental body of
competent jurisdiction or through other means, give prompt notice to the Company and allow the
Company, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a
protective order for, the Records deemed confidential. Nothing herein (or in any other
confidentiality agreement between the Company and such Investor, if any) shall be deemed to limit
any Investors ability to sell Registrable Securities in a manner which is otherwise consistent
with applicable laws and regulations.
(j) The Company shall hold in confidence and not make any disclosure of information concerning
an Investor provided to the Company unless (i) disclosure of such information is necessary to
comply with federal or state securities laws, (ii) the disclosure of such information is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise
required to be disclosed in such Registration Statement pursuant to the 1933 Act, (iii) the release
of such information is ordered pursuant to a subpoena or other final, non-appealable order from a
court or governmental body of competent jurisdiction, or (iv) such information has been made
generally available to the public other than by disclosure in violation
9
of this Agreement or any other Transaction Document. The Company agrees that it shall, upon
learning that disclosure of such information concerning an Investor is sought in or by a court or
governmental body of competent jurisdiction or through other means, give prompt written notice to
such Investor and allow such Investor, at such Investors expense, to undertake appropriate action
to prevent disclosure of, or to obtain a protective order for, such information.
(k) Without limiting any obligation of the Company under the Securities Purchase Agreement,
the Company shall use its reasonable best efforts either to (i) cause all of the Registrable
Securities covered by each Registration Statement to be listed on each securities exchange on which
securities of the same class or series issued by the Company are then listed, if any, if the
listing of such Registrable Securities is then permitted under the rules of such exchange, (ii)
secure designation and quotation of all of the Registrable Securities covered by each Registration
Statement on the OTC Bulletin Board, or (iii) if, despite the Companys reasonable best efforts to
satisfy the preceding clauses (i) or (ii) the Company is unsuccessful in satisfying the preceding
clauses (i) or (ii), without limiting the generality of the foregoing, to use its reasonable best
efforts to arrange for at least two market makers to register with the Financial Industry
Regulatory Authority (FINRA) as such with respect to such Registrable Securities. In addition,
the Company shall cooperate with each Investor and any broker or dealer through which any such
Investor proposes to sell its Registrable Securities in effecting a filing with FINRA pursuant to
FINRA Rule 5110 as requested by such Investor. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this Section 3(k).
(l) The Company shall cooperate with the Investors who hold Registrable Securities being
offered and, to the extent applicable, facilitate the timely preparation and delivery of
certificates (not bearing any restrictive legend) representing the Registrable Securities to be
offered pursuant to a Registration Statement and enable such certificates to be in such
denominations or amounts (as the case may be) as the Investors may reasonably request from time to
time and registered in such names as the Investors may request.
(m) If requested by an Investor, the Company shall as soon as practicable after receipt of
notice from such Investor and subject to Section 3(r) hereof, (i) incorporate in a prospectus
supplement or post-effective amendment such information as an Investor reasonably requests to be
included therein relating to the sale and distribution of Registrable Securities, including,
without limitation, information with respect to the number of Registrable Securities being offered
or sold, the purchase price being paid therefor and any other terms of the offering of the
Registrable Securities to be sold in such offering; (ii) make all required filings of such
prospectus supplement or post-effective amendment after being notified of the matters to be
incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or
make amendments to any Registration Statement or prospectus contained therein if reasonably
requested by an Investor holding any Registrable Securities.
(n) The Company shall use its reasonable best efforts to cause the Registrable Securities
covered by a Registration Statement to be registered with or approved by such other governmental
agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.
(o) The Company shall make generally available to its security holders as soon as
10
practical, but not later than ninety (90) days after the close of the period covered thereby,
an earnings statement (in form complying with, and in the manner provided by, the provisions of
Rule 158 under the 1933 Act) covering a twelve-month period beginning not later than the first day
of the Companys fiscal quarter next following the applicable Effective Date of each Registration
Statement.
(p) The Company shall otherwise use its reasonable best efforts to comply with all applicable
rules and regulations of the SEC in connection with any registration hereunder.
(q) Within one (1) Business Day after a Registration Statement which covers Registrable
Securities is declared effective by the SEC, the Company shall deliver, and shall cause legal
counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with
copies to the Investors whose Registrable Securities are included in such Registration Statement)
confirmation that such Registration Statement has been declared effective by the SEC.
(r) Notwithstanding anything to the contrary herein (but subject to the last sentence of this
Section 3(r)), at any time after the Effective Date of a particular Registration Statement, the
Company may delay the disclosure of material, non-public information concerning the Company the
disclosure of which at the time is not, in the good faith opinion of the board of directors of the
Company, in the best interest of the Company and, in the opinion of counsel to the Company,
otherwise required (a Grace Period), provided that the Company shall promptly notify the
Investors in writing of the (i) existence of material, non-public information giving rise to a
Grace Period (provided that in each such notice the Company shall not disclose the content of such
material, non-public information to any of the Investors) and the date on which such Grace Period
will begin and (ii) date on which such Grace Period ends, provided further that (I) no Grace Period
shall exceed thirty (30) consecutive days and during any three hundred sixty five (365) day period
all such Grace Periods shall not exceed an aggregate of ninety (90) days, and (II) the first day of
any Grace Period must be at least five (5) Trading Days after the last day of any prior Grace
Period (each, an Allowable Grace Period). For purposes of determining the length of a Grace
Period above, such Grace Period shall begin on and include the date the Investors receive the
notice referred to in clause (i) above and shall end on and include the later of the date the
Investors receive the notice referred to in clause (ii) above and the date referred to in such
notice. The provisions of Section 3(g) hereof shall not be applicable during the period of any
Allowable Grace Period. Upon expiration of each Grace Period, the Company shall again be bound by
the first sentence of Section 3(f) with respect to the information giving rise thereto unless such
material, non-public information is no longer applicable. Notwithstanding anything to the contrary
contained in this Section 3(r), the Company shall cause its transfer agent to deliver unlegended
shares of Common Stock to a transferee of an Investor in accordance with the terms of the
Securities Purchase Agreement in connection with any sale of Registrable Securities with respect to
which such Investor has entered into a contract for sale, and delivered a copy of the prospectus
included as part of the particular Registration Statement to the extent applicable, prior to such
Investors receipt of the notice of a Grace Period and for which the Investor has not yet settled.
(s) If at any time after the date hereof the Company shall become eligible to use Form S-3 for
the registration of the resale of all the Registrable Securities, thereafter the
11
Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or
any successor form thereto) for the registration of the resale of all the Registrable Securities.
(t) The Company shall take all other reasonable actions necessary to expedite and facilitate
disposition by each Investor of its Registrable Securities pursuant to each Registration Statement.
4. Obligations of the Investors.
(a) At least five (5) Business Days prior to the first anticipated filing date of each
Registration Statement under this Agreement, the Company shall notify each Investor in writing of
the information the Company requires from each such Investor with respect to such Registration
Statement. It shall be a condition precedent to the obligations of the Company to complete the
registration pursuant to this Agreement with respect to the Registrable Securities of a particular
Investor that such Investor shall furnish to the Company such information regarding itself, the
Registrable Securities held by it and the intended method of disposition of the Registrable
Securities held by it, as shall be reasonably required to effect and maintain the effectiveness of
the registration of such Registrable Securities and shall execute such documents in connection with
such registration as the Company may reasonably request.
(b) Each Investor, by such Investors acceptance of the Registrable Securities, agrees to
cooperate with the Company as reasonably requested by the Company in connection with the
preparation and filing of each Registration Statement hereunder, unless such Investor has notified
the Company in writing of such Investors election to exclude all of such Investors Registrable
Securities from such Registration Statement.
(c) Each Investor agrees that, upon receipt of any notice from the Company of the happening of
any event of the kind described in Section 3(g) or the first sentence of 3(f), such Investor will
immediately discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until such Investors receipt of the copies of
the supplemented or amended prospectus contemplated by Section 3(g) or the first sentence of
Section 3(f) or receipt of notice that no supplement or amendment is required. Notwithstanding
anything to the contrary in this Section 4(c), the Company shall cause its transfer agent to
deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with the
terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities
with respect to which such Investor has entered into a contract for sale prior to the Investors
receipt of a notice from the Company of the happening of any event of the kind described in Section
3(g) or the first sentence of Section 3(f) and for which such Investor has not yet settled.
(d) Each Investor covenants and agrees that it will comply with the prospectus delivery
requirements of the 1933 Act as applicable to it in connection with sales of Registrable Securities
pursuant to a Registration Statement.
5. Expenses of Registration.
All reasonable expenses, other than underwriting discounts and commissions, incurred in
connection with registrations, filings or qualifications pursuant to Sections 2 and 3,
12
including, without limitation, all registration, listing and qualifications fees, printers and
accounting fees, FINRA filing fees (if any) and fees and disbursements of counsel for the Company
shall be paid by the Company. The Company shall also reimburse the Lead Investor for the fees and
disbursements of Legal Counsel in connection with registration, filing or qualification pursuant to
Sections 2 and 3 of this Agreement which amount shall be limited to $10,000.
6. Indemnification.
(a) In the event any Registrable Securities are included in any Registration Statement under
this Agreement, to the fullest extent permitted by law, the Company will, and hereby does,
indemnify, hold harmless and defend each Investor and each of its directors, officers,
shareholders, members, partners, employees, agents, advisors, representatives (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding the
lack of such title or any other title) and each Person, if any, who controls such Investor within
the meaning of the 1933 Act or the 1934 Act and each of the directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding the lack of such title
or any other title) of such controlling Persons (each, an Indemnified Person), against any
losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties,
charges, costs (including, without limitation, court costs, reasonable attorneys fees and costs of
defense and investigation), amounts paid in settlement or expenses, joint or several,
(collectively, Claims) incurred in investigating, preparing or defending any action, claim, suit,
inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or
governmental, administrative or other regulatory agency, body or the SEC, whether pending or
threatened, whether or not an indemnified party is or may be a party thereto (Indemnified
Damages), to which any of them may become subject insofar as such Claims (or actions or
proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon:
(i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement
or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other blue sky laws of any jurisdiction in which
Registrable Securities are offered (Blue Sky Filing), or the omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in
any preliminary prospectus if used prior to the effective date of such Registration Statement, or
contained in the final prospectus (as amended or supplemented, if the Company files any amendment
thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein
any material fact necessary to make the statements made therein, in light of the circumstances
under which the statements therein were made, not misleading (the matters in the foregoing clauses
(i) through (ii) being, collectively, Violations). Subject to Section 6(c), the Company shall
reimburse the Indemnified Persons, promptly as such expenses are incurred and are due and payable,
for any legal fees or other reasonable expenses incurred by them in connection with investigating
or defending any such Claim. Notwithstanding anything to the contrary contained herein, the
indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an
Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in
conformity with information furnished in writing to the Company by such Indemnified Person for such
Indemnified Person expressly for use in
13
connection with the preparation of such Registration Statement or any such amendment thereof
or supplement thereto and (ii) shall not be available to a particular Investor to the extent such
Claim is based on a failure of such Investor to deliver or to cause to be delivered the prospectus
made available by the Company (to the extent applicable), including, without limitation, a
corrected prospectus, if such prospectus or corrected prospectus was timely made available by the
Company pursuant to Section 3(d) and then only if, and to the extent that, following the receipt of
the corrected prospectus no grounds for such Claim would have existed; and (iii) shall not apply to
amounts paid in settlement of any Claim if such settlement is effected without the prior written
consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of the
Indemnified Person and shall survive the transfer of any of the Registrable Securities by any of
the Investors pursuant to Section 9.
(b) In connection with any Registration Statement in which an Investor is participating, such
Investor agrees to severally and not jointly indemnify, hold harmless and defend, to the same
extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if any, who controls the
Company within the meaning of the 1933 Act or the 1934 Act (each, an Indemnified Party), against
any Claim or Indemnified Damages to which any of them may become subject, under the 1933 Act, the
1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon
any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in
reliance upon and in conformity with written information furnished to the Company by such Investor
expressly for use in connection with such Registration Statement; and, subject to Section 6(c) and
the below provisos in this Section 6(b), such Investor will reimburse an Indemnified Party any
legal or other expenses reasonably incurred by such Indemnified Party in connection with
investigating or defending any such Claim; provided, however, the indemnity agreement contained in
this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not
apply to amounts paid in settlement of any Claim if such settlement is effected without the prior
written consent of such Investor, which consent shall not be unreasonably withheld or delayed,
provided further that such Investor shall be liable under this Section 6(b) for only that amount of
a Claim or Indemnified Damages as does not exceed the net proceeds to such Investor as a result of
the applicable sale of Registrable Securities pursuant to such Registration Statement. Such
indemnity shall remain in full force and effect regardless of any investigation made by or on
behalf of such Indemnified Party and shall survive the transfer of any of the Registrable
Securities by any of the Investors pursuant to Section 9.
(c) Promptly after receipt by an Indemnified Person or Indemnified Party (as the case may be)
under this Section 6 of notice of the commencement of any action or proceeding (including, without
limitation, any governmental action or proceeding) involving a Claim, such Indemnified Person or
Indemnified Party (as the case may be) shall, if a Claim in respect thereof is to be made against
any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of
the commencement thereof, and the indemnifying party shall have the right to participate in, and,
to the extent the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to
the indemnifying party and the Indemnified Person or the Indemnified Party (as the case may be);
provided, however, an Indemnified Person or Indemnified Party (as
14
the case may be) shall have the right to retain its own counsel with the fees and expenses of
such counsel to be paid by the indemnifying party if: (i) the indemnifying party has agreed in
writing to pay such fees and expenses; (ii) the indemnifying party shall have failed promptly to
assume the defense of such Claim and to employ counsel reasonably satisfactory to such Indemnified
Person or Indemnified Party (as the case may be) in any such Claim; or (iii) the named parties to
any such Claim (including, without limitation, any impleaded parties) include both such Indemnified
Person or Indemnified Party (as the case may be) and the indemnifying party, and such Indemnified
Person or such Indemnified Party (as the case may be) shall have been advised by counsel that a
conflict of interest is likely to exist if the same counsel were to represent such Indemnified
Person or such Indemnified Party and the indemnifying party (in which case, if such Indemnified
Person or such Indemnified Party (as the case may be) notifies the indemnifying party in writing
that it elects to employ separate counsel at the expense of the indemnifying party, then the
indemnifying party shall not have the right to assume the defense thereof and such counsel shall be
at the expense of the Indemnifying Party, provided further that in the case of clause (iii) above
the indemnifying party shall not be responsible for the reasonable fees and expenses of more than
one (1) separate legal counsel for such Indemnified Person or Indemnified Party (as the case may
be). The Indemnified Party or Indemnified Person (as the case may be) shall reasonably cooperate
with the indemnifying party in connection with any negotiation or defense of any such action or
Claim by the indemnifying party and shall furnish to the indemnifying party all information
reasonably available to the Indemnified Party or Indemnified Person (as the case may be) which
relates to such action or Claim. The indemnifying party shall keep the Indemnified Party or
Indemnified Person (as the case may be) reasonably apprised at all times as to the status of the
defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable
for any settlement of any action, claim or proceeding effected without its prior written consent;
provided, however, the indemnifying party shall not unreasonably withhold, delay or condition its
consent. No indemnifying party shall, without the prior written consent of the Indemnified Party
or Indemnified Person (as the case may be), consent to entry of any judgment or enter into any
settlement or other compromise which does not include as an unconditional term thereof the giving
by the claimant or plaintiff to such Indemnified Party or Indemnified Person (as the case may be)
of a release from all liability in respect to such Claim or litigation, and such settlement shall
not include any admission as to fault on the part of the Indemnified Party. Following
indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights
of the Indemnified Party or Indemnified Person (as the case may be) with respect to all third
parties, firms or corporations relating to the matter for which indemnification has been made. The
failure to deliver written notice to the indemnifying party within a reasonable time of the
commencement of any such action shall not relieve such indemnifying party of any liability to the
Indemnified Person or Indemnified Party (as the case may be) under this Section 6, except to the
extent that the indemnifying party is materially and adversely prejudiced in its ability to defend
such action.
(d) No Person involved in the sale of Registrable Securities who is guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with such
sale shall be entitled to indemnification from any Person involved in such sale of Registrable
Securities who is not guilty of fraudulent misrepresentation.
(e) The indemnification required by this Section 6 shall be made by periodic payments of the
amount thereof during the course of the investigation or defense, as and when
15
bills are received or Indemnified Damages are incurred, provided that each Indemnified Person
shall promptly reimburse the Company for all such payments received by such Indemnified Person to
the extent (but only to the extent) that a court of competent jurisdiction determines that such
Indemnified Person was not entitled to such payments.
(f) The indemnity and contribution agreements contained herein shall be in addition to (i) any
cause of action or similar right of the Indemnified Party or Indemnified Person against the
indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to
pursuant to the law.
7. Contribution.
To the extent any indemnification by an indemnifying party is prohibited or limited by law,
the indemnifying party agrees to make the maximum contribution with respect to any amounts for
which it would otherwise be liable under Section 6 to the fullest extent permitted by law;
provided, however: (i) no contribution shall be made under circumstances where the maker would not
have been liable for indemnification under the fault standards set forth in Section 6 of this
Agreement, (ii) no Person involved in the sale of Registrable Securities which Person is guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection
with such sale shall be entitled to contribution from any Person involved in such sale of
Registrable Securities who was not guilty of fraudulent misrepresentation; and (iii) contribution
by any seller of Registrable Securities shall be limited in amount to the amount of net proceeds
received by such seller from the applicable sale of such Registrable Securities pursuant to such
Registration Statement. Notwithstanding the provisions of this Section 7, no Investor shall be
required to contribute, in the aggregate, any amount in excess of the amount by which the net
proceeds actually received by such Investor from the applicable sale of the Registrable Securities
subject to the Claim exceeds the amount of any damages that such Investor has otherwise been
required to pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue
or alleged untrue statement or omission or alleged omission.
8. Reports Under the 1934 Act.
With a view to making available to the Investors the benefits of Rule 144, the Company agrees
to:
(a) make and keep public information available, as those terms are understood and defined in
Rule 144;
(b) file with the SEC in a timely manner all reports and other documents required of the
Company under the 1933 Act and the 1934 Act so long as the Company remains subject to such
requirements (it being understood and agreed that nothing herein shall limit any obligations of the
Company under the Securities Purchase Agreement) and the filing of such reports and other documents
is required for the applicable provisions of Rule 144; and
(c) furnish to each Investor so long as such Investor owns Registrable Securities, promptly
upon request, (i) a written statement by the Company, if true, that it has complied with the
reporting, submission and posting requirements of Rule 144 and the 1934 Act, (ii) a copy of
16
the most recent annual or quarterly report of the Company and such other reports and documents
so filed by the Company with the SEC if such reports are not publicly available via EDGAR, and
(iii) such other information as may be reasonably requested to permit the Investors to sell such
securities pursuant to Rule 144 without registration.
9. Assignment of Registration Rights.
All or any portion of the rights under this Agreement shall be automatically assignable by
each Investor to any transferee or assignee (as the case may be) of all or any portion of such
Investors Registrable Securities or Warrants if: (i) such Investor agrees in writing with such
transferee or assignee (as the case may be) to assign all or any portion of such rights, and a copy
of such agreement is furnished to the Company within a reasonable time after such transfer or
assignment (as the case may be); (ii) the Company is, within a reasonable time after such transfer
or assignment (as the case may be), furnished with written notice of (a) the name and address of
such transferee or assignee (as the case may be), and (b) the securities with respect to which such
registration rights are being transferred or assigned (as the case may be); (iii) immediately
following such transfer or assignment (as the case may be) the further disposition of such
securities by such transferee or assignee (as the case may be) is restricted under the 1933 Act or
applicable state securities laws if so required; (iv) at or before the time the Company receives
the written notice contemplated by clause (ii) of this sentence such transferee or assignee (as the
case may be) agrees in writing with the Company to be bound by all of the provisions contained
herein; (v) such transfer or assignment (as the case may be) shall have been made in accordance
with the applicable requirements of the Securities Purchase Agreement and the Warrants (as the case
may be); and (vi) such transfer or assignment (as the case may be) shall have been conducted in
accordance with all applicable federal and state securities laws.
10. Amendment of Registration Rights.
Provisions of this Agreement may be amended only with the written consent of the Company and
the Required Holders. Any amendment effected in accordance with this Section 10 shall be binding
upon each Investor and the Company. No waiver shall be effective unless it is in writing and signed
by an authorized representative of the waiving party. No consideration shall be offered or paid to
any Person to amend or consent to a waiver or modification of any provision of this Agreement
unless the same consideration also is offered to all of the parties to this Agreement.
11. Miscellaneous.
(a) Solely for purposes of this Agreement, a Person is deemed to be a holder of Registrable
Securities whenever such Person owns, or is deemed to own, of record such Registrable Securities.
If the Company receives conflicting instructions, notices or elections from two or more Persons
with respect to the same Registrable Securities, the Company shall act upon the basis of
instructions, notice or election received from such record owner of such Registrable Securities.
(b) Any notices, consents, waivers or other communications required or permitted to be given
under the terms of this Agreement must be in writing and will be deemed to have been
17
delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile or electronic mail (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party); (iii) with respect to Section
3(c), by electronic mail (provided confirmation of transmission is electronically generated and
kept on file by the sending party); or (iv) one (1) Business Day after deposit with a nationally
recognized overnight delivery service with next day delivery specified, in each case, properly
addressed to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:
If to the Company:
Emisphere Technologies, Inc.
240 Cedar Knolls, Suite 200
Cedar Knolls, New Jersey 07927
Telephone: (973) 532-8000
Facsimile: (973) 532-8115
Attention: Chief Financial Officer
Email: mgarone@emisphere.com
With a copy (for informational purposes only) to:
Brown Rudnick LLP
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 856-8200
Facsimile: (617) 856-8201
Attention: Timothy C. Maguire, Esq.
Email: tmaguire@brownrudnick.com
If to the Transfer Agent:
The Bank of New York Mellon Shareowner Services
111 Founders Plaza, Suite 1100
East Harford, Connecticut 06108
Telephone: (860) 282-3513
Facsimile: (860) 528-6472
Attention: John Boryczki
Email:
If to a Buyer, to its address and facsimile number set forth on the Schedule of Buyers attached to
the Securities Purchase Agreement, with copies to such Buyers representatives as set forth on the
Schedule of Buyers, or to such other address and/or facsimile number and/or to the attention of
such other Person as the recipient party has specified by written notice given to each other party
five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given
by the recipient of such notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the senders facsimile machine or electronic mail transmission
containing the time, date, recipient facsimile number or electronic mail address and an image of
the first page of such transmission or (C) provided by a courier or overnight courier service shall
be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally
18
recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.
(c) Failure of any party to exercise any right or remedy under this Agreement or otherwise, or
delay by a party in exercising such right or remedy, shall not operate as a waiver thereof. The
Company and each Investor acknowledge and agree that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with their specific
terms or were otherwise breached. It is accordingly agreed that each party hereto shall be entitled
to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by
any other party hereto and to enforce specifically the terms and provisions hereof (without the
necessity of showing economic loss and without any bond or other security being required), this
being in addition to any other remedy to which any party may be entitled by law or equity.
(d) All questions concerning the construction, validity, enforcement and interpretation of
this Agreement shall be governed by the internal laws of the State of New York, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of New York
or any other jurisdictions) that would cause the application of the laws of any jurisdictions other
than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of
the state and federal courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the
validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity
or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR
ANY TRANSACTION CONTEMPLATED HEREBY.
(e) This Agreement, the other Transaction Documents, the schedules and exhibits attached
hereto and thereto and the instruments referenced herein and therein constitute the entire
agreement among the parties hereto and thereto solely with respect to the subject matter hereof and
thereof. There are no restrictions, promises, warranties or undertakings, other than those set
forth or referred to herein and therein. This Agreement, the other Transaction Documents, the
schedules and exhibits attached hereto and thereto and the instruments referenced herein and
therein supersede all prior agreements and understandings among the parties hereto solely with
respect to the subject matter hereof and thereof; provided, however, nothing contained in this
Agreement or any other Transaction Document shall (or shall be deemed to) (i) have any effect
19
on any agreements any Investor has entered into with the Company prior to the date hereof with
respect to any prior investment made by such Investor in the Company, (ii) waive, alter, modify or
amend in any respect any obligations of the Company or any rights of or benefits to any Investor or
any other Person in any agreement entered into prior to the date hereof between or among the
Company and any Investor and all such agreements shall continue in full force and effect or (iii)
limit any obligations of the Company under any of the other Transaction Documents.
(f) Subject to compliance with Section 9 (if applicable), this Agreement shall inure to the
benefit of and be binding upon the permitted successors and assigns of each of the parties hereto.
This Agreement is not for the benefit of, nor may any provision hereof be enforced by, any Person,
other than the parties hereto, their respective permitted successors and assigns and the Persons
referred to in Sections 6 and 7 hereof.
(g) The headings in this Agreement are for convenience of reference only and shall not limit
or otherwise affect the meaning hereof. Unless the context clearly indicates otherwise, each
pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural
forms thereof. The terms including, includes, include and words of like import shall be
construed broadly as if followed by the words without limitation. The terms herein,
hereunder, hereof and words of like import refer to this entire Agreement instead of just the
provision in which they are found.
(h) This Agreement may be executed in two or more identical counterparts, all of which shall
be considered one and the same agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party. In the event that any signature is delivered
by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of
an executed signature page, such signature page shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as
if such signature page were an original thereof.
(i) Each party shall do and perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and
documents as any other party may reasonably request in order to carry out the intent and accomplish
the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(j) The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent and no rules of strict construction will be applied against
any party. Notwithstanding anything to the contrary set forth in Section 10, terms used in this
Agreement but defined in the other Transaction Documents shall have the meanings ascribed to such
terms on the Closing Date in such other Transaction Documents unless otherwise consented to in
writing by each Investor.
(k) All consents and other determinations required to be made by the Investors pursuant to
this Agreement shall be made, unless otherwise specified in this Agreement, by the Required
Holders.
20
(l) The obligations of each Investor under this Agreement and the other Transaction Documents
are several and not joint with the obligations of any other Investor, and no Investor shall be
responsible in any way for the performance of the obligations of any other Investor under this
Agreement or any other Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to
constitute the Investors as, and the Company acknowledges that the Investors do not so constitute,
a partnership, an association, a joint venture or any other kind of group or entity, or create a
presumption that the Investors are in any way acting in concert or as a group or entity with
respect to such obligations or the transactions contemplated by the Transaction Documents or any
matters, and the Company acknowledges that the Investors are not acting in concert or as a group,
and the Company shall not assert any such claim, with respect to such obligations or the
transactions contemplated by this Agreement or any of the other the Transaction Documents. Each
Investor shall be entitled to independently protect and enforce its rights, including, without
limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and
it shall not be necessary for any other Investor to be joined as an additional party in any
proceeding for such purpose. The use of a single agreement with respect to the obligations of the
Company contained herein was solely in the control of the Company, not the action or decision of
any Investor, and was done solely for the convenience of the Company and not because it was
required or requested to do so by any Investor. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company
and an Investor, solely, and not between the Company and the Investors collectively and not between
and among Investors.
[signature pages follow]
21
IN WITNESS WHEREOF, Buyer and the Company have caused their respective signature page to this
Registration Rights Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
|
COMPANY: |
|
|
|
|
|
|
|
EMISPHERE TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name: Michael R. Garone |
|
|
|
|
Title: Chief Financial Officer |
IN WITNESS WHEREOF, Buyer and the Company have caused their respective signature page to
this Registration Rights Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
|
BUYERS: |
|
|
|
|
|
|
|
HUAIDONG WANG |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Huaidong Wang |
|
|
|
|
Title: |
|
|
|
|
|
|
|
SHIPMAN & GOODWIN LLP |
|
|
PROFIT SHARING RETIREMENT TRUST |
|
|
FBO JAMES T. BETTS |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
James T. Betts |
|
|
|
|
Title: |
|
|
|
|
|
|
|
HF H VICTOR UW VICTOR ART 7 |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Lawrence Remmel |
|
|
|
|
Title: Authorized Signatory |
|
|
|
|
|
|
|
FREESTONE ADVANTAGE PARTNERSHIP |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Keith Goodman |
|
|
|
|
Title: Authorized Signatory |
|
|
|
|
|
|
|
CRANSHIRE CAPITAL LP |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Keith A. Goodman |
|
|
|
|
Title: COO-Downsview Capital, Inc. |
|
|
|
|
The General Partner |
|
|
|
|
|
|
|
BAI YE FENG |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Bai Ye Feng |
|
|
|
|
Title: |
|
|
|
|
|
|
|
KINGSBROOK OPPORTUNITIES MASTER FUND LP |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Adam J. Chill |
|
|
|
|
Title: Managing Member |
|
|
|
|
|
|
|
PINE LODGE CAPITAL COMPANY LTD. |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Barry Freeman |
|
|
|
|
Title: Director |
|
|
|
|
|
|
|
EOS HOLDINGS LLC |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Joseph W. Ramelli |
|
|
|
|
Title: Director |
|
|
|
|
|
|
|
SON NAM NGUYEN |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Son Nam Nguyen |
|
|
|
|
Title: |
|
|
|
|
|
|
|
IROQUOIS MASTER FUND LTD. |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Joshua Silverman |
|
|
|
|
Title: Authorized Signatory |
|
|
|
|
|
|
|
ANSON INVESTMENTS MASTER FUND LP |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
Adam Spears |
|
|
|
|
Title: Portfolio Manager |
EXHIBIT A
SELLING STOCKHOLDERS
The shares of common stock being offered by the selling stockholders are those previously
issued to the selling stockholders and those issuable to the selling stockholders upon exercise of
the warrants. For additional information regarding the issuance of common stock and the warrants,
see Private Placement of Common Shares and Warrants above. We are registering the shares of
common stock in order to permit the selling stockholders to offer the shares for resale from time
to time. Except for the ownership of the common stock and the warrants issued pursuant to the
Securities Purchase Agreement, the selling stockholders have not had any material relationship with
us within the past three years.
The table below lists the selling stockholders and other information regarding the beneficial
ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended,
and the rules and regulations thereunder) of the shares of common stock held by each of the selling
stockholders. The second column lists the number of shares of common stock beneficially owned by
the selling stockholders, based on their respective ownership of shares of common stock and
warrants, as of ________, 2011, assuming exercise of the warrants held by each such selling
stockholder on that date but taking account of any limitations on exercise set forth therein.
The third column lists the shares of common stock being offered by this prospectus by the
selling stockholders and does not take in account any limitations on exercise of the warrants set
forth therein.
In accordance with the terms of a registration rights agreement with the holders of the common
stock and the warrants, this prospectus generally covers the resale of the sum of (i) the number of
shares of common stock issued in connection with the Securities Purchase Agreement and (ii) maximum
number of shares of common stock issuable upon exercise of the warrants, in each case, determined
as if the outstanding warrants were exercised in full (without regard to any limitations on
exercise contained therein) as of the trading day immediately preceding the date this registration
statement was initially filed with the SEC. Because the exercise price of the warrants may be
adjusted, the number of shares that will actually be issued may be more or less than the number of
shares being offered by this prospectus. The fourth column assumes the sale of all of the shares
offered by the selling stockholders pursuant to this prospectus.
Under the terms of the warrants, a selling stockholder may not exercise the warrants to the
extent (but only to the extent) such selling stockholder or any of its affiliates would
beneficially own a number of shares of our common stock which would exceed 4.99%. The number of
shares in the second column reflects these limitations. The selling stockholders may sell all, some
or none of their shares in this offering. See Plan of Distribution.
|
|
|
|
|
|
|
|
|
|
|
Maximum Number of |
|
|
|
|
Number of Shares of |
|
Shares of Common Stock to |
|
Number of Shares of |
|
|
Common Stock Owned |
|
be Sold Pursuant to this |
|
Common Stock of Owned |
Name of Selling Stockholder |
|
Prior to Offering |
|
Prospectus |
|
After Offering |
|
|
|
|
|
|
|
PLAN OF DISTRIBUTION
We are registering the shares of common stock previously issued and the shares of common stock
issuable upon exercise of the warrants to permit the resale of these shares of common stock by the
holders of the common stock and warrants from time to time after the date of this prospectus. We
will not receive any of the proceeds from the sale by the selling stockholders of the shares of
common stock. We will bear all fees and expenses incident to our obligation to register the shares
of common stock.
The selling stockholders may sell all or a portion of the shares of common stock held by them
and offered hereby from time to time directly or through one or more underwriters, broker-dealers
or agents. If the shares of common stock are sold through underwriters or broker-dealers, the
selling stockholders will be responsible for underwriting discounts or commissions or agents
commissions. The shares of common stock may be sold in one or more transactions at fixed prices, at
prevailing market prices at the time of the sale, at varying prices determined at the time of sale
or at negotiated prices. These sales may be effected in transactions, which may involve crosses or
block transactions, pursuant to one or more of the following methods:
|
|
|
on any national securities exchange or quotation service on which the securities may
be listed or quoted at the time of sale; |
|
|
|
|
in the over-the-counter market; |
|
|
|
|
in transactions otherwise than on these exchanges or systems or in the
over-the-counter market; |
|
|
|
|
through the writing or settlement of options, whether such options are listed on an
options exchange or otherwise; |
|
|
|
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits
purchasers; |
|
|
|
|
block trades in which the broker-dealer will attempt to sell the shares as agent but
may position and resell a portion of the block as principal to facilitate the
transaction; |
|
|
|
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its
account; |
|
|
|
|
an exchange distribution in accordance with the rules of the applicable exchange; |
|
|
|
|
privately negotiated transactions; |
|
|
|
|
short sales made after the date the Registration Statement is declared effective by
the SEC; |
|
|
|
|
agreements entered into between broker-dealers and a selling securityholder to sell
a specified number of such shares at a stipulated price per share; |
|
|
|
a combination of any such methods of sale; and |
|
|
|
|
any other method permitted pursuant to applicable law. |
The selling stockholders may also sell shares of common stock under Rule 144 promulgated under
the Securities Act of 1933, as amended, if available, rather than under this prospectus. In
addition, the selling stockholders may transfer the shares of common stock by other means not
described in this prospectus. If the selling stockholders effect such transactions by selling
shares of common stock to or through underwriters, broker-dealers or agents, such underwriters,
broker-dealers or agents may receive commissions in the form of discounts, concessions or
commissions from the selling stockholders or commissions from purchasers of the shares of common
stock for whom they may act as agent or to whom they may sell as principal (which discounts,
concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess
of those customary in the types of transactions involved). In connection with sales of the shares
of common stock or otherwise, the selling stockholders may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of the shares of common stock in the course
of hedging in positions they assume. The selling stockholders may also sell shares of common stock
short and deliver shares of common stock covered by this prospectus to close out short positions
and to return borrowed shares in connection with such short sales. The selling stockholders may
also loan or pledge shares of common stock to broker-dealers that in turn may sell such shares.
The selling stockholders may pledge or grant a security interest in some or all of the
warrants or shares of common stock owned by them and, if they default in the performance of their
secured obligations, the pledgees or secured parties may offer and sell the shares of common stock
from time to time pursuant to this prospectus or any amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of
selling stockholders to include the pledgee, transferee or other successors in interest as selling
stockholders under this prospectus. The selling stockholders also may transfer and donate the
shares of common stock in other circumstances in which case the transferees, donees, pledgees or
other successors in interest will be the selling beneficial owners for purposes of this prospectus.
To the extent required by the Securities Act and the rules and regulations thereunder, the
selling stockholders and any broker-dealer participating in the distribution of the shares of
common stock may be deemed to be underwriters within the meaning of the Securities Act, and any
commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed
to be underwriting commissions or discounts under the Securities Act. At the time a particular
offering of the shares of common stock is made, a prospectus supplement, if required, will be
distributed, which will set forth the aggregate amount of shares of common stock being offered and
the terms of the offering, including the name or names of any broker-dealers or agents, any
discounts, commissions and other terms constituting compensation from the selling stockholders and
any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.
Under the securities laws of some states, the shares of common stock may be sold in such
states only through registered or licensed brokers or dealers. In addition, in some states the
shares of common stock may not be sold unless such shares have been registered or qualified
for sale in such state or an exemption from registration or qualification is available and is
complied with.
There can be no assurance that any selling stockholder will sell any or all of the shares of
common stock registered pursuant to the registration statement, of which this prospectus forms a
part.
The selling stockholders and any other person participating in such distribution will be
subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder, including, without limitation, to the extent applicable, Regulation M
of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of
common stock by the selling stockholders and any other participating person. To the extent
applicable, Regulation M may also restrict the ability of any person engaged in the distribution of
the shares of common stock to engage in market-making activities with respect to the shares of
common stock. All of the foregoing may affect the marketability of the shares of common stock and
the ability of any person or entity to engage in market-making activities with respect to the
shares of common stock.
We will pay all expenses of the registration of the shares of common stock pursuant to the
registration rights agreement, estimated to be $[ ] in total, including, without limitation,
Securities and Exchange Commission filing fees and expenses of compliance with state securities or
blue sky laws; provided, however, a selling stockholder will pay all underwriting discounts and
selling commissions, if any. We will indemnify the selling stockholders against liabilities,
including some liabilities under the Securities Act in accordance with the registration rights
agreements or the selling stockholders will be entitled to contribution. We may be indemnified by
the selling stockholders against civil liabilities, including liabilities under the Securities Act
that may arise from any written information furnished to us by the selling stockholder specifically
for use in this prospectus, in accordance with the related registration rights agreements or we may
be entitled to contribution.
Once sold under the registration statement, of which this prospectus forms a part, the shares
of common stock will be freely tradable in the hands of persons other than our affiliates.
Exhibit 4.3
FORM OF MHR WARRANT
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES
INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER
(IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS
NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
EMISPHERE TECHNOLOGIES, INC.
WARRANT
|
|
|
|
|
|
Warrant No. A-[XX]
|
|
Original Issue Date: _______, 2011 |
EMISPHERE TECHNOLOGIES, INC., a Delaware corporation (the Company), hereby certifies
that, for value received, [NAME OF HOLDER] or its permitted registered assigns (the
Holder), is entitled to purchase from the Company up to a total of [NUMBER] shares of
Common Stock (as defined below) of the Company (each such share, a Warrant Share and all
such shares, the Warrant Shares) at an
exercise price equal to $1.09 per share (as
adjusted from time to time as provided herein, the Exercise Price), at any time and from
time to time on or after the Original Issue Date and through and including the Expiration Date (as
defined below), and subject to the following terms and conditions:
This Warrant is one of a series of warrants issued pursuant to that certain Securities
Purchase Agreement dated June 30, 2011 (the Subscription Date), by and between the
Company and each of the purchasers identified therein (the Purchase Agreement). All such
warrants are referred to herein, collectively, as the Warrants.
1. Definitions. In addition to the terms defined elsewhere in this Warrant,
capitalized terms that are not otherwise defined herein have the meanings given to such terms in
Section 18.
2. List of Warrant Holders. The Company shall register this Warrant, upon records to
be maintained by the Company for that purpose (the Warrant Register), in the name of the
record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder from time to time). The
Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.
3. List of Transfers; Restrictions on Transfer.
(a) This Warrant may be offered for sale, sold, transferred or assigned without the consent of
the Company, except as may otherwise be required by Section 2(g) of the Purchase Agreement.
(b) The Company shall register any such transfer of all or any portion of this Warrant in the
Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto duly
completed and signed, to the Company at its address specified herein. Upon any such registration
or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (in
accordance with Section 3(e)), evidencing the portion of this Warrant so transferred shall be
issued to the transferee and a new Warrant evidencing the remaining portion of this Warrant not so
transferred, if any, shall be issued to the transferring Holder. The acceptance of the new Warrant
by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights
and obligations in respect of the new Warrant that the Holder has in respect of this Warrant.
(c) This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Warrant or Warrants (in accordance with Section 3(e)) representing
in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant,
and each such new Warrant will represent the right to purchase such portion of such Warrant Shares
as is designated by the Holder at the time of such surrender; provided, however, no warrants for
fractional shares of Common Stock shall be given.
(d) If, at the time of the surrender of this Warrant in connection with any transfer of this
Warrant, transfer of this Warrant shall not be registered pursuant to an effective registration
statement under the Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the Holder or transferee of
this Warrant, as the case may be, furnish to the Company a written opinion of counsel (which
opinion shall be in form, substance and scope customary for opinions of counsel in comparable
transactions) to the effect that such transfer may be made without registration under the
Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or
transferee execute and deliver to the Company an investment letter in form and substance acceptable
to the Company and (iii) that the transferee be an accredited investor as defined in Rule 501(a)
promulgated under the Securities Act.
(e) Whenever the Company is required to issue a new Warrant pursuant to the terms of this
Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as
indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying
this Warrant (or in the case of a new Warrant being issued pursuant to this Section 3 or Section 7,
the Warrant Shares designated by the Holder which, when added to the number of shares of Common
Stock underlying the other new Warrants issued in connection with such issuance, does not exceed
the number of Warrant Shares then underlying this Warrant), (iii) shall
2
have an issuance date, as indicated on the face of such new Warrant which is the same as the
Original Issue Date, and (iv) shall have the same rights and conditions as this Warrant.
4. Exercise and Duration of Warrants.
(a) All or any part of this Warrant shall be exercisable by the registered Holder in any
manner permitted by Section 4 of this Warrant at any time and from time to time on or after the
Original Issue Date and through and including the Expiration Date. At 5:00 p.m., New York City
time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and
become void and of no value and this Warrant shall be terminated and no longer outstanding. In
addition, if cashless exercise would be permitted under Section 4(c) of this Warrant, then all or
part of this Warrant may be exercised by the registered Holder utilizing such cashless exercise
provisions at any time, or from time to time, on or after the Original Issue Date and through and
including the Expiration Date.
(b) The Holder may exercise this Warrant by delivering to the Company an exercise notice, in
the form attached hereto (the Exercise Notice), completed and duly signed. If such
Holder is not utilizing the cashless exercise provisions set forth in this Warrant, within one (1)
Trading Day following an exercise of this Warrant as aforesaid, the Holder shall deliver payment to
the Company of an amount equal to the Exercise Price for the number of Warrant Shares as to which
this Warrant is being exercised (the Aggregate Exercise Price). The date the Exercise
Notice is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an Exercise Date. The Holder shall not be required to deliver the original Warrant in
order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing
the right to purchase the remaining number of Warrant Shares. Additionally, at the request of the
Holder, if this Warrant shall have been exercised in part and the Holder shall have surrendered
this Warrant certificate, the Company shall, at the time of delivery of the certificate or
certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of
Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.
(c) Notwithstanding anything contained herein to the contrary, if at the time of exercise
hereof, a Registration Statement (as defined in the Registration Rights Agreement (as defined in
the Purchase Agreement)) is not effective (or the prospectus contained therein is not available for
use) for the resale by the Holder of all of the Warrant Shares, then the Holder may, in its sole
discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment
otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate
Exercise Price, elect instead to receive upon such exercise the Net Number of shares of Common
Stock determined according to the following formula (a Cashless Exercise):
|
|
|
|
|
Net Number =
|
|
(A x B) - (A x C)
|
|
|
|
|
|
|
|
|
|
B |
|
|
For purposes of the foregoing formula:
3
|
|
|
A= the total number of shares with respect to which this Warrant
is then being exercised. |
|
|
|
|
B= as applicable: (i) the Closing Sale Price of the Common Stock
on the Trading Day immediately preceding the date of the applicable Exercise
Notice if such Exercise Notice is (1) both executed and delivered pursuant to
Section 4 hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 4 hereof on a Trading Day prior to the opening of
regular trading hours (as defined in Rule 600(b)(64) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii) the
Bid Price of the Common Stock as of the time of the Holders execution of the
applicable Exercise Notice if such Exercise Notice is executed during regular
trading hours on a Trading Day and is delivered within two (2) hours
thereafter pursuant to Section 4 hereof and (iii) the Closing Sale Price of the
Common Stock on the date of the applicable Exercise Notice if the date of such
Exercise Notice is a Trading Day and such Exercise Notice is both executed and
delivered pursuant to Section 4 hereof after the close of regular trading
hours on such Trading Day. |
|
|
|
|
C= the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise. |
(d) In the case of a dispute as to the determination of the Exercise Price or the arithmetic
calculation of the number of Warrant Shares to be issued pursuant to the terms hereof, the Company
shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve
such dispute in accordance with Section 15.
5. Delivery of Warrant Shares.
(a) On or before the first (1st) Trading Day following the date on which the
Company has received an Exercise Notice, the Company shall transmit by facsimile or electronic mail
an acknowledgment of confirmation of receipt of such Exercise Notice, to the Holder and the
Companys transfer agent (the Transfer Agent). On or before the third (3rd)
Trading Day following the date on which the Company has received such Exercise Notice, the Company
shall (X) provided that the Transfer Agent is participating in The Depository Trust Company
(DTC) Fast Automated Securities Transfer Program and the Warrant Shares can be issued
without restrictive legends, upon the request of the Holder, credit such aggregate number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise to the Holders or its
designees balance account with DTC through its Deposit/Withdrawal at Custodian system, or (Y) if
the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or
the Warrant Shares cannot be issued without restrictive legends, issue and deliver to the Holder
or, at the Holders instruction pursuant to the Exercise Notice, the Holders agent or designee, in
each case, sent by reputable overnight courier to the address as specified in the applicable
Exercise Notice, a certificate, registered in the Companys share register in the name of the
Holder or its designee (as indicated in the applicable Exercise Notice), for the number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise. Upon
4
delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date such Warrant Shares are credited to the Holders DTC account or
the date of delivery of the certificates evidencing such Warrant Shares (as the case may be). The
Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be
deemed to have become the holder of record of such Warrant Shares as of the Exercise Date.
Notwithstanding the foregoing, except in the case where an exercise of this Warrant is validly made
pursuant to a cashless exercise, the Companys failure to deliver Warrant Shares to the Holder on
or prior to the later of (x) the close of the third Trading Day after delivery of an Exercise
Notice and (y) the Trading Day in which the Companys receives the Aggregate Exercise Price (such
later date, the Share Delivery Deadline) shall not be deemed to be a breach of this
Warrant.
(b) If by the Share Delivery Deadline, the Company fails to deliver to the Holder a
certificate representing the required number of Warrant Shares in the manner required pursuant to
Section 5(a), and if after such third Trading Day and prior to the receipt of such Warrant Shares,
the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a Buy-In), then the Company shall, within three Trading
Days after the Holders request and in the Holders sole discretion, either (i) pay in cash to the
Holder an amount equal to the Holders total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased (the Buy-In Price), at which point the
Companys obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate
or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such shares of Common Stock or credit the Holders balance account with DTC for the
number of shares of Common Stock to which the Holder is entitled upon the Holders exercise
hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any)
of the Buy-In Price over the product of (A) such number of shares of Common Stock times (B) the
Closing Sale Price of the Common Stock on the Trading Day immediately preceding the date of the
applicable Exercise Notice.
(c) To the extent permitted by law, the Companys obligations to issue and deliver Warrant
Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any
provision hereof, the recovery of any judgment against any Person or any action to enforce the
same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other
circumstance that might otherwise limit such obligation of the Company to the Holder in connection
with the issuance of Warrant Shares. Nothing herein shall limit a Holders right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the Companys failure to
timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.
6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of
Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any
5
issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense
in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by
the Company; provided, however, that the Company shall not be required to pay any tax that may be
payable in respect of any transfer involved in the registration of any certificates for Warrant
Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for
all other tax liability that may arise as a result of holding or transferring this Warrant or
receiving Warrant Shares upon exercise hereof.
7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant (in accordance
with Section 3(e)), but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction and customary and reasonable indemnity (which shall not include a
surety bond), if requested. Applicants for a new Warrant under such circumstances shall also
comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a new Warrant is requested as a result of a
mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as
a condition precedent to the Companys obligation to issue the new Warrant.
8. Reservation of Warrant Shares. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable
and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other
contingent purchase rights of persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and
deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. If,
notwithstanding the foregoing, and not in limitation thereof, at any time while any of the Warrants
remain outstanding the Company does not have a sufficient number of authorized and unreserved
shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of the
Warrants at least a number of shares of Common Stock equal to the number of shares of Common Stock
as shall from time to time be necessary to effect the exercise of all of the Warrants then
outstanding (the Required Reserve Amount, and such reservation failure, an
Authorized Share Failure), then the Company shall promptly take all action necessary to
increase the Companys authorized shares of Common Stock to an amount sufficient to allow the
Company to reserve the Required Reserve Amount for all the Warrants then outstanding. Without
limiting the generality of the foregoing sentence, as soon as practicable after the date of the
occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the
occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders
for the approval of an increase in the number of authorized shares of Common Stock. In connection
with such meeting, the Company shall provide each stockholder with a proxy statement and shall use
its best efforts to solicit its stockholders approval of such increase in authorized shares of
Common Stock and to cause its board of directors to recommend to the stockholders that they approve
such proposal.
9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable
6
upon exercise of this Warrant are subject to adjustment from time to time as set forth in this
Section 9.
(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any
class of capital stock that is payable in shares of Common Stock, (ii) subdivides (by any stock
split, stock dividend, recapitalization or otherwise) outstanding shares of Common Stock into a
larger number of shares, or (iii) combines (by combination, reverse stock split or otherwise)
outstanding shares of Common Stock into a smaller number of shares, then in each such case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment
made pursuant to clause (i) of this paragraph shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution, and
any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this paragraph occurs during the period that an Exercise Price is calculated
hereunder, then the calculation of such Exercise Price shall be adjusted appropriately to reflect
such event.
(b) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its
indebtedness, (ii) any security (other than a distribution of Common Stock covered by Section
9(a)), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset
(in each case, Distributed Property), then, upon any exercise of this Warrant that occurs
after the record date fixed for determination of stockholders entitled to receive such
distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise
issuable upon such exercise (if applicable) (without regard to any limitations on exercise hereof),
the Distributed Property that such Holder would have been entitled to receive in respect of such
number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately
prior to such record date.
(c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i)
the Company effects any merger or consolidation of the Company with or into another Person, in
which the shareholders of the Company as of immediately prior to the transaction own less than a
majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for other securities, cash
or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (each, a Fundamental Transaction), then the Holder
shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind
of securities, cash or property as it would have been entitled to receive upon the occurrence of
such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the
Alternate Consideration). The Company shall not effect
7
any such Fundamental Transaction unless prior to or simultaneously with the consummation
thereof, any successor to the Company, surviving entity or the corporation purchasing or otherwise
acquiring such assets or other appropriate corporation or entity shall assume the obligation to
deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing
provisions, the Holder may be entitled to purchase, and the other obligations under this Warrant.
The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous to
a Fundamental Transaction.
(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise
Price pursuant to paragraphs (a) and (b) of this Section 9, the number of Warrant Shares that may
be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that
after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of
Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to
such adjustment.
(e) Calculations. All calculations under this Section 9 shall be made to the nearest
cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for the account of the
Company, and the disposition of any such shares shall be considered an issue or sale of Common
Stock.
(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this
Section 9, the Company at its expense will, at the written request of the Holder, promptly compute
such adjustment in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or
type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon
which such adjustment is based. Upon written request, the Company will promptly deliver a copy of
each such certificate to the Holder and to the Companys Transfer Agent.
(g) Notice of Events. The Company will give written notice to the Holder at least two
(2) days prior to the date on which the Company closes its books or takes a record (A) with respect
to any dividend or distribution upon the shares of Common Stock, or (B) for determining rights to
vote with respect to any Fundamental Transaction, dissolution or liquidation. Notwithstanding the
foregoing, the failure deliver such notice or any defect therein shall not affect the validity of
the corporate action required to be described in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company
(including its subsidiaries), the Company shall simultaneously file such notice with the SEC (as
defined in the Purchase Agreement) pursuant to a Current Report on Form 8-K. It is expressly
understood and agreed that the time of execution specified by the Holder in each Exercise Notice
shall be definitive and may not be disputed or challenged by the Company.
10. Payment of Exercise Price. The Holder shall pay the Exercise Price by delivering
immediately available funds to the Company unless the Holder has specified a Cashless Exercise in
the applicable Exercise Notice.
8
11. No Fractional Shares. No fractional Warrant Shares will be issued in connection
with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be
issuable, the Company shall pay cash equal to the product of such fraction multiplied by the
Closing Bid Price of one Warrant Share on the applicable Exercise Date.
12. Notices. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given
and effective on the earliest of (i) upon confirmation of receipt, if such notice or communication
is delivered via facsimile or electronic mail at the facsimile number or e-mail address specified
in this Section at or prior to 5:00 p.m. (New York City time) on a Trading Day (provided
confirmation of transmission is mechanically or electronically generated and kept on file by the
sending party), (ii) the next Trading Day after the date of confirmation of receipt, if such notice
or communication is delivered via facsimile or electronic mail at the facsimile number or e-mail
address specified in this Section on a day that is not a Trading Day or later than 5:00 p.m. (New
York City time) on any Trading Day (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party), (iii) the Trading Day following
the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon
actual receipt by the party to whom such notice is required to be given. The addresses for such
notices or communications shall be: if to the Company, to Emisphere Technologies, Inc., 240 Cedar
Knolls Road, Suite 200, Cedar Knolls, New Jersey 07927. Attention: Chief Financial Officer,
Facsimile No.: (973) 532-8121, e-mail address: mgarone@emisphere.com (or such other address as the
Company shall indicate in writing in accordance with this Section) or (ii) if to the Holder, to the
address, facsimile number or e-mail address appearing on the Warrant Register (or such other
address as the Company shall indicate in writing in accordance with this Section).
13. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon
30 days notice to the Holder, the Company may appoint a new warrant agent. Any corporation into
which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to
which the Company or any new warrant agent transfers substantially all of its corporate trust or
shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as
warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holders
last address as shown on the Warrant Register.
14. Noncircumvention. The Company hereby covenants and agrees that the Company will
not, by amendment of its Articles of Incorporation, as amended, its Bylaws as amended or through
any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, and will at all times in good faith carry out
all the provisions of this Warrant and take all action as may be required to protect the rights of
the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase
the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the
Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant, and (iii) shall, so long
9
as any of the Warrants are outstanding, take all action necessary to reserve and keep
available out of its authorized and unissued shares of Common Stock, solely for the purpose of
effecting the exercise of the Warrants, the maximum number of shares of Common Stock as shall from
time to time be necessary to effect the exercise of the Warrants then outstanding (without regard
to any limitations on exercise).
15. Dispute Resolution. In the case of a dispute as to the determination of the
Exercise Price, the Closing Bid Price, the Closing Sale Price, the Bid Price or fair market value
or the arithmetic calculation of the number of Warrant Shares (as the case may be), the Company or
the Holder (as the case may be) shall submit the disputed determinations or arithmetic calculations
(as the case may be) via facsimile (i) within two (2) Business Days after receipt of the applicable
notice giving rise to such dispute to the Company or the Holder (as the case may be) or (ii) if no
notice gave rise to such dispute, at any time after the Holder learned of the circumstances giving
rise to such dispute. If the Holder and the Company are unable to agree upon such determination or
calculation (as the case may be) of the Exercise Price, the Closing Bid Price, the Closing Sale
Price, the Bid Price or fair market value or the number of Warrant Shares (as the case may be)
within three (3) Business Days of such disputed determination or arithmetic calculation being
submitted to the Company or the Holder (as the case may be), then the Company shall, within two (2)
Business Days submit via facsimile (a) the disputed determination of the Exercise Price, the
Closing Bid Price, the Closing Sale Price, the Bid Price or fair market value (as the case may be)
to an independent, reputable investment bank selected by the Company and approved by the Holder or
(b) the disputed arithmetic calculation of the number of Warrant Shares to the Companys
independent, outside accountant. The Company shall cause the investment bank or the accountant (as
the case may be) to perform the determinations or calculations (as the case may be) and notify the
Company and the Holder of the results no later than ten (10) Business Days from the time it
receives such disputed determinations or calculations (as the case may be). Such investment banks
or accountants determination or calculation (as the case may be) shall be binding upon all parties
absent demonstrable error. If a disputed determination or arithmetic calculation is submitted to
the investment bank or the accountant (as the case may be) pursuant to this Section 16, then the
prevailing party in such determination or calculation shall be reimbursed by the other party for
its costs and expenses (including any and all fees and expenses charged by the investment back or
accountant) incurred in connection with the determination or calculation (as the case may be).
16. Remedies, Characterization, Other Obligations, Breaches and Injunctive Relief. The
remedies provided in this Warrant shall be cumulative and in addition to all other remedies
available under this Warrant and the other Transaction Documents, at law or in equity (including a
decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
right of the Holder to pursue actual damages for any failure by the Company to comply with the
terms of this Warrant. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. Amounts set forth or provided
for herein with respect to payments, exercises and the like (and the computation thereof) shall be
the amounts to be received by the Holder and shall not, except as expressly provided herein, be
subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Holder and that the remedy at law for any such breach may be inadequate. The Company therefore
agrees that, in the event of any such breach
10
or threatened breach, the holder of this Warrant shall be entitled, in addition to all other
available remedies, to an injunction restraining any breach, without the necessity of showing
economic loss and without any bond or other security being required. The Company shall provide all
information and documentation to the Holder that is requested by the Holder that is reasonably
necessary to enable the Holder to confirm the Companys compliance with the terms and conditions of
this Warrant. The issuance of shares and certificates for shares as contemplated hereby upon the
exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance
tax or other costs in respect thereof, provided that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than the Holder or its agent on its behalf.
17. Miscellaneous.
(a) This Warrant shall be binding on and inure to the benefit of the parties hereto and their
respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant
shall be construed to give to any Person other than the Company and the Holder any legal or
equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in
writing signed by the Company and the Holder, or their successors and assigns. No waiver shall be
effective unless it is in writing and signed by an authorized representative of the waiving party.
(b) This Warrant shall be governed by and construed and enforced in accordance with, and all
questions concerning the construction, validity, interpretation and performance of this Warrant
shall be governed by, the internal laws of the State of New York, without giving effect to any
choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York. The parties hereby irrevocably submits to the exclusive jurisdiction of the
state and federal courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. THE PARTIES HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY
TRANSACTION CONTEMPLATED HEREBY.
(c) If any provision of this Warrant is prohibited by law or otherwise determined to be
invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise
be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent
that it would be valid and enforceable, and the invalidity or unenforceability of such provision
shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant
as so modified continues to express, without material change, the original intentions of the
parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective
11
expectations or reciprocal obligations of the parties or the practical realization of the
benefits that would otherwise be conferred upon the parties. The parties will endeavor in good
faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid
provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or
unenforceable provision(s).
(d) The headings herein are for convenience only, do not constitute a part of this Warrant and
shall not be deemed to limit or affect any of the provisions hereof.
(e) In case any one or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision
in this Warrant.
(f) Prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a
Holder, be entitled to any rights of a stockholder with respect to the Warrant Shares.
18. Certain Definitions. For purposes of this Warrant, the following terms shall have
the following meanings:
(a) Bid Price means, for any security as of the particular time of determination, the bid
price for such security on the Principal Market as reported by Bloomberg as of such time of
determination, or, if the Principal Market is not the principal securities exchange or trading
market for such security, the bid price of such security on the principal securities exchange or
trading market where such security is listed or traded as reported by Bloomberg as of such time of
determination, or if the foregoing does not apply, the bid price of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg
as of such time of determination, or, if no bid price is reported for such security by Bloomberg as
of such time of determination, the average of the bid prices of any market makers for such security
as reported in the pink sheets by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.)
as of such time of determination. If the Bid Price cannot be calculated for a security as of the
particular time of determination on any of the foregoing bases, the Bid Price of such security as
of such time of determination shall be the fair market value as mutually determined by the Company
and the Holder. If the Company and the Holder are unable to agree upon the fair market value of
such security, then such dispute shall be resolved in accordance with the procedures in Section 15.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during such period.
(b) Bloomberg means Bloomberg, L.P.
(c) Business Day means any day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to remain closed.
(d) Closing Bid Price and Closing Sale Price means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the
12
Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on
an extended hours basis and does not designate the closing bid price or the closing trade price (as
the case may be) then the last bid price or last trade price, respectively, of such security prior
to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or
last trade price, respectively, of such security on the principal securities exchange or trading
market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not
apply, the last closing bid price or last trade price, respectively, of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by
Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such
security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any
market makers for such security as reported in the pink sheets by Pink Sheets LLC (formerly the
National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be
calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price
or the Closing Sale Price (as the case may be) of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder
are unable to agree upon the fair market value of such security, then such dispute shall be
resolved in accordance with the procedures in Section 15. All such determinations shall be
appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during such period.
(e) Common Stock means (i) the Companys shares of common stock, $0.01 par value per share,
and (ii) any capital stock into which such common stock shall have been changed or any share
capital resulting from a reclassification of such common stock.
(f) Eligible Market means The New York Stock Exchange, the NYSE Amex, the Nasdaq Global
Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the Principal Market.
(g) Expiration Date means the date that is the fifth (5th) anniversary of the
Original Issue Date or, if such date falls on a day other than a Business Day or on which trading
does not take place on the Principal Market (a Holiday), the next date that is not a Holiday.
(h) Parent Entity of a Person means an entity that, directly or indirectly, controls the
applicable Person and whose common stock or equivalent equity security is quoted or listed on an
Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent
Entity with the largest public market capitalization as of the date of consummation of the
Fundamental Transaction.
(i) Person means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization, any other entity or a government or any
department or agency thereof.
(j) Principal Market means the OTC Bulletin Board.
(k) Successor Entity means the Person (or, if so elected by the Holder, the Parent Entity)
formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if
13
so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall
have been entered into.
(l) Trading Day means any day on which the Common Stock is traded on the Principal Market,
or, if the Principal Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common Stock is then traded,
provided that Trading Day shall not include any day on which the Common Stock is scheduled to
trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is
suspended from trading during the final hour of trading on such exchange or market (or if such
exchange or market does not designate in advance the closing time of trading on such exchange or
market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise
designated as a Trading Day in writing by the Holder and the Company.
(m) Voting Stock of a Person means capital stock of such Person of the class or classes
pursuant to which the holders thereof have the general voting power to elect, or the general power
to appoint, at least a majority of the board of directors, managers or trustees of such Person
(irrespective of whether or not at the time capital stock of any other class or classes shall have
or might have voting power by reason of the happening of any contingency).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
SIGNATURE PAGE FOLLOWS]
14
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.
|
|
|
|
|
|
|
|
|
EMISPHERE TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
Name:
|
|
Michael R. Garone
|
|
|
|
|
Title:
|
|
Chief Financial Officer |
|
|
15
EXERCISE NOTICE
EMISPHERE TECHNOLOGIES, INC.
WARRANT NO. A-[XX] DATED __________, 2011
Ladies and Gentlemen:
(1) Form of Exercise Price. The Holder intends that payment of the Exercise Price
shall be made as:
|
|
|
|
|
____________
|
|
a Cash
Exercise with respect to
Warrant Shares; and/or
|
|
_________________ |
|
|
|
|
|
____________
|
|
a Cashless Exercise with respect to
Warrant Shares.
|
|
_______________ |
In the event that the Holder has elected a Cashless Exercise with respect to some or all of
the Warrant Shares to be issued pursuant hereto, the Holder hereby represents and warrants that (i)
this Exercise Notice was executed by the Holder at __________ [a.m.][p.m.] on the date set forth
below and (ii) if applicable, the Bid Price as of such time of execution of this Exercise Notice
was $_______.
(2) Payment of Exercise Price. In the event that the Holder has elected a Cash
Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder
shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in
accordance with the terms of the Warrant.
(3) Delivery of Warrant Shares. The Company shall deliver to Holder, or its designee
or agent as specified below, __________ Warrant Shares in accordance with the terms of the Warrant.
Delivery shall be made to Holder, or for its benefit, to the following address:
_______________________
_______________________
_______________________
_______________________
|
|
|
|
|
|
|
|
|
HOLDER |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
16
WARRANT ORIGINALLY ISSUED _________, 2011
WARRANT NO. A-[XX]
FORM OF ASSIGNMENT
To be completed and signed only upon transfer of Warrant
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto ________________
the right represented by the within Warrant to purchase ______________________ shares of Common
Stock to which the within Warrant relates and appoints __________________ attorney to transfer said
right on the books of the Company with full power of substitution in the premises.
|
|
|
|
|
|
|
|
|
Dated: |
|
|
|
TRANSFEROR: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TRANSFEREE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Print name) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Address of Transferee) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the presence of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17
Exhibit 10.1
SECURITIES PURCHASE AGREEMENT
This
SECURITIES PURCHASE AGREEMENT (the
Agreement), dated as of June 30, 2011, is by and
among Emisphere Technologies, Inc., a Delaware corporation with headquarters located at 240 Cedar
Knolls Rd, Suite 200, Cedar Knolls, New Jersey 07927 (the Company), and each of the investors
listed on the Schedule of Buyers attached hereto (individually, a Buyer and collectively, the
Buyers).
RECITALS
A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the
exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as
amended (the 1933 Act), and Rule 506 of Regulation D (Regulation D) as promulgated by the
United States Securities and Exchange Commission (the SEC) under the 1933 Act.
B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, (i) the aggregate number of shares of common stock, $0.01 par
value, of the Company (the Common Stock), set forth opposite such Buyers name in column (3) on
the Schedule of Buyers (which aggregate amount for all Buyers shall
be 4,300,438 shares of Common
Stock and shall collectively be referred to herein as the Common Shares) and (ii) a warrant to
initially acquire up to that number of shares of Common Stock set forth opposite such Buyers name
in column (4) on the Schedule of Buyers, in the form attached hereto as Exhibit A (the
Warrants) (as exercised, collectively, the Warrant Shares).
C. At the Closing (as defined below), the parties hereto shall execute and deliver a
Registration Rights Agreement, in the form attached hereto as Exhibit B (the Registration
Rights Agreement), pursuant to which the Company has agreed to provide certain registration rights
with respect to the Registrable Securities (as defined in the Registration Rights Agreement), under
the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities
laws.
D. The Common Shares, the Warrants and the Warrant Shares are collectively referred to herein
as the Securities.
AGREEMENT
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Buyer hereby agree as follows:
1. |
|
PURCHASE AND SALE OF COMMON SHARES AND WARRANTS. |
(a) Common Shares and Warrants. Subject to the satisfaction (or waiver) of the
conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each Buyer, and
each Buyer severally, but not jointly, shall purchase from the Company on the Closing Date
(as defined below), the number of Common Shares as is set forth opposite such Buyers name in
column (3) on the Schedule of Buyers along with a Warrant to initially acquire up to that number of
Warrant Shares as is set forth opposite such Buyers name in column (4) on the Schedule of Buyers.
(b) Closing. The closing (the Closing) of the purchase of the Common Shares and the
Warrants by the Buyers shall occur at the offices of Brown Rudnick LLP. The date and time
of the Closing (the Closing Date) shall be 10:00 a.m., New York time, on the first
(1st) Business Day on which the conditions to the Closing set forth in Sections 6 and 7
below are satisfied or waived (or such later date as is mutually agreed to by the Company and each
Buyer). As used herein Business Day means any day other than a Saturday, Sunday or other day on
which commercial banks in New York, New York are authorized or required by law to remain closed.
(c) Purchase Price. The aggregate purchase price for the Common Shares and the Warrants to
be purchased by each Buyer (the Purchase Price) shall be the amount set forth opposite such
Buyers name in column (5) on the Schedule of Buyers.
(d) Form of Payment. On the Closing Date, (i) each Buyer shall pay its respective
Purchase Price to the Company for the Common Shares and the Warrants to be issued and sold to such
Buyer at the Closing, by wire transfer of immediately available funds in accordance with the
Companys written wire instructions and (ii) the Company shall deliver to each Buyer (A) a copy of
the irrevocable instructions to the Companys transfer agent instructing the transfer agent to
deliver the Common Shares as is set forth opposite such Buyers name in column (3) of the Schedule
of Buyers and (B) a Warrant pursuant to which such Buyer shall have the right to initially acquire
up to the number of Warrant Shares as is set forth opposite such Buyers name in column (4) of the
Schedule of Buyers, in all cases, duly executed on behalf of the Company and registered in the name
of such Buyer or its designee (such Warrant certificate shall be delivered within three (3) Trading
Days (as defined in the Warrant) of the Closing Date).
2. |
|
BUYERS REPRESENTATIONS AND WARRANTIES. |
Each Buyer, severally and not jointly, represents and warrants to the Company with respect to
only itself that, as of the date hereof and as of the Closing Date:
(a) Organization; Authority. Such Buyer is an entity duly organized, validly existing
and in good standing under the laws of the jurisdiction of its organization with the requisite
power and authority to enter into and to consummate the transactions contemplated by the
Transaction Documents (as defined below) to which it is a party and otherwise to carry out its
obligations hereunder and thereunder.
(b) No Public Sale or Distribution. Such Buyer (i) is acquiring its Common Shares and
Warrants, and (ii) upon exercise of its Warrants, will acquire the Warrant Shares issuable upon
exercise thereof, in each case, for its own account and not with a view towards, or for resale in
connection with, the public sale or distribution thereof in violation of applicable securities
laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by
making the representations herein, such Buyer does not agree, or make any
2
representation or warranty, to hold any of the Securities for any minimum or other specific
term and reserves the right to dispose of the Securities at any time in accordance with or pursuant
to a registration statement or an exemption under the 1933 Act. Such Buyer is acquiring the
Securities hereunder in the ordinary course of its business. Such Buyer does not presently have any
agreement or understanding, directly or indirectly, with any Person (as defined below) to
distribute any of the Securities in violation of applicable securities laws.
(c) Accredited Investor Status. Such Buyer is either (i) an accredited investor as
that term is defined in Rule 501(a) of Regulation D or (ii) a qualified institutional investor as
defined in Rule 144A of the 1933 Act.
(d) Reliance on Exemptions. Such Buyer understands that the Securities are being
offered and sold to it in reliance on specific exemptions from the registration requirements of
United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Buyers compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Buyer set forth herein in order to determine
the availability of such exemptions and the eligibility of such Buyer to acquire the Securities.
(e) Information. Such Buyer and its advisors, if any, have been furnished with all
materials relating to the business, finances and operations of the Company and materials relating
to the offer and sale of the Securities which have been requested by such Buyer. Such Buyer and its
advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if
any, or its representatives shall modify, amend or affect such Buyers right to rely on the
Companys representations and warranties contained herein or any representations and warranties
contained in any other Transaction Document (as defined below) or any other document or instrument
executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby. Such Buyer understands that its investment in the Securities involves a high
degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the
Securities. Such Buyer is not relying, and has not relied, upon any statement, advice (whether
accounting, tax, financial, legal or other), representation or warranty made by the Company or any
of its affiliates or representatives except for (A) the SEC Documents (as defined below), and (B)
the representations and warranties made by the Company in this Agreement.
(f) No Governmental Review. Such Buyer understands that no United States federal or
state agency or any other government or governmental agency has passed on or made any
recommendation or endorsement of the Securities or the fairness or suitability of the investment in
the Securities nor have such authorities passed upon or endorsed the merits of the offering of the
Securities.
(g) Transfer or Resale. Such Buyer understands that except as provided in the
Registration Rights Agreement and Section 4(h) hereof: (i) the Securities have not been and are not
being registered under the 1933 Act or any state securities laws, and may not be offered for sale,
sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Buyer
3
shall have delivered to the Company (if requested by the Company) an opinion of counsel to
such Buyer, in a form reasonably acceptable to the Company, to the effect that such Securities to
be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from
such registration, or (C) such Buyer provides the Company with reasonable assurance that such
Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under
the 1933 Act (or a successor rule thereto) (collectively, Rule 144); (ii) any sale of the
Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144,
and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in
which the seller (or the Person (as defined below) through whom the sale is made) may be deemed to
be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other
exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and
(iii) neither the Company nor any other Person is under any obligation to register the Securities
under the 1933 Act or any state securities laws or to comply with the terms and conditions of any
exemption thereunder.
(h) Validity; Enforcement. This Agreement and the Registration Rights Agreement have
been duly and validly authorized, executed and delivered on behalf of such Buyer and constitute the
legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance
with their respective terms, except as such enforceability may be limited by general principles of
equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable creditors rights
and remedies.
(i) No Conflicts. The execution, delivery and performance by such Buyer of this
Agreement and the Registration Rights Agreement and the consummation by such Buyer of the
transactions contemplated hereby and thereby will not (i) result in a violation of the
organizational documents of such Buyer, (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or
instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities laws) applicable to
such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to
have a material adverse effect on the ability of such Buyer to perform its obligations hereunder.
(j) Residency. Such Buyer is a resident of that jurisdiction specified below its
address on the Schedule of Buyers.
(k) Certain Trading Activities; Confidentiality. Other than consummating the
transactions contemplated hereunder, such Buyer has not directly or indirectly, nor has any Person
acting on behalf of or pursuant to any understanding with such Buyer, engaged in any transactions
in the securities of the Company (including, without limitation, any Short Sales (as defined below)
involving the Companys securities) during the period commencing as of the time that such Buyer was
first contacted by the Company or the Placement Agent (as defined below) regarding the specific
investment in the Company contemplated by this Agreement and ending immediately prior to the
execution of this Agreement by such Buyer. Notwithstanding the foregoing, in the case of a Buyer
that is a multi-managed investment vehicle whereby
4
separate portfolio managers manage separate portions of such Buyers assets and the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Buyers assets, the representation set forth above shall only apply
with respect to the portion of assets managed by the portfolio manager that made the investment
decision to purchase the Securities covered by this Agreement. Other than to other Persons party
to this Agreement and its advisors, such Buyer has maintained the confidentiality of all
disclosures made to it in connection with this transaction (including the existence and terms of
this transaction). Short Sales means all short sales as defined in Rule 200 promulgated under
Regulation SHO under the 1934 Act (as defined below) (but shall not be deemed to include the
location and/or reservation of borrowable shares of Common Stock). Such Buyer covenants that
neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage
in any transactions in the securities of the Company (including Short Sales) prior to the time that
the transactions contemplated by this Agreement are publicly disclosed. Notwithstanding the
foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or
warranty, or preclude any actions, with respect to the identification of the availability of, or
securing of, available shares to borrow in order to effect Short Sales or similar transactions in
the future. Such Buyer (other than Bai Feng) does not as of the date hereof, and will not
immediately following the Closing, own 10% or more of the Companys issued and outstanding shares
of Common Stock (calculated based on the assumption that all Convertible Securities (as defined
below) owned by such Buyer, whether or not presently exercisable or convertible, have been fully
exercised or converted (as the case may be) but taking into account any limitations on exercise or
conversion (including blockers) contained therein).
(l) No International Sales. Such Buyer acknowledges, represents and agrees that no
action has been or will be taken in any jurisdiction outside the United States by the Company that
would permit an offering of the Securities, or possession or distribution of offering materials in
connection with the issue of the Securities in any jurisdiction outside the United States where
action for that purpose is required. Each Buyer outside the United States will comply with all
applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells
or delivers Securities or has in its possession or distributes any offering material, in all cases
at its own expense.
(m) Experience of Such Buyer. Such Buyer, either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such investment. Such Buyer is able to
bear the economic risk of an investment in the Securities and, at the present time, is able to
afford a complete loss of such investment. Such Buyer, in connection with its decision to purchase
the number of Commons Shares and Warrants set forth opposite such Buyers name on columns 3 and 4
of the Schedule of Buyers, relied only upon any or all of the following: the Companys regular
reports on Forms 10-K, 10-Q and 8-K as filed by the Company with the SEC, and other information
provided to the Buyer and the representations and warranties of the Company contained herein.
(n) No Investment Advice. Such Buyer understands that nothing in this Agreement or
any other materials presented to the Buyer in connection with the purchase and sale of the
Securities constitutes legal, tax or investment advice. Such Buyer has consulted such legal, tax
5
and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of the Securities.
3. |
|
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. |
The Company hereby represents and warrants to each of the Buyers that:
(a) Organization and Qualification; Subsidiaries. The Company is duly incorporated
and validly existing and in good standing under the laws of the State of Delaware, and has the
requisite power and authorization to own its properties and to carry on its business as described
in the Companys SEC Documents. The Company is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the
failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used
in this Agreement, Material Adverse Effect means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), or condition (financial or
otherwise) of the Company, (ii) the transactions contemplated hereby or in any of the other
Transaction Documents or (iii) the authority or ability of the Company to perform any of its
obligations under any of the Transaction Documents, provided, however, that none of the following
shall constitute, or shall be considered in determining whether there has occurred, and no event,
circumstance, change or effect resulting from or arising out of any of the following shall
constitute, a Material Adverse Effect: (A) the announcement of the execution of this Agreement; (B)
changes in the national or world economy or financial markets as a whole or changes in general
economic conditions that affect the industries in which the Company conducts its business, so long
as such changes or conditions do not adversely affect the Company in a materially disproportionate
manner relative to other similarly situated participants in the industries or markets in which they
operate; (C) any change in applicable law, rule or regulation or GAAP or interpretation thereof
after the date hereof, so long as such changes do not adversely affect the Company, in a materially
disproportionate manner relative to other similarly situated participants in the industries or
markets in which they operate; (D) the failure, in and of itself, of the Company to meet any
published or internally prepared estimates of revenues, earnings or other financial projections,
performance measures or operating statistics; provided, however, that the facts and circumstances
underlying any such failure may, except as may be provided in subsections (A), (B), (C), (E), and
(F) of this definition, be considered in determining whether a Material Adverse Effect has
occurred; (E) a decline in the price, or a change in the trading volume, of the Company Common
Stock on the Principal Market (as defined below); and (F) compliance with the terms of, and taking
any action required by, this Agreement. The Company has no significant subsidiaries (as such term
is defined in Rule 1-02(w) of Regulation S-X promulgated by the Commission) and does not own any
beneficial interest, directly or indirectly, in any corporation, partnership, joint venture or
other business entity.
(b) Authorization; Enforcement; Validity. The Company has the requisite corporate
power and authority to enter into and perform its obligations under this Agreement and the other
Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof.
The execution and delivery of this Agreement and the other Transaction Documents by the Company and
the consummation by the Company of the transactions contemplated hereby and thereby (including,
without limitation, the issuance of the Common Shares, the issuance of
6
the Warrants and the reservation for issuance and issuance of the Warrant Shares issuable upon
exercise of the Warrants) have been duly authorized by the Companys board of directors and (other
than the filing with the SEC of one or more Registration Statements in accordance with the
requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as
may be required by any state securities agencies) no further filing, consent or authorization or
action is required by the Company, its board of directors or its stockholders or other governing
body other than Required Approvals (as defined below). This Agreement has been, and the other
Transaction Documents will be prior to the Closing, duly executed and delivered by the Company, and
each constitutes the legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with its respective terms, except as such enforceability may be limited by
general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of applicable
creditors rights and remedies as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and except as rights to indemnification
and to contribution may be limited by federal or state securities law. Transaction Documents
means, collectively, this Agreement, the Warrants, the Registration Rights Agreement, the
Irrevocable Transfer Agent Instructions (as defined below) and each of the other agreements and
instruments entered into or delivered by any of the parties hereto in connection with the
transactions contemplated hereby and thereby, as may be amended from time to time.
(c) Issuance of Securities. The issuance of the Common Shares and the Warrants are
duly authorized and, upon issuance in accordance with the terms of the Transaction Documents, will
be validly issued, fully paid and non-assessable and free from all preemptive or similar rights,
taxes, liens, charges and other encumbrances with respect to the issue thereof. As of the Closing,
the Company shall have reserved from its duly authorized capital stock not less than the maximum
number of shares of Common Stock issuable upon exercise of the Warrants (without taking into
account any limitations on the exercise of the Warrants set forth therein). The issuance of the
Warrant Shares is duly authorized, and upon exercise in accordance with the Warrants, the Warrant
Shares, when issued, will be validly issued, fully paid and non-assessable and free from all
preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the
issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
Subject to the accuracy of the representations and warranties of the Buyers in this Agreement, the
offer and issuance by the Company of the Securities is exempt from registration under the 1933 Act.
(d) No Conflicts. Except as disclosed in the SEC Documents, the execution, delivery
and performance of the Transaction Documents by the Company and the consummation by the Company of
the transactions contemplated hereby and thereby (including, without limitation, the issuance of
the Common Shares, the Warrants and Warrant Shares and the reservation for issuance of the Warrant
Shares) will not (i) result in a violation of the Certificate of Incorporation (as defined below)
(including, without limitation, any certificates of designation contained therein) or other
organizational documents of the Company, any capital stock of the Company, or Bylaws, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any material agreement, indenture
or instrument to which the Company is a party, or (iii) subject to
7
Required Approvals, result in a violation of any law, rule, regulation, order, judgment or
decree (including, without limitation, federal and state securities laws and regulations and the
rules and regulations of the OTC Bulletin Board (the Principal Market)) applicable to the Company
or by which any property or asset of the Company is bound or affected except, in the case of clause
(ii) or (iii) above, to the extent such violations that could not reasonably be expected to have a
Material Adverse Effect.
(e) Consents. Except as disclosed in the SEC Documents, the Company is not required
to obtain any consent from, authorization or order of, or make any filing or registration with
(other than the filing with the SEC of one or more Registration Statements in accordance with the
requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as
may be required by any state securities agencies (collectively, the Required Approvals)), any
court, governmental agency or any regulatory or self-regulatory agency or any other Person in order
for it to execute, deliver or perform any of its obligations under, or contemplated, by the
Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents,
authorizations, orders, filings and registrations which the Company is required to obtain at or
prior to the Closing have been obtained or effected on or prior to the Closing Date, and the
Company is not aware of any facts or circumstances which might prevent the Company from obtaining
or effecting any of the registration, application or filings contemplated by the Transaction
Documents. The Company is not in violation of the requirements of the Principal Market and has no
knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of
the Common Stock in the foreseeable future.
(f) Acknowledgment Regarding Buyers Purchase of Securities. The Company acknowledges
and agrees that each Buyer is acting solely in the capacity of an arms length purchaser with
respect to the Transaction Documents and the transactions contemplated hereby and thereby and that
no Buyer (other than Bai Feng) is (i) an officer or director of the Company, (ii) an affiliate
(as defined in Rule 144) of the Company or (iii) to its knowledge, a beneficial owner of more
than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the Securities
Exchange Act of 1934, as amended (the 1934 Act)). The Company further acknowledges that no Buyer
is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any
advice given by a Buyer or any of its representatives or agents in connection with the Transaction
Documents and the transactions contemplated hereby and thereby is merely incidental to such Buyers
purchase of the Securities. The Company further represents to each Buyer that the Companys
decision to enter into the Transaction Documents has been based solely on the independent
evaluation by the Company and its representatives.
(g) No General Solicitation; Placement Agents Fees. Neither the Company, nor any of
its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D) in connection with the
offer or sale of the Securities. The Company shall be responsible for the payment of any placement
agents fees, financial advisory fees, or brokers commissions (other than for Persons engaged by
any Buyer or its investment advisor) relating to or arising out of the transactions contemplated
hereby. Other than Roth Capital Partners, LLC (the Placement Agent), the Company has not engaged
any placement agent or other agent in connection with the offer or
8
sale of the Securities.
(i) Dilutive Effect. The Company acknowledges that its obligation to issue the Warrant
Shares upon exercise of the Warrants in accordance with this Agreement and the Warrants is absolute
and unconditional, regardless of the dilutive effect that such issuance may have on the ownership
interests of other stockholders of the Company.
(j) Application of Takeover Protections; Rights Agreement. The Company and its board
of directors have taken all necessary action, if any, in order to render inapplicable any control
share acquisition, interested stockholder, business combination, poison pill (including, without
limitation, any distribution under a rights agreement) or other similar anti-takeover provision
under the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the
jurisdiction of its incorporation or otherwise which is or could become applicable to any Buyer as
a result of the transactions contemplated by this Agreement, including, without limitation, the
Companys issuance of the Securities and any Buyers ownership of the Securities. The Company and
its board of directors have taken all necessary action, if any, in order to render inapplicable any
stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of
shares of Common Stock or a change in control of the Company.
(k) SEC Documents; Financial Statements. During the two (2) years prior to the date
hereof, the Company has timely filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all
of the foregoing filed prior to the date hereof and all exhibits included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein being
hereinafter referred to as the SEC Documents). As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not
misleading. As of their respective dates, except as disclosed in the SEC Documents, the financial
statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC
with respect thereto as in effect as of the time of filing. Except as disclosed in the SEC
Documents, such financial statements have been prepared in accordance with generally accepted
accounting principles (GAAP), consistently applied, during the periods involved (except (i) as
may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case
of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial position of the
Company as of the dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments
which will not be material, either individually or in the aggregate). No other information provided
by or on behalf of the Company to any of the Buyers which is not included in the SEC Documents
(including, without limitation, information referred to in Section 2(e) of this Agreement) contains
any untrue statement of a material fact or omits to state any
9
material fact necessary in order to make the statements therein not misleading, in the light
of the circumstance under which they are or were made.
(l) Absence of Certain Changes; Solvency. Except as disclosed in the SEC Documents,
since the date of the Companys most recent audited financial statements contained in a Form 10-K,
there has been no material adverse change and no material adverse development in the business,
assets, liabilities, properties, operations (including results thereof), condition (financial or
otherwise) or prospects of the Company. Except as disclosed in the SEC Documents, since the date
of the Companys most recent audited financial statements contained in a Form 10-K, the Company has
not (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate,
outside of the ordinary course of business or (iii) made any material capital expenditures,
individually or in the aggregate. Except as disclosed in the SEC Documents, the Company has not
taken any steps to seek protection pursuant to any law or statute relating to bankruptcy,
insolvency, reorganization, receivership, liquidation or winding up, nor does the Company have any
knowledge or reason to believe that any of their respective creditors intend to initiate
involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead
a creditor to do so. Except as disclosed in the SEC Documents, the Company does not intend to
incur debts beyond its ability to pay such debts as they mature (taking into account the timing and
amounts of cash to be payable on or in respect of its debt). Except as disclosed in the SEC
Documents, the Company has no knowledge of any facts or circumstances which lead it to believe that
it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any
jurisdiction within one year from the Closing Date.
(m) No Undisclosed Events, Liabilities, Developments or Circumstances. Except as
disclosed in the SEC Documents, no event, liability, development or circumstance has occurred or
exists, or is to the Companys knowledge, reasonably expected to occur or exist, with respect to
the Company or any of their respective businesses, properties, liabilities, prospects, operations
(including results thereof) or condition (financial or otherwise) that (i) would be required to be
disclosed by the Company under applicable securities laws on a registration statement on Form S-1
filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which
has not been publicly announced, (ii) could have a material adverse effect on any Buyers
investment hereunder or (iii) could have a Material Adverse Effect.
(n) Conduct of Business; Regulatory Permits. The Company is not in violation of any
term of or in default under its Certificate of Incorporation, any certificate of designation,
preferences or rights of any other outstanding series of preferred stock of the Company or Bylaws.
Except as disclosed in the SEC Documents, the Company is not in violation of any judgment, decree
or order or any statute, ordinance, rule or regulation applicable to the Company, and the Company
will not conduct its business in violation of any of the foregoing, except in all cases for
possible violations which could not, individually or in the aggregate, have a Material Adverse
Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of
the rules, regulations or requirements of the Principal Market and has no knowledge of any facts or
circumstances that could reasonably lead to delisting or suspension of the Common Stock by the
Principal Market in the foreseeable future. Since June 9, 2009, (i) the Common Stock has been
listed or designated for quotation on the Principal Market, (ii) trading in the Common Stock has
not been suspended by the SEC or the Principal Market and (iii) the
10
Company has received no communication, written or oral, from the SEC or the Principal Market
regarding the suspension or delisting of the Common Stock from the Principal Market. The Company
possess all certificates, authorizations and permits issued by the appropriate regulatory
authorities necessary to conduct its respective businesses, except where the failure to possess
such certificates, authorizations or permits would not have, individually or in the aggregate, a
Material Adverse Effect, and the Company has not received any notice of proceedings relating to the
revocation or modification of any such certificate, authorization or permit.
(o) Foreign Corrupt Practices. Neither the Company nor, to the knowledge of the
Company, any director, officer, any agent, employee or other Person acting on behalf of the Company
has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or is in violation of any provision of
the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.
(p) Sarbanes-Oxley Act. Except as disclosed in the SEC Documents, the Company is in
material compliance with all applicable requirements of the Sarbanes-Oxley Act of 2002 that are
effective as of the date hereof, and all applicable rules and regulations promulgated by the SEC
thereunder that are effective as of the date hereof.
(q) Transactions With Affiliates. Except as disclosed in the SEC Documents or as set
forth on Schedule 3(p), none of the officers, directors or to the knowledge of the Company,
employees of the Company is presently a party to any transaction with the Company (other than for
ordinary course services as employees, officers or directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, or otherwise requiring payments to or from any such officer,
director or employee or, to the knowledge of the Company, any corporation, partnership, trust or
other Person in which any such officer, director, or employee has a substantial interest or is an
employee, officer, director, trustee or partner.
(r) Capitalization. Except as disclosed in the SEC Documents, the Company has not
issued any capital stock since its most recently filed periodic report under the 1934 Act, other
than pursuant to the exercise of employee stock options under the Companys stock option plans, the
issuance of shares of Common Stock to employees pursuant to the Companys employee stock purchase
plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of
the date of the most recently filed periodic report under the 1934 Act. Except as disclosed in the
SEC Documents or as set forth in Schedule 3(q)(i), no Person has any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents. Except as disclosed in the SEC Documents
or as set forth in Schedule 3(q)(ii), as a result of the purchase and sale of the
Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock, or contracts, commitments, understandings or
11
arrangements by which the Company is or may become bound to issue additional shares of Common
Stock or Common Stock Equivalents. Except as disclosed in the SEC Documents or as set forth in
Schedule 3(q)(iii), the issuance and sale of the Securities will not obligate the Company
to issue shares of Common Stock or other securities to any Person (other than the Buyers) and will
not result in a right of any holder of Company securities to adjust the exercise, conversion,
exchange or reset price under any of such securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and nonassessable, have been issued in
compliance with all federal and state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any stockholder, the Board of Directors or
others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Companys capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of
the Companys stockholders. Common Stock Equivalents means any securities of the Company which
would entitle the holder thereof to acquire at any time Common Stock, including, without
limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, Common Stock.
(s) Indebtedness and Other Contracts. Except as disclosed in the SEC Documents, the
Company (i) has no outstanding Indebtedness (as defined below), (ii) is not a party to any
contract, agreement or instrument, the violation of which, or default under which, by the other
party(ies) to such contract, agreement or instrument could reasonably be expected to result in a
Material Adverse Effect, (iii) is not in violation of any term of or in default under any contract,
agreement or instrument relating to any Indebtedness, except where such violations and defaults
would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is not a
party to any contract, agreement or instrument relating to any Indebtedness, the performance of
which, in the judgment of the Companys officers, has or is expected to have a Material Adverse
Effect. For purposes of this Agreement: (x) Indebtedness of any Person means, without duplication
(A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the
deferred purchase price of property or services (including, without limitation, capital leases in
accordance with generally accepted accounting principles) (other than trade payables entered into
in the ordinary course of business), (C) all reimbursement or payment obligations with respect to
letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by
notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in
connection with the acquisition of property, assets or businesses, (E) all indebtedness created or
arising under any conditional sale or other title retention agreement, or incurred as financing, in
either case with respect to any property or assets acquired with the proceeds of such indebtedness
(even though the rights and remedies of the seller or bank under such agreement in the event of
default are limited to repossession or sale of such property), (F) all monetary obligations under
any leasing or similar arrangement which, in connection with generally accepted accounting
principles, consistently applied for the periods covered thereby, is classified as a capital lease,
(G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the
holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any
mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or
assets (including accounts and contract rights) owned by any Person, even though the Person which
owns such assets or property has not assumed or
12
become liable for the payment of such indebtedness, and (H) all Contingent Obligations in
respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through
(G) above; (y) Contingent Obligation means, as to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to any indebtedness, lease, dividend or other
obligation of another Person if the primary purpose or intent of the Person incurring such
liability, or the primary effect thereof, is to provide assurance to the obligee of such liability
that such liability will be paid or discharged, or that any agreements relating thereto will be
complied with, or that the holders of such liability will be protected (in whole or in part)
against loss with respect thereto; and (z) Person means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.
(t) Absence of Litigation. Except as disclosed in the SEC Documents, there is no
action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge
of the Company, threatened against or affecting the Company, the Common Stock or any of the
Companys officers or directors which is outside of the ordinary course of business or individually
or in the aggregate would have or reasonably expect to result in a Material Adverse Effect. There
has not been, and to the knowledge of the Company, there is not pending or contemplated, any
investigation by the SEC involving the Company or any current director or officer of the Company.
The SEC has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company under the 1933 Act or the 1934 Act.
(u) Insurance. The Company is insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as management of the Company
believes to be prudent and customary in the businesses in which the Company are engaged. The
Company has not been refused any insurance coverage sought or applied for, and the Company has no
reason to believe that it will be unable to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.
(v) Employee Relations. The Company is not a party to any collective bargaining
agreement or employs any member of a union. The Company believes that its relations with its
employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933
Act) or other key employee of the Company has notified the Company that such officer intends to
leave the Company or otherwise terminate such officers employment with the Company. No executive
officer or other key employee of the Company is, or is now expected to be, in violation of any
material term of any employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any restrictive
covenant, and the continued employment of each such executive officer or other key employee (as the
case may be) does not subject the Company to any liability with respect to any of the foregoing
matters. The Company is in compliance with all federal, state and local laws and regulations
respecting labor, employment and employment practices and benefits, terms and conditions of
employment and wages and hours, except where failure to be in compliance would not, either
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
13
(w) Title. Except as disclosed in the SEC Documents or as set forth on Schedule
3(v), the Company has good and marketable title in fee simple to all real property, and have
good and marketable title to all personal property, owned by it which is material to the business
of the Company free and clear of all liens, charges, security interests, encumbrances, rights of
first refusal, preemptive rights or other restrictions (Liens), encumbrances and defects except
such as do not materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company. Any real property and facilities held
under lease by the Company are held by it under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of
such property and buildings by the Company.
(x) Intellectual Property Rights. The Company has or has adequate rights or licenses
to use all trademarks, trade names, service marks, service mark registrations, service names,
patents, patent rights, copyrights, original works, inventions, licenses, approvals, governmental
authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (Intellectual Property Rights) necessary to conduct its business as
described in the SEC Documents. None of the Companys Intellectual Property Rights have expired,
terminated or been abandoned, or are expected to expire, terminate or be abandoned, within three
years from the date of this Agreement, except as set forth in the SEC Documents or except where
such expiration, termination or abandonment would not, either individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. The Company has not received a
notice (written or otherwise) that any of the Intellectual Property Rights used by the Company
violates or infringes upon the rights of any Person. To the knowledge of the Company, all such
Intellectual Property Rights are enforceable. The Company has taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except
where failure to do so could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect.
(y) Environmental Laws. The Company (i) is in material compliance with all
Environmental Laws (as defined below), (ii) has received all permits, licenses or other approvals
required of it under applicable Environmental Laws to conduct its business and (iii) is in
compliance with all terms and conditions of any such permit, license or approval where, in each of
the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect. The term Environmental Laws
means all federal, state, local or foreign laws relating to pollution or protection of human health
or the environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata), including, without limitation, laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, Hazardous Materials) into the environment, or
otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees,
demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations issued, entered, promulgated or approved thereunder.
(z) Tax Status. Except for matters that would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect, the Company has filed all
necessary federal, state and foreign income and franchise tax returns and has paid or accrued all
14
taxes shown as due thereon, and the Company has no knowledge of a tax deficiency which has
been asserted or threatened against the Company. The Company is not operated in such a manner as
to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal
Revenue Code of 1986, as amended.
(aa) Internal Accounting and Disclosure Controls. Except as disclosed in the SEC
Documents, the Company maintains internal control over financial reporting (as such term is defined
in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including that (i) transactions are executed in accordance with
managements general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset and
liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in
accordance with managements general or specific authorization and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable
intervals and appropriate action is taken with respect to any difference. Except as disclosed in
the SEC Documents, the Company maintains disclosure controls and procedures (as such term is
defined in Rule 13a-15(e) under the 1934 Act) that are effective in ensuring that information
required to be disclosed by the Company in the reports that it files or submits under the 1934 Act
is recorded, processed, summarized and reported, within the time periods specified in the rules and
forms of the SEC, including, without limitation, controls and procedures designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under
the 1934 Act is accumulated and communicated to the Companys management, including its principal
executive officer or officers and its principal financial officer or officers, as appropriate, to
allow timely decisions regarding required disclosure. The Company presented in its most recently
filed periodic report under the 1934 Act the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on their evaluations as of the end of
the period covered by the Companys most recently filed periodic report under the 1934 Act (the
Evaluation Date). Since the Evaluation Date, there have been no changes in the Companys
internal control over financial reporting (as such term is defined in the 1934 Act) that has
materially affected, or is reasonably likely to materially affect, the Companys internal control
over financial reporting.
(bb) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other
relationship between the Company and an unconsolidated or other off balance sheet entity that is
required to be disclosed by the Company in its 1934 Act filings and is not so disclosed or that
otherwise could be reasonably likely to have a Material Adverse Effect.
(cc) Investment Company Status. The Company is not, and upon consummation of the sale
of the Securities will not be, an investment company, as such term is defined in the Investment
Company Act of 1940, as amended.
(dd) Acknowledgement Regarding Buyers Trading Activity. It is understood and
acknowledged by the Company that (i) except as set forth in Section 2(k), none of the Buyers have
been asked by the Company to agree, nor has any Buyer agreed with the Company, to desist from
effecting any transactions in or with respect to (including, without limitation, purchasing or
selling, long and/or short) any securities of the Company, or derivative securities
15
based on securities issued by the Company or to hold any of the Securities for any specified
term; (ii) past or future open market or other transactions by any Buyer, specifically including,
without limitation, Short Sales or derivative transactions, before or after the closing of this
or future private placement transactions, may negatively impact the market price of the Companys
publicly-traded securities; (iii) any Buyer, and counterparties in derivative transactions to
which any such Buyer is a party, directly or indirectly, presently may have a short position in
the Common Stock which was established prior to such Buyers knowledge of the transactions
contemplated by the Transaction Documents; and (iv) each Buyer shall not be deemed to have any
affiliation with or control over any arms length counterparty in any derivative transaction. The
Company further understands and acknowledges that, subject to Section 2(k), (a) one or more Buyers
may engage in hedging and/or trading activities at various times during the period that the
Securities are outstanding, including, without limitation, during the periods that the value and/or
number of the Warrant Shares deliverable with respect to the Securities are being determined and
(b) such hedging and/or trading activities, if any, can reduce the value of the existing
stockholders equity interest in the Company both at and after the time the hedging and/or trading
activities are being conducted. The Company acknowledges that such aforementioned hedging and/or
trading activities do not constitute a breach of this Agreement or any other Transaction Document
or any of the documents executed in connection herewith or therewith.
(ee) Manipulation of Price. The Company has not, and, to the knowledge of the Company,
no Person acting on its behalf has, directly or indirectly, (i) taken any action designed to cause
or to result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any
compensation for soliciting purchases of, any of the Securities (other than the Placement Agent),
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase
any other securities of the Company.
(ff) U.S. Real Property Holding Corporation. The Company is not nor has ever been, a
U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue
Code of 1986, as amended, and the Company shall so certify upon any Buyers request.
(gg) Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other
than income or similar taxes) which are required to be paid in connection with the issuance, sale
and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been
complied with.
(hh) Bank Holding Company Act. The Company is not subject to the Bank Holding Company
Act of 1956, as amended (the BHCA) and to regulation by the Board of Governors of the Federal
Reserve System (the Federal Reserve). Neither the Company nor any of its affiliates owns or
controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class
of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any
equity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company
nor any of its affiliates exercises a controlling influence over the management or policies of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
16
(ii) Shell Company Status. The Company is not, and has never been, an issuer
identified in, or subject to, Rule 144(i).
(jj) Public Utility Holding Act. The Company is not a holding company, or an
affiliate of a holding company, as such terms are defined in the Public Utility Holding Act of
2005.
(kk) Federal Power Act. The Company is not subject to regulation as a public
utility under the Federal Power Act, as amended.
(ll) FDA. Except as disclosed in the SEC Documents, as to each product subject to the
jurisdiction of the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug and
Cosmetic Act, as amended, and the regulations thereunder (FDCA) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a
Pharmaceutical Product), such Pharmaceutical Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable
requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing
practices, good laboratory practices, good clinical practices, product listing, quotas, labeling,
advertising, record keeping and filing of reports, except where the failure to be in compliance
would not have a Material Adverse Effect. Except as disclosed in the SEC Documents, there is no
pending, completed or, to the Companys knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or
investigation) against the Company, and the Company has not received any notice, warning letter or
other communication from the FDA or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the
manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure
of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating
to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the
Company, (iv) enjoins production at any facility of the Company, (v) enters or proposes to enter
into a consent decree of permanent injunction with the Company, or (vi) otherwise alleges any
violation of any laws, rules or regulations by the Company, and which, either individually or in
the aggregate, would have a Material Adverse Effect. Except as disclosed in the SEC Documents, the
properties, business and operations of the Company have been and are being conducted in all
material respects in accordance with all applicable laws, rules and regulations of the FDA.
Except as disclosed in the SEC Documents, the Company has not been informed by the FDA that the FDA
will prohibit the marketing, sale, license or use in the United States of any product proposed to
be developed, produced or marketed by the Company nor has the FDA to the Companys knowledge
expressed any concern as to approving or clearing for marketing any product being developed or
proposed to be developed by the Company.
(mm) Money Laundering. The Company is in compliance with, and has not previously
violated, the USA Patriot Act of 2001 and any other applicable U.S. and non-U.S. anti-money
laundering laws and regulations, including, but not limited to, the laws, regulations and Executive
Orders and sanctions programs administered by the U.S. Office of Foreign Assets
17
Control, including, but not limited, to (i) Executive Order 13224 of September 23, 2001
entitled, Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to
Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31
CFR, Subtitle B, Chapter V.
(nn) Management. Except as disclosed in the SEC Documents, during the past five year
period, no current officer or director has been the subject of:
(i) a petition under bankruptcy laws or any other insolvency or moratorium law or the
appointment by a court of a receiver, fiscal agent or similar officer for such Person, or
any partnership in which such person was a general partner at, or any corporation or
business association of which such person was an executive officer at;
(ii) a conviction in a criminal proceeding or a named subject of a pending criminal
proceeding (excluding traffic violations that do not relate to driving while intoxicated or
driving under the influence);
(iii) any order, judgment or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining any such person
from, or otherwise limiting, the following activities:
(1) Acting as a futures commission merchant, introducing broker, commodity
trading advisor, commodity pool operator, floor broker, leverage transaction
merchant, any other person regulated by the United States Commodity Futures Trading
Commission or an associated person of any of the foregoing, or as an investment
adviser, underwriter, broker or dealer in securities, or as an affiliated person,
director or employee of any investment company, bank, savings and loan association
or insurance company, or engaging in or continuing any conduct or practice in
connection with such activity;
(2) Engaging in any type of business practice; or
(3) Engaging in any activity in connection with the purchase or sale of any
security or commodity or in connection with any violation of securities laws or
commodities laws;
(iv) any order, judgment or decree, not subsequently reversed, suspended or vacated, of
any authority barring, suspending or otherwise limiting for more than 60 days the right of
any such person to engage in any activity described in the preceding sub paragraph, or to be
associated with persons engaged in any such activity;
(v) a finding by a court of competent jurisdiction in a civil action or by the SEC or
other authority to have violated any securities law, regulation or decree and the judgment
in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or
(vi) a finding by a court of competent jurisdiction in a civil action or by the
Commodity Futures Trading Commission to have violated any federal commodities law,
18
and the judgment in such civil action or finding has not been subsequently reversed,
suspended or vacated.
(oo) No Additional Agreements. The Company does not have any agreement or
understanding with any Buyer with respect to the transactions contemplated by the Transaction
Documents other than as specified in the Transaction Documents.
(pp) Disclosure. The Company confirms that neither it nor any other Person acting on
its behalf has provided any of the Buyers or their agents or counsel with any information that
constitutes or could reasonably be expected to constitute material, non-public information
concerning the Company, other than the existence of the transactions contemplated by this Agreement
and the other Transaction Documents. The Company understands and confirms that each of the Buyers
will rely on the foregoing representations in effecting transactions in securities of the Company.
All disclosure provided to the Buyers regarding the Company, its business and the transactions
contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the
Company is true and correct and does not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. Each press release issued by the Company
during the twelve (12) months preceding the date of this Agreement did not at the time of release
contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they are made, not misleading. No event or circumstance has occurred or
information exists with respect to the Company or its business, properties, liabilities, prospects,
operations (including results thereof) or conditions (financial or otherwise), which, under
applicable law, rule or regulation, requires public disclosure at or before the date hereof or
announcement by the Company but which has not been so publicly disclosed. The Company acknowledges
and agrees that no Buyer makes or has made any representations or warranties with respect to the
transactions contemplated hereby other than those specifically set forth in Section 2.
(a) Best Efforts. Each Buyer shall use its reasonable best efforts to timely satisfy
each of the conditions to be satisfied by it as provided in Section 6 of this Agreement. The
Company shall use its reasonable best efforts to timely satisfy each of the conditions to be
satisfied by it as provided in Section 7 of this Agreement.
(b) Form D and Blue Sky. The Company shall file a Form D with respect to the
Securities as required under Regulation D. The Company shall, on or before the Closing Date, take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to, qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement
under applicable securities or Blue Sky laws of the states of the United States (or to obtain an
exemption from such qualification) if so required by such applicable state laws. Without limiting
any other obligation of the Company under this Agreement, the Company shall timely make all filings
and reports relating to the offer and sale of the Securities required under all applicable
securities laws (including, without limitation, all applicable federal securities laws and all
applicable Blue Sky laws), and the Company shall comply with all applicable federal,
19
state and local laws, statutes, rules, regulations and the like relating to the offering and
sale of the Securities to the Buyers.
(c) Reporting Status. Until the date on which the Buyers shall have sold all of the
Registrable Securities (the Reporting Period), the Company shall timely file all reports required
to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status
as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and
regulations thereunder would no longer require or otherwise permit such termination.
(d) Use of Proceeds. The Company shall use the proceeds from the sale of the
Securities solely as set forth on Schedule 4(d), and, without limitation of the foregoing,
except as set forth on Schedule 4(d), none of such proceeds shall be used, directly or
indirectly, for (i) the satisfaction of any debt of the Company (other than payment of trade
payables incurred after the date hereof in the ordinary course of business of the Company and
consistent with prior practices), (ii) the redemption of any securities of the Company or (iii) the
settlement of any outstanding litigation.
(e) Financial Information. The Company agrees to send the following to each Investor
(as defined in the Registration Rights Agreement) during the Reporting Period (i) unless the
following are filed with the SEC through EDGAR and are available to the public through the EDGAR
system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim reports or any consolidated
balance sheets, income statements, stockholders equity statements and/or cash flow statements for
any period other than annual, any Current Reports on Form 8-K and any registration statements
(other than on Form S-8) or amendments filed pursuant to the 1933 Act and (ii) copies of any
notices and other information made available or given to the stockholders of the Company generally,
contemporaneously with the making available or giving thereof to the stockholders. Notwithstanding
the foregoing, nothing in this Section 4(e) shall require the Company to disclose to any Investor
any redacted part of any filing in which the Company has requested confidential treatment by the
SEC.
(f) Listing. The Company shall promptly secure the listing or designation for
quotation (as the case may be) of all of the Registrable Securities upon each national securities
exchange and automated quotation system, if any, upon which the Common Stock is then listed or
designated for quotation (as the case may be) (subject to official notice of issuance) (but in no
event later than the Closing Date) and shall maintain such listing or designation for quotation (as
the case may be) of all Registrable Securities from time to time issuable under the terms of the
Transaction Documents on such national securities exchange or automated quotation system. The
Company further agrees, if the Company applies to have the Common Stock traded on any other
national securities exchange or automated quotation system, it will then include in such
application all of the Registrable Securities, and will take such other action as is necessary to
cause all of the Registrable Securities to be listed or quoted on such other exchange as promptly
as possible. The Company shall maintain the Common Stocks designation for quotation (as the case
may be) on the Principal Market, or, if applicable, listing on The NYSE Amex, The New York Stock
Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market
(as the case may be) (each, an Eligible Market), and shall take all action reasonably necessary
to continue the listing and trading of its Common Stock on an
20
Eligible Market and will comply in all respects with the Companys reporting, filing, and
other obligations under the bylaws or rules of such Eligible Market. The Company shall not take
any action which could be reasonably expected to result in the delisting or suspension of the
Common Stock on an Eligible Market. The Company shall pay all fees and expenses in connection with
satisfying its obligations under this Section 4(d).
(g) Fees. The Company shall be responsible for the payment of any placement agents
fees, financial advisory fees, or brokers commissions (other than for Persons engaged by any
Buyer) relating to or arising out of the transactions contemplated hereby (including, without
limitation, any fees payable to the Placement Agent, who is the Companys sole placement agent in
connection with the transactions contemplated by this Agreement). The Company shall pay, and hold
each Buyer harmless against, any liability, loss or expense (including, without limitation,
reasonable attorneys fees and out-of-pocket expenses) arising in connection with any claim
relating to any such payment. Except as otherwise set forth in the Transaction Documents, each
party to this Agreement shall bear its own expenses in connection with the sale of the Securities
to the Buyers.
(h) Pledge of Securities. Notwithstanding anything to the contrary contained in this
Agreement, the Company acknowledges and agrees that the Securities may be pledged by a Buyer in
connection with a bona fide margin agreement or other loan or financing arrangement that is secured
by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or
assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities shall be
required to provide the Company with any notice thereof or otherwise make any delivery to the
Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees to
execute and deliver such documentation as a pledgee of the Securities may reasonably request in
connection with a pledge of the Securities to such pledgee by a Buyer.
(i) Disclosure of Transactions and Other Material Information. The Company shall, on
or before 9:30 a.m., New York time, (but in no event prior to 9:15 a.m., New York time) on the date
of this Agreement, issue a press release (the Press Release) reasonably acceptable to the Buyers
disclosing all the material terms of the transactions contemplated by the Transaction Documents. On
or before 9:30 a.m., New York time, (but in no event prior to 9:15 a.m., New York time) on the date
of this Agreement, the Company shall file a Current Report on Form 8-K describing all the material
terms of the transactions contemplated by the Transaction Documents in the form required by the
1934 Act and attaching all the material Transaction Documents (including, without limitation, this
Agreement, the form of Warrants and the form of the Registration Rights Agreement) (including all
attachments, the 8-K Filing). From and after the issuance of the Press Release, the Company
shall have disclosed all material, non-public information (if any) delivered to any of the Buyers
by the Company, or any of its officers, directors, employees or agents in connection with the
transactions contemplated by the Transaction Documents. The Company shall not, and the Company
shall cause each of its officers, directors, employees and agents, not to, provide any Buyer with
any material, non-public information regarding the Company from and after the issuance of the Press
Release without the express prior written consent of such Buyer. Neither the Company nor any Buyer
shall issue any press releases or any other public statements with respect to the transactions
contemplated hereby; provided, however, the Company shall be entitled, without the prior approval
of any Buyer, to make any press release or other public disclosure with respect to such
21
transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith
and (ii) as is required by applicable law and regulations (provided that in the case of clause (i)
each Buyer shall be consulted by the Company in connection with any such press release or other
public disclosure prior to its release). Other than in the Securities Purchase Agreement attached
to the 8-K Filing, without the prior written consent of the applicable Buyer, the Company shall not
(and shall cause each of affiliates to not) disclose the name of such Buyer in any filing,
announcement, release or otherwise.
(j) Additional Issuance of Securities. The Company agrees that for the period
commencing on the date hereof and ending on the date immediately following the earlier to occur of
(i) the thirtieth (30th) Trading Day after the earlier of (x) the Applicable Date (as defined
below) and (y) the first date on which Rule 144 is available for the sale of any Securities and
(ii) the three (3) month anniversary of the Closing Date (the Restricted Period), the Company
shall not directly or indirectly issue, offer, sell, grant any option or right to purchase, or
otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to
purchase or other disposition of) any equity security or any equity-linked security (including,
without limitation, any equity security (as that term is defined under Rule 405 promulgated under
the 1933 Act), any Convertible Securities or any preferred stock) (any such issuance, offer, sale,
grant, disposition or announcement (whether occurring during the Restricted Period or at any time
thereafter) is referred to as a Subsequent Placement), unless each purchaser (each a Subsequent
Purchaser) of securities in such Subsequent Placement (including, without limitation, any
securities issuable upon conversion, exercise or exchange thereof) (collectively, the Subsequent
Placement Securities) irrevocably agrees that during the Restricted Period it will not, directly
or indirectly, sell, offer to sell, contract or agree to sell, or grant any option to purchase any
Subsequent Placement Securities pursuant to an effective registration statement or usable
prospectus or in reliance on the Section 4(1) exemption under the 1933 Act (the foregoing
restrictions are referred to as the Subsequent Transfer Restrictions). For the avoidance of
doubt, Subsequent Transfer Restrictions shall not include (A) any sale, offer to sell, contract or
agreement to sell any of the Subsequent Placement Securities directly or indirectly to any Person
in a private sale transaction in reliance on the 4(11/2) exemption under the 1933 Act, or (B) any
sales, transfers, grants or gifts of any Subsequent Placement Securities to (i) any spouse or
lineal descendants, heirs, executors, administrators, testamentary trustees, legatees or
beneficiaries of such Subsequent Purchaser; (ii) any trust, charitable trust, or any corporation,
limited liability company, partnership or other entity, the stockholders, members, general or
limited partners or owners of which include only such Subsequent Purchaser or its affiliates, or
(iii) any affiliate of such Subsequent Purchaser (collectively, a Permitted Transferee), so long
as each such Permitted Transferee, prior to acquisition of any Subsequent Placement Securities,
agrees in writing with the Company to be bound by the Subsequent Transfer Restrictions with respect
to all Subsequent Placement Securities such Permitted Transferee acquires. Notwithstanding the
foregoing, this Section 4(j) shall not apply to the issuance of: (A) shares of Common Stock or
standard options to purchase Common Stock to directors, officers, consultants or employees of the
Company in their capacity as such pursuant to an Approved Share Plan (as defined below), (B) shares
of Common Stock issued upon the conversion or exercise of Convertible Securities (other than
standard options to purchase Common Stock issued pursuant to an Approved Share Plan that are
covered by clause (A) above) issued prior to the date hereof, provided, that, none of the terms or
conditions of any such Convertible Securities (other than standard options to purchase Common Stock
issued pursuant to an Approved Share Plan that are covered by clause
22
(A) above) are otherwise materially changed (except pursuant to the terms thereof) in any
manner that adversely affects any of the Buyers, (C) the Warrant Shares, (D) any securities issued
in the Concurrent Offering or any securities issued upon the exercise or conversion of any
securities issued in connection therewith, including but not limited to any securities issued in
connection with the Waiver Agreement, dated as of the date hereof, between the Company and the
holders of the MHR Securities (as defined in the Warrants), (E) any equity security, any equity
linked security, any Convertible Securities, or any preferred stock issued or issuable in
connection with bona fide, arms length bank financings, corporate partnering or intellectual
property licensing transactions, equipment leases or acquisitions of all or any portion of a
business or its assets whether by merger, stock or asset purchase or any other bona fide strategic
transaction (each a Strategic Transaction) on terms approved by the Companys board of directors,
provided that (x) the primary purpose of such issuance is not to raise capital, (y) the purchasers
or acquirers of the securities in such issuance does not include an entity whose primary business
is investing in securities and (z) the number or amount of securities issued to any Person by the
Company shall not be disproportionate to such Persons actual participation in such Strategic
Transaction or ownership of such assets or securities to be acquired by the Company in such
Strategic Transaction, as applicable, (F) any equity security, equity linked security, any
Convertible Securities or preferred stock issued by the Company to all holders of Common Stock or
any other class of Company capital stock, pro rata (including without limitation, in connection
with a recapitalization, stock split, reverse stock split or rights offering), including any equity
security, equity linked security, Convertible Security or preferred stock issuable upon exercise or
conversion of such Convertible Securities, and (G) any equity security, any equity linked security,
any Convertible Securities, or any preferred stock to the holders of the Companys equity
securities or any equity-linked securities, any Convertible Securities or any preferred stock in
connection with the waiver of any of such holders anti-dilution rights in connection with any
Subsequent Placement, provided that the consideration being provided to such holder for such waiver
is on terms approved by the Companys board of directors as advised by independent member(s) of the
Board (each of the foregoing in clauses (A) through (G), collectively the Excluded Securities).
Approved Share Plan means any employee benefit plan which has been approved by the board of
directors of the Company prior to or subsequent to the date hereof pursuant to which shares of
Common Stock and standard options to purchase Common Stock may be issued to any employee, officer,
consultant or director for services provided to the Company in their capacity as such. Convertible
Securities means any capital stock or other security of the Company that is at any time and under
any circumstances directly or indirectly convertible into, exercisable or exchangeable for, or
which otherwise entitles the holder thereof to acquire, any capital stock or other security of the
Company (including, without limitation, Common Stock). Applicable Date means the first date on
which the resale by the Buyers of all Registrable Securities is covered by one or more effective
Registration Statements (as defined in the Registration Rights Agreement) (and each prospectus
contained therein is available for use on such date).
(k) Reservation of Shares. So long as any of the Warrants remain outstanding, the
Company shall take all action necessary to at all times have authorized, and reserved for the
purpose of issuance, no less than the maximum number of shares of Common Stock issuable upon
exercise of all the Warrants (without regard to any limitations on the exercise of the Warrants set
forth therein).
23
(l) Conduct of Business. The business of the Company shall not be conducted in
violation of any law, ordinance or regulation of any governmental entity, except where such
violations would not result, either individually or in the aggregate, in a Material Adverse Effect.
(m) Passive Foreign Investment Company. The Company shall conduct its business in
such a manner as will ensure that the Company will not be deemed to constitute a passive foreign
investment company within the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as
amended.
(n) Closing Documents. Within a reasonable time after the Closing Date, the Company
agrees to deliver, or cause to be delivered, to each Buyer and [insert placement agent counsel]
executed copies of the Transaction Documents, Securities and other document required to be
delivered to any party pursuant to Section 7 hereof.
(o) Delivery of Warrants After Closing. The Company shall deliver, or cause to be
delivered, the respective Warrants purchased by each Buyer to such Buyer within three (3) Trading
Days of the Closing Date.
(p) Shareholder Rights Plan. No claim will be made or enforced by the Company or, with
the consent of the Company, any other Person, that any Buyer is an Acquiring Person under any
control share acquisition, business combination, poison pill (including any distribution under a
rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Buyer could be deemed to trigger the provisions of any such plan or
arrangement, by virtue of receiving Securities under the Transaction Documents.
5. |
|
REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND. |
(a) Register. The Company shall maintain at its principal executive offices (or such
other office or agency of the Company as it may designate by notice to each holder of Securities),
a register for the Warrants in which the Company shall record the name and address of the Person in
whose name the Warrants have been issued (including the name and address of each transferee), the
number of Warrant Shares issuable upon exercise of the Warrants held by such Person. The Company
shall keep the register open and available for inspection during business hours, upon reasonable
request of any Buyer or its legal representatives.
(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to
its transfer agent and any subsequent transfer agent in a form acceptable to each of the Buyers
(the Irrevocable Transfer Agent Instructions) to issue certificates or credit shares to the
applicable balance accounts at The Depository Trust Company (DTC), registered in the name of each
Buyer or its respective nominee(s), for the Common Shares and the Warrant Shares in such amounts as
specified from time to time by each Buyer to the Company upon delivery of the Common Shares or the
exercise of the Warrants (as the case may be). The Company represents and warrants that no
instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section
5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the
Company to its transfer agent with respect to the Securities, and that the Securities shall
otherwise be freely transferable on the books and records of the Company, as applicable, to the
extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a
24
sale, assignment or transfer of the Securities in accordance with Section 2(g), the Company
shall permit the transfer and shall promptly instruct its transfer agent to issue one or more
certificates or credit shares to the applicable balance accounts at DTC in such name and in such
denominations as specified by such Buyer to effect such sale, transfer or assignment. In the event
that such sale, assignment or transfer involves Common Shares or Warrant Shares sold, assigned or
transferred pursuant to an effective registration statement or in compliance with Rule 144, the
transfer agent shall issue such shares to such Buyer, assignee or transferee (as the case may be)
without any restrictive legend in accordance with Section 5(d) below. The Company acknowledges that
a breach by it of its obligations hereunder will cause irreparable harm to each Buyer. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Section
5(b) will be inadequate and agrees, in the event of a breach or threatened breach by the Company of
the provisions of this Section 5(b), that each Buyer shall be entitled, in addition to all other
available remedies, to an order and/or injunction restraining any breach and requiring immediate
issuance and transfer, without the necessity of showing economic loss and without any bond or other
security being required. The Company shall cause its counsel to issue such legal opinions as may be
requested from time to time in order to enable the sale of the Securities pursuant to the terms
hereof Any fees (with respect to the transfer agent, counsel to the Company or otherwise)
associated with the issuance of such opinion or the removal of any legends on any of the Securities
shall be borne by the Company.
(c) Legends. Each Buyer understands that the Securities have been issued (or will be
issued in the case of the Warrant Shares) pursuant to an exemption from registration or
qualification under the 1933 Act and applicable state securities laws, and except as set forth
below, the Securities shall bear any legend as required by the blue sky laws of any state and a
restrictive legend in substantially the following form (and a stop-transfer order may be placed
against transfer of such stock certificates):
[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR
THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE] HAVE BEEN][THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE
ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF
REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE
SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE
FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
25
(d) Removal of Legends. Certificates evidencing Securities shall not be required to
contain the legend set forth in Section 5(c) above or any other legend (i) while a registration
statement (including a Registration Statement) covering the resale of such Securities is effective
under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the
transferor is not an affiliate of the Company), (iii) if such Securities are eligible to be sold,
assigned or transferred under Rule 144 (provided that a Buyer provides the Company with reasonable
assurances that such Securities are eligible for sale, assignment or transfer under Rule 144 which
shall not include an opinion of counsel), (iv) in connection with a sale, assignment or other
transfer (other than under Rule 144), provided that such Buyer provides the Company with an opinion
of counsel to such Buyer, in a generally acceptable form, to the effect that such sale, assignment
or transfer of the Securities may be made without registration under the applicable requirements of
the 1933 Act or (v) if such legend is not required under applicable requirements of the 1933 Act
(including, without limitation, controlling judicial interpretations and pronouncements issued by
the SEC). If a legend is not required pursuant to the foregoing, the Company shall no later than
three (3) Trading Days following the delivery by a Buyer to the Company or the transfer agent (with
notice to the Company) of a legended certificate representing such Securities (endorsed or with
stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the
reissuance and/or transfer, if applicable), together with any other deliveries from such Buyer as
may be required above in this Section 5(d), as directed by such Buyer, either: (A) provided that
the Companys transfer agent is participating in the DTC Fast Automated Securities Transfer Program
and such Securities are Common Shares or Warrant Shares, credit the aggregate number of shares of
Common Stock to which such Buyer shall be entitled to such Buyers or its designees balance
account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Companys
transfer agent is not participating in the DTC Fast Automated Securities Transfer Program, issue
and deliver (via reputable overnight courier) to such Buyer, a certificate representing such
Securities that is free from all restrictive and other legends, registered in the name of such
Buyer or its designee (the date by which such credit is so required to be made to the balance
account of such Buyers or such Buyers nominee with DTC or such certificate is required to be
delivered to such Buyer pursuant to the foregoing is referred to herein as the Required Delivery
Date).
(e) Failure to Timely Deliver; Buy-In. If the Company fails to (i) issue and deliver
(or cause to be delivered) to a Buyer by the Required Delivery Date a certificate representing the
Securities so delivered to the Company by such Buyer that is free from all restrictive and other
legends or (ii) credit the balance account of such Buyers or such Buyers nominee with DTC for
such number of shares of Common Shares or Warrant Shares so delivered to the Company, and if on or
after the Required Delivery Date such Buyer purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by such Buyer of shares of Common Stock
that such Buyer anticipated receiving from the Company without any restrictive legend, then, in
addition to all other remedies available to such Buyer, the Company shall, within three (3) Trading
Days after such Buyers request and in such Buyers sole discretion, either (i) pay cash to such
Buyer in an amount equal to such Buyers total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased (the Buy-In Price), at which point the Companys
obligation to deliver such certificate or credit such Buyers balance account shall terminate and
such shares shall be cancelled, or (ii) promptly honor its obligation to deliver to such Buyer a
certificate or certificates or credit such Buyers DTC account representing such number of shares
of Common Stock that would have been issued
26
if the Company timely complied with its obligations hereunder and pay cash to such Buyer in an
amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Shares or Warrant Shares (as the case may be) that the Company was required to
deliver to such Buyer by the Required Delivery Date times (B) the Closing Sale Price of the Common
Stock on the Trading Day immediately preceding the Required Delivery Date.
6. |
|
CONDITIONS TO THE COMPANYS OBLIGATION TO SELL. |
(a) The obligation of the Company hereunder to issue and sell the Common Shares and the
related Warrants to each Buyer at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions, provided that these conditions are for the
Companys sole benefit and may be waived by the Company at any time in its sole discretion by
providing each Buyer with prior written notice thereof:
(i) Such Buyer shall have executed each of the other Transaction Documents to which it
is a party and delivered the same to the Company.
(ii) Such Buyer and each other Buyer shall have delivered to the Company the Purchase
Price for the Common Shares and the related Warrants being purchased by such Buyer at the
Closing by wire transfer of immediately available funds pursuant to the wire instructions
provided by the Company.
(iii) The representations and warranties of such Buyer shall be true and correct in all
material respects (except for those representations and warranties that are qualified by
materiality or Material Adverse Effect, which shall be true and correct in all respects) as
of the date when made and as of the Closing Date as though originally made at that time
(except for representations and warranties that speak as of a specific date, which shall be
true and correct as of such date), and such Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by such Buyer at or prior to the
Closing Date.
7. |
|
CONDITIONS TO EACH BUYERS OBLIGATION TO PURCHASE. |
(a) The obligation of each Buyer hereunder to purchase the Common Shares and the related
Warrants at the Closing is subject to the satisfaction, at or before the Closing Date, of each of
the following conditions, provided that these conditions are for each Buyers sole benefit and may
be waived by such Buyer at any time in its sole discretion by providing the Company with prior
written notice thereof:
(i) The Company shall have duly executed and delivered to such Buyer (A) each of the
other Transaction Documents and (B) a copy of the irrevocable instructions to the Companys
transfer agent instructing the transfer agent to deliver the Common Shares (in the number as
is set forth across from such Buyers name in column (3) of the Schedule of Buyers) and the
related Warrants (for the number of Warrant Shares as is set forth across from such Buyers
name in column (4) of the Schedule of Buyers) (such Warrant certificate may be delivered
within three (3) Trading Days of the Closing Date) being purchased by such Buyer at the
Closing pursuant to this Agreement.
27
(ii) Such Buyer shall have received the opinion of Brown Rudnick LLP, the
Companys counsel, dated as of the Closing Date, in the form acceptable to such Buyer.
(iii) The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer
Agent Instructions, in the form acceptable to such Buyer, which instructions shall have been
delivered to and acknowledged in writing by the Companys transfer agent.
(iv) The Company shall have delivered to such Buyer a certificate evidencing the
formation and good standing of the Company issued by the Secretary of State of the State of
Delaware as of a date within ten (10) days of the Closing Date.
(v) The Company shall have delivered to such Buyer a certificate evidencing the
Companys qualification as a foreign corporation and good standing issued by the Secretary
of State of the State of New Jersey and the Secretary of State of the State of New York, as
of a date within ten (10) days of the Closing Date.
(vi) The Company shall have delivered to such Buyer a certificate, in the form
acceptable to such Buyer, executed by the Secretary of the Company and dated as of the
Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the
Companys board of directors in a form reasonably acceptable to such Buyer, (ii) the
Certificate of Incorporation and (iii) the Bylaws, each as in effect at the Closing.
(vii) Each and every representation and warranty of the Company shall be true and
correct in all material respects (except for those representations and warranties that are
qualified by materiality or Material Adverse Effect, which shall be true and correct in all
respects) as of the date when made and as of the Closing Date as though originally made at
that time (except for representations and warranties that speak as of a specific date) and
the Company shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required to be performed, satisfied or complied with by
the Company at or prior to the Closing Date. Such Buyer shall have received a certificate,
executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the
foregoing effect and as to such other matters as may be reasonably requested by such Buyer
in the form acceptable to such Buyer.
(viii) The Company shall have delivered to such Buyer a letter from the Companys
transfer agent certifying the number of shares of Common Stock outstanding on the Closing
Date immediately prior to the Closing.
(ix) The Common Stock (I) shall be designated for quotation or listed on the Principal
Market and (II) shall not have been suspended, as of the Closing Date, by the SEC or the
Principal Market from trading on the Principal Market nor shall suspension by the SEC or the
Principal Market have been threatened, as of the Closing Date, either (A) in writing by the
SEC or the Principal Market or (B) by falling below the minimum maintenance requirements of
the Principal Market.
28
(x) The Company shall have obtained all governmental, regulatory or third party
consents and approvals, if any, necessary for the sale of the Securities, including without
limitation, those required by the Principal Market.
(xi) No statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental authority
of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.
(xii) Since the date of execution of this Agreement, no event or series of events shall
have occurred that reasonably would have or result in a Material Adverse Effect.
(xiii) Such Buyer shall have received a letter on the letterhead of the Company, duly
executed by an appropriate officer of the Company, setting forth the wire instructions of
the Company.
(xiv) Such Buyer shall have received (A) a duly executed copy of the Securities
Purchase Agreement, by and between the Company and MHR Fund Management, LLC (MHR) and/or
certain of MHRs affiliates (collectively, the MHR Purchasers), dated as of the date
hereof (the MHR Agreement) with respect to an
offering of an aggregate of 4,300,438 shares
of Common Stock and related warrants (in the form of the Warrants) to
purchase 3,010,307 shares of Common Stock for an aggregate purchase
price of $0.872 (the MHR Purchase
Price), pursuant to the terms hereof, (B) evidence reasonably satisfactory to such Buyer of
the closing of the transactions contemplated by the MHR Agreement shall have occurred, (C)
evidence reasonably satisfactory to such Buyer that the Company shall have received the MHR
Purchase Price from the MHR Purchasers by one or more wire transfers of U.S. dollars and
immediately available funds and (D) a duly executed copy of the Waiver Agreement (as defined
in the MHR Agreement) (the foregoing transactions, collectively, the Concurrent Offering).
(xv) The Company shall have delivered to such Buyer such other documents, instruments
or certificates relating to the transactions contemplated by this Agreement as such Buyer or
its counsel may reasonably request.
In the event that the Closing shall not have occurred with respect to a Buyer within five (5)
Business
days of the date hereof, then such Buyer shall have the right to terminate its obligations under
this Agreement with respect to itself at any time on or after the close of business on such date
without liability of such Buyer to any other party; provided, however, (i) the right to terminate
this Agreement under this Section 8 shall not be available to such Buyer if the failure of the
transactions contemplated by this Agreement to have been consummated by such date is the result of
such Buyers breach of this Agreement and (ii) the abandonment of the sale and purchase of the
Common Shares and the Warrants shall be applicable only to such Buyer providing such written
notice. Nothing contained in this Section 8 shall be deemed to release any party from any liability
for any breach by such party of the terms and provisions of this
29
Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other
Transaction Documents.
(a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by the
internal laws of the State of New York, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Each party hereby irrevocably waives personal service of process and consents to
process being served in any such suit, action or proceeding by mailing a copy thereof to such party
at the address for such notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL
FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
(b) Counterparts. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party. In the
event that any signature is delivered by facsimile transmission or by an e-mail which contains a
portable document format (.pdf) file of an executed signature page, such signature page shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such signature page were an original thereof.
(c) Headings; Gender. The headings of this Agreement are for convenience of reference
and shall not form part of, or affect the interpretation of, this Agreement. Unless the context
clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms including, includes, include
and words of like import shall be construed broadly as if followed by the words without
limitation. The terms herein, hereunder, hereof and words of like import refer to this
entire Agreement instead of just the provision in which they are found.
(d) Severability. If any provision of this Agreement is prohibited by law or otherwise
determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that
would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to
30
the broadest extent that it would be valid and enforceable, and the invalidity or
unenforceability of such provision shall not affect the validity of the remaining provisions of
this Agreement so long as this Agreement as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially
impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of
the prohibited, invalid or unenforceable provision(s).
(e) Entire Agreement; Amendments. This Agreement, the other Transaction Documents and
the schedules and exhibits attached hereto and thereto and the instruments referenced herein and
therein supersede all other prior oral or written agreements between the Buyers, the Company, their
affiliates and Persons acting on their behalf solely with respect to the matters contained herein
and therein, and this Agreement, the other Transaction Documents, the schedules and exhibits
attached hereto and thereto and the instruments referenced herein and therein contain the entire
understanding of the parties solely with respect to the matters covered herein and therein;
provided, however, nothing contained in this Agreement or any other Transaction Document shall (or
shall be deemed to) (i) have any effect on any agreements any Buyer has entered into with the
Company prior to the date hereof with respect to any prior investment made by such Buyer in the
Company or (ii) waive, alter, modify or amend in any respect any obligations of the Company, or any
rights of or benefits to any Buyer or any other Person, in any agreement entered into prior to the
date hereof between or among the Company and any Buyer and all such agreements shall continue in
full force and effect. Except as specifically set forth herein or therein, neither the Company nor
any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.
For clarification purposes, the Recitals are part of this Agreement. No provision of this Agreement
may be amended or waived other than by an instrument in writing signed by the Company and the
holders of at least 67% of the Common Shares initially issued hereunder on the Closing Date, and
any amendment or to, or waiver of any provision of, this Agreement made in conformity with the
provisions of this Section 9(d) shall be binding on all Buyers and holders of Securities, as
applicable, provided that any party may give a waiver in writing as to itself. No such amendment or
waiver (unless given pursuant to the foregoing proviso in the case of a waiver) shall be effective
to the extent that it applies to less than all of the Buyers and holders of Securities. No
consideration shall be offered or paid to any Person to amend or consent to a waiver or
modification of any provision of this Agreement unless the same consideration also is offered to
all of the parties to this Agreement, all holders of Common Shares or all holders of the Warrants
(as the case may be). The Company has not, directly or indirectly, made any agreements with any
Buyers relating to the terms or conditions of the transactions contemplated by the Transaction
Documents except as set forth in the Transaction Documents. Without limiting the foregoing, the
Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or
promise or has any other obligation to provide any financing to the Company, or otherwise. As a
material inducement for each Buyer to enter into this Agreement, the Company expressly acknowledges
and agrees that (i) no due diligence or other investigation conducted by a Buyer, any of its
advisors or any of its representatives shall affect such Buyers right to rely on, or shall modify
or qualify in any manner or be an exception
31
to any of, the Companys representations and warranties contained in this Agreement or any
other Transaction Document and (ii) unless a provision of this Agreement or any other Transaction
Document is expressly preceded by the phrase except as disclosed in the SEC Documents, nothing
contained in any of the SEC Documents shall affect such Buyers right to rely on, or shall modify
or qualify in any manner or be an exception to any of, the Companys representations and warranties
contained in this Agreement or any other Transaction Document.
(f) Notices. Any notices, consents, waivers or other communications required or
permitted to be given under the terms of this Agreement must be in writing and will be deemed to
have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile or electronic mail (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party); or (iii) one (1) Business Day
after deposit with an overnight courier service with next day delivery specified, in each case,
properly addressed to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:
If to the Company:
Emisphere Technologies, Inc.
240 Cedar Knolls Rd
Suite 200
Cedar Knolls, New Jersey 07927
Telephone: (973) 532-8000
Facsimile: (973) 532-8115
Attention: Chief Financial Officer
Email: mgarone@emisphere.com
With a copy (for informational purposes only) to:
Brown Rudnick LLP
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 856-8200
Facsimile: (617) 856-8201
Attention: Timothy C. Maguire, Esq.
email: tmaguire@brownrudnick.com
If to the Transfer Agent:
The Bank of New York Mellon Shareowner Services
111 Founders Plaza, Suite 1100
East Harford, Connecticut 06108
Telephone: (860) 282-3513
Facsimile: (860) 528-6472
Attention: John Boryczki
email:
32
If to a Buyer, to its address and facsimile number set forth on the Schedule of
Buyers, with copies to such Buyers representatives as set forth on the Schedule of
Buyers.
or to such other address and/or facsimile number and/or to the attention of such other Person as
the recipient party has specified by written notice given to each other party five (5) days prior
to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the senders facsimile machine containing the time, date, recipient facsimile number and an
image of the first page of such transmission or (C) provided by an overnight courier service shall
be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight
courier service in accordance with clause (i), (ii) or (iii) above, respectively.
(g) Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns, including, as contemplated
below, any assignee of any of the Securities. The Company shall not assign this Agreement or any
rights or obligations hereunder without the prior written consent of the holders of at least a
majority of the aggregate number of Registrable Securities issued and issuable under the
Transaction Documents, including, without limitation, by way of a Fundamental Transaction (as
defined in the Warrants) (unless the Company is in compliance with the applicable provisions
governing Fundamental Transactions set forth in the Warrants). A Buyer may assign some or all of
its rights hereunder in connection with any transfer of any of its Securities without the consent
of the Company, in which event such assignee shall be deemed to be a Buyer hereunder with respect
to such assigned rights.
(h) No Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees
referred to in Section 9(k).
(i) Survival. The representations, warranties, agreements and covenants shall survive
the Closing for the applicable statute of limitations. Each Buyer shall be responsible only for its
own representations, warranties, agreements and covenants hereunder.
(j) Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as any other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.
(k) Indemnification. In consideration of each Buyers execution and delivery of the
Transaction Documents and acquiring the Securities thereunder and in addition to all of the
Companys other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless each Buyer and each holder of any Securities and all of their
stockholders, partners, members, officers, directors, employees and direct or indirect investors
and any of the foregoing Persons agents or other representatives (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding a lack
33
of such title or any other title), each Person who controls or is controlled by such Buyer
(within the meaning of Section 15 of the 1933 Act and Section 20 of the 1934 Act), and the
directors, officers, shareholders, agents, members, partners or employees (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling or controlled persons (including, without limitation,
those retained in connection with the transactions contemplated by this Agreement) (collectively,
the Indemnitees) from and against any and all actions, causes of action, suits, claims,
contingencies, losses, costs, penalties, fees, liabilities and damages, and expenses in connection
therewith (irrespective of whether any such Indemnitee is a party to the action for which
indemnification hereunder is sought), and including all judgments, amounts paid in settlements,
court costs and reasonable attorneys fees and disbursements and costs of investigation (the
Indemnified Liabilities), incurred by any Indemnitee as a result of, or arising out of, or
relating to (a) any misrepresentation or breach of any representation or warranty made by the
Company in any of the Transaction Documents, (b) any breach of any covenant, agreement or
obligation of the Company contained in any of the Transaction Documents or (c) any cause of action,
suit or claim brought or made against such Indemnitee by a third party (including for these
purposes a derivative action brought on behalf of the Company) and arising out of or resulting from
(i) the execution, delivery, performance or enforcement of any of the Transaction Documents or the
transactions contemplated by the Transaction Documents, (ii) any disclosure properly made by such
Buyer pursuant to Section 4(i), or (iii) the status of such Buyer or holder of the Securities as an
investor in the Company pursuant to the transactions contemplated by the Transaction Documents. To
the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the
Company shall make the maximum contribution to the payment and satisfaction of each of the
Indemnified Liabilities which is permissible under applicable law. Except as otherwise set forth
herein, the mechanics and procedures with respect to the rights and obligations under this Section
9(k) shall be the same as those set forth in Section 6 of the Registration Rights Agreement.
(l) No Strict Construction. The language used in this Agreement will be deemed to be
the language chosen by the parties to express their mutual intent, and no rules of strict
construction will be applied against any party.
(m) Remedies. Each Buyer and each holder of any Securities shall have all rights and
remedies set forth in the Transaction Documents and all rights and remedies which such holders have
been granted at any time under any other agreement or contract and all of the rights which such
holders have under any law. Any Person having any rights under any provision of this Agreement
shall be entitled to enforce such rights specifically (without posting a bond or other security),
to recover damages by reason of any breach of any provision of this Agreement and to exercise all
other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to
perform, observe, or discharge any or all of its obligations under the Transaction Documents, any
remedy at law may prove to be inadequate relief to the Buyers. The Company therefore agrees that
the Buyers shall be entitled to seek specific performance and/or temporary, preliminary and
permanent injunctive or other equitable relief from any court of competent jurisdiction in any such
case without the necessity of proving actual damages and without posting a bond or other security.
34
(n) Withdrawal Right. Notwithstanding anything to the contrary contained in (and
without limiting any similar provisions of) the Transaction Documents, whenever any Buyer exercises
a right, election, demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then such Buyer may rescind or
withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights.
(o) Payment Set Aside; Currency. To the extent that the Company makes a payment or
payments to any Buyer hereunder or pursuant to any of the other Transaction Documents or any of the
Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or
the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other
Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the
obligation or part thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement or setoff had not
occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement
and the other Transaction Documents are in United States Dollars (U.S. Dollars), and all amounts
owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All
amounts denominated in other currencies (if any) shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. Exchange Rate means, in
relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement,
the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation.
(p) Judgment Currency.
(i) If for the purpose of obtaining or enforcing judgment against the Company in any
court in any jurisdiction it becomes necessary to convert into any other currency (such
other currency being hereinafter in this Section 9(p) referred to as the Judgment
Currency) an amount due in U.S. Dollars under this Agreement or any other Transaction
Document, the conversion shall be made at the Exchange Rate prevailing on the Trading Day
immediately preceding: (1) the date actual payment of the amount due, in the case of any
proceeding in the courts of New York or in the courts of any other jurisdiction that will
give effect to such conversion being made on such date or (2) the date on which the foreign
court determines, in the case of any proceeding in the courts of any other jurisdiction (the
date as of which such conversion is made pursuant to this Section 9(p)(i) being hereinafter
referred to as the Judgment Conversion Date).
(ii) If in the case of any proceeding in the court of any jurisdiction referred to in
Section 9(p)(i) above, there is a change in the Exchange Rate prevailing between the
Judgment Conversion Date and the date of actual payment of the amount due, the applicable
party shall pay such adjusted amount as may be necessary to ensure that the amount paid in
the Judgment Currency, when converted at the Exchange Rate prevailing on the date of
payment, will produce the amount of U.S. Dollars which could have been
35
purchased with the amount of Judgment Currency stipulated in the judgment or judicial
order at the Exchange Rate prevailing on the Judgment Conversion Date.
(iii) Any amount due from the Company under this provision shall be due as a separate
debt and shall not be affected by judgment being obtained for any other amounts due under or
in respect of this Agreement or any other Transaction Document.
(q) Independent Nature of Buyers Obligations and Rights. The obligations of each
Buyer under the Transaction Documents are several and not joint with the obligations of any other
Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any
other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to
constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute, a
partnership, an association, a joint venture or any other kind of group or entity, or create a
presumption that the Buyers are in any way acting in concert or as a group or entity with respect
to such obligations or the transactions contemplated by the Transaction Documents or any matters,
and the Company acknowledges that the Buyers are not acting in concert or as a group, and the
Company shall not assert any such claim, with respect to such obligations or the transactions
contemplated by the Transaction Documents. The decision of each Buyer to purchase Securities
pursuant to the Transaction Documents has been made by such Buyer independently of any other Buyer.
Each Buyer acknowledges that no other Buyer has acted as agent for such Buyer in connection with
such Buyer making its investment hereunder and that no other Buyer will be acting as agent of such
Buyer in connection with monitoring such Buyers investment in the Securities or enforcing its
rights under the Transaction Documents. The Company and each Buyer confirms that each Buyer has
independently participated with the Company in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to
independently protect and enforce its rights, including, without limitation, the rights arising out
of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any
other Buyer to be joined as an additional party in any proceeding for such purpose. The use of a
single agreement to effectuate the purchase and sale of the Securities contemplated hereby was
solely in the control of the Company, not the action or decision of any Buyer, and was done solely
for the convenience of the Company and not because it was required or requested to do so by any
Buyer. It is expressly understood and agreed that each provision contained in this Agreement and
in each other Transaction Document is between the Company and a Buyer, solely, and not between the
Company and the Buyers collectively and not between and among the Buyers.
[signature pages follow]
36
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
COMPANY:
EMISPHERE TECHNOLOGIES, INC.
|
|
|
By: |
/s/ Michael R. Garone |
|
|
|
Name: |
Michael R. Garone |
|
|
|
Title: |
Interim Chief Executive Officer
and Chief Financial Officer |
|
|
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
BUYERS:
HUAIDONG WANG
|
|
|
By: |
/s/ Huaidong Wang
|
|
|
|
Name: |
Huaidong Wang |
|
|
|
Title: |
|
|
|
|
SHIPMAN & GOODWIN LLP
PROFIT SHARING RETIREMENT TRUST FBO JAMES T. BETTS
|
|
|
By: |
/s/ James T. Betts
|
|
|
|
Name: |
James T. Betts |
|
|
|
|
|
|
|
HF H VICTOR UW VICTOR ART 7
|
|
|
By: |
/s/ Lawrence Remmel
|
|
|
|
Name: |
Lawrence Remmel |
|
|
|
Title: |
Authorized Signatory |
|
|
Signature Page to Investor SPA
|
|
|
|
|
|
FREESTONE ADVANTAGE PARTNERSHIP
|
|
|
By: |
/s/ Keith Goodman
|
|
|
|
Name: |
Keith Goodman |
|
|
|
Title: |
Authorized Signatory |
|
|
|
CRANSHIRE CAPITAL LP
|
|
|
By: |
/s/ Keith A. Goodman
|
|
|
|
Name: |
Keith A. Goodman |
|
|
|
Title: |
COO - Downsview Capital, Inc.
The General Partner |
|
|
|
BAI YE FENG
|
|
|
By: |
/s/ Bai Ye Feng
|
|
|
|
Name: |
Bai Ye Feng |
|
|
|
|
|
|
|
KINGSBROOK OPPORTUNITIES MASTER
FUND LP
|
|
|
By: |
/s/ Adam J. Chill
|
|
|
|
Name: |
Adam J. Chill |
|
|
|
Title: |
Managing Member |
|
|
Signature Page to Investor SPA
|
|
|
|
|
|
PINE LODGE CAPITAL COMPANY LTD
|
|
|
By: |
/s/ Barry Freeman
|
|
|
|
Name: |
Barry Freeman |
|
|
|
Title: |
Director |
|
|
|
EOS HOLDINGS LLC
|
|
|
By: |
/s/ Joseph W. Rammelli
|
|
|
|
Name: |
Joseph W. Rammelli |
|
|
|
Title: |
Director |
|
|
|
SON NAM NGUYEN
|
|
|
By: |
/s/ Son Nam Nguyen
|
|
|
|
Name: |
Son Nam Nguyen |
|
|
|
|
|
|
|
IROQUOIS MASTER FUND LTD.
|
|
|
By: |
/s/ Joshua Silverman
|
|
|
|
Name: |
Joshua Silverman |
|
|
|
Title: |
Authorized Signatory |
|
|
Signature Page to Investor SPA
|
|
|
|
|
|
ANSON INVESTMENTS MASTER FUND LP
|
|
|
By: |
/s/ Adam Spears
|
|
|
|
Name: |
Adam Spears |
|
|
|
Title: |
Portfolio Manager |
|
Signature Page to Investor SPA
SCHEDULE OF BUYERS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(5) |
|
(6) |
|
|
|
|
Number of |
|
Number of |
|
|
|
|
|
Legal Representatives |
|
|
|
|
Common |
|
Warrant |
|
Purchase |
|
Address and Facsimile |
Buyer |
|
Address and Facsimile Number |
|
Shares |
|
Shares |
|
Price |
|
Number |
Anson Investments
Master Fund LP
|
|
Anson Investments
5950 Berkshire Lane, Suite 510
Dallas, TX 75225
Attn: Summer Keith
skeith@ansonfunds.com
|
|
|
573,394 |
|
|
|
401,375 |
|
|
$ |
500,000.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HF H VICTOR UW VICTOR ART 7
|
|
c/o Nancy Huddleston
Vice President
U.S. Trust, Bank of America
208 Harristown Road Fourth Floor
Glen Rock, NJ 07452
Ph: (201) 251-5452
Fax (800) 976-1232
Nancy.huddleston@untrust.com
|
|
|
57,339 |
|
|
|
40,137 |
|
|
$ |
50,000.00 |
|
|
Lawrence Remmel
Pryor Cashman LLP
7 Times Square
New York, NY 10036-6569
Direct Tel: 212-326-0881
Direct Fax: 212-798-6365
E-mail:
LRemmel@pryorcashman.com |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EOS Holdings LLC
|
|
EOS Holdings LLC
900 Avenida Acaso, Suite H
Camarillo, CA 93012
|
|
|
917,431 |
|
|
|
642,202 |
|
|
$ |
800,000.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kingsbrook
Opportunities
Master Fund LP
|
|
c/o Kingsbrook Partners LP
590 Madison Avenue, 27th Floor
New York, New York 10022
Attn: Ari J. Storch/Adam J. Chill
E-mail:
|
|
|
573,394 |
|
|
|
401,376 |
|
|
$ |
499,999.56 |
|
|
N/A |
|
|
investments@kingsbrookpartners.com
/ operations@kingsbrookpartners.com
Facsimile: (212) 600-8290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bai Ye Feng
|
|
Flat F, 9/F, Tower 1, Harbour Green
8 Sham Mong Rd. Hong Kong
Fax 852-30158525
|
|
|
688,073 |
|
|
|
481,651 |
|
|
$ |
600,000.00 |
|
|
Flat F, 9/F, Tower 1,
Harbour Green
8 Sham Mong Rd. Hong Kong
Fax 852 30158525 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cranshire Capital LP
|
|
c/o Downsview Capital Inc
3100 Dundee Road, Ste 703
Northbrook, IL 60062
Attn: Mitch Kopin/Keith Goodman
T: 847-562-9030
F: 847-562-9031
mkopin@cranshirecapital.com/
kgoodman@cranshirecapital.com
|
|
|
538,991 |
|
|
|
377,294 |
|
|
$ |
470,000.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Freestone Advantage
Partnership
|
|
c/o Downsview Capital Inc
3100 Dundee Road, Ste 703
Northbrook, IL 60062
Attn: Mitch Kopin/Keith Goodman
T: 847-562-9030
F: 847-562-9031
mkopin@cranshirecapital.com/
kgoodman@cranshirecapital.com
|
|
|
34,404 |
|
|
|
24,083 |
|
|
$ |
30,000.29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Iroquois Master
Fund Ltd.
|
|
Iroquois Capital Management, LLC
641 Lexington Ave., 26th Fl.
New York, NY 10022
Attn: Josh Silverman
T: 212-974-3070
F: 212-207-3452
jsilverman@icfund.com
|
|
|
573,394 |
|
|
|
401,376 |
|
|
$ |
500,000.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shipman & Goodwin
LLP Profit Sharing
Retirement Trust
FBO James T. Betts
|
|
|
|
|
114,679 |
|
|
|
80,275 |
|
|
$ |
100,000.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Son Nam Nguyen
|
|
1975 South Lake Road
Lakewood, CO 80227
|
|
|
70,000 |
|
|
|
49,000 |
|
|
$ |
61,040.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Huaidong Wang
|
|
Bldg. 3, K1C Plaza,
270 Song Hu Road, Shanghai, China
Fax +86-21-6140 7778
|
|
|
102,000 |
|
|
|
71,400 |
|
|
$ |
88,944.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pine Lodge Capital
Company LTD
|
|
Barry Freeman
Huasong Capital
570 Yongjia Lu, Building 2, Suite 302
Shanghai, 200031, PR China
D: +86 21 6195 0316
M: +86 186-2113-3360
|
|
|
57,339 |
|
|
|
40,137 |
|
|
$ |
49,999.61 |
|
|
|
Exhibit A
Form of Warrant
See attached.
Exhibit B
Registration Rights Agreement
See attached.
Exhibit 10.2
SECURITIES PURCHASE AGREEMENT
This
SECURITIES PURCHASE AGREEMENT (the
Agreement), dated as of June 30, 2011, is by
and among Emisphere Technologies, Inc., a Delaware corporation with headquarters located at 240
Cedar Knolls Rd, Suite 200, Cedar Knolls, New Jersey 07927 (the Company), and each of the
investors listed on the Schedule of Buyers attached hereto (individually, a Buyer and
collectively, the Buyers).
RECITALS
A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the
exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as
amended (the 1933 Act), and Rule 506 of Regulation D (Regulation D) as promulgated by the
United States Securities and Exchange Commission (the SEC) under the 1933 Act.
B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, (i) the aggregate number of shares of common stock, $0.01 par
value, of the Company (the Common Stock), set forth opposite such Buyers name in column (3) on
the Schedule of Buyers (which aggregate amount for all Buyers shall
be 4,300,438 shares of Common
Stock and shall collectively be referred to herein as the Common Shares) and (ii) a warrant to
initially acquire up to that number of shares of Common Stock set forth opposite such Buyers name
in column (4) on the Schedule of Buyers, in the form attached hereto as Exhibit A (the MHR
Warrants) (as exercised, collectively, the MHR Warrant Shares).
C. Each Buyer has registration rights pursuant to that certain Registration Rights Agreement,
dated as of September 26, 2005, by and between the Company and MHR Capital Partners (500) LP, MHR
Capital Partners (100) LP, MHR Institutional Partners II LP and MHR Institutional Partners IIA LP
(collectively, and including any of their respective Affiliates, MHR) (the Registration Rights
Agreement), and all of the Securities purchased hereunder shall constitute Registrable
Securities under the terms of such agreement.
D. Simultaneously herewith, the Company shall enter into that certain Waiver Agreement, by and
between the Company and MHR Capital Partners Master Account LP, MHR Capital Partners (100) LP, MHR
Institutional Partners II LP and MHR Institutional Partners IIA LP (the Waiver Agreement),
whereby, in consideration for the waiver by MHR of certain its rights in connection with the
offering contemplated by this Agreement and the Concurrent Offering (as defined below), the Company
shall issue on the date hereof warrants to purchase 795,000 shares of Common Stock on the same
terms and conditions as the Warrants purchased hereunder (the Waiver Warrants (as exercised,
collectively, the Waiver Warrant Shares and together with the MHR Warrant Shares, the Warrant
Shares) and together with the MHR Warrants, the Warrants).
E. The Common Shares, the Warrants, and the Warrant Shares are collectively referred to herein
as the Securities.
AGREEMENT
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Buyer hereby agree as follows:
1. PURCHASE AND SALE OF COMMON SHARES AND WARRANTS.
(a) Common Shares and Warrants. Subject to the satisfaction (or waiver) of the
conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each Buyer, and
each Buyer severally, but not jointly, shall purchase from the Company on the Closing Date (as
defined below), the number of Common Shares as is set forth opposite such Buyers name in column
(3) on the Schedule of Buyers along with a Warrant to initially acquire up to that number of
Warrant Shares as is set forth opposite such Buyers name in column (4) on the Schedule of Buyers.
(b) Closing. The closing (the Closing) of the purchase of the Common Shares and the
Warrants by the Buyers shall occur at Brown Rudnick LLP. The date and time of the Closing (the
"Closing Date) shall be 10:00 a.m., New York time, on the first (1st) Business Day on
which the conditions to the Closing set forth in Sections 6 and 7 below are satisfied or waived (or
such later date as is mutually agreed to by the Company and each Buyer). As used herein Business
Day means any day other than a Saturday, Sunday or other day on which commercial banks in New
York, New York are authorized or required by law to remain closed.
(c) Purchase Price. The aggregate purchase price for the Common Shares and the Warrants to
be purchased by each Buyer (the Purchase Price) shall be the amount set forth opposite such
Buyers name in column (5) on the Schedule of Buyers.
(d) Form of Payment. On the Closing Date, (i) each Buyer shall pay its respective
Purchase Price to the Company for the Common Shares and the Warrants to be issued and sold to such
Buyer at the Closing, by wire transfer of immediately available funds in accordance with the
Companys written wire instructions and (ii) the Company shall deliver to each Buyer (A) a copy of
the irrevocable instructions to the Companys transfer agent instructing the transfer agent to
deliver the Common Shares as is set forth opposite such Buyers name in column (3) of the Schedule
of Buyers and (B) a Warrant pursuant to which such Buyer shall have the right to initially acquire
up to the number of Warrant Shares as is set forth opposite such Buyers name in column (4) of the
Schedule of Buyers, in all cases, duly executed on behalf of the Company and registered in the name
of such Buyer or its designee (such Warrant certificate shall be delivered within three (3) Trading
Days (as defined in the Warrant) of the Closing Date).
2. BUYERS REPRESENTATIONS AND WARRANTIES.
Each Buyer, severally and not jointly, represents and warrants to the Company with respect to
only itself that, as of the date hereof and as of the Closing Date:
(a) Organization; Authority. Such Buyer is an entity duly organized, validly existing
2
and in good standing under the laws of the jurisdiction of its organization with the requisite
power and authority to enter into and to consummate the transactions contemplated by the
Transaction Documents (as defined below) to which it is a party and otherwise to carry out its
obligations hereunder and thereunder.
(b) No Public Sale or Distribution. Such Buyer (i) is acquiring its Common Shares and
Warrants, and (ii) upon exercise of its Warrants, will acquire the Warrant Shares issuable upon
exercise thereof, in each case, for its own account and not with a view towards, or for resale in
connection with, the public sale or distribution thereof in violation of applicable securities
laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by
making the representations herein, such Buyer does not agree, or make any representation or
warranty, to hold any of the Securities for any minimum or other specific term and reserves the
right to dispose of the Securities at any time in accordance with or pursuant to a registration
statement or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder in
the ordinary course of its business. Such Buyer does not presently have any agreement or
understanding, directly or indirectly, with any Person (as defined below) to distribute any of the
Securities in violation of applicable securities laws.
(c) Accredited Investor Status. Such Buyer is either (i) an accredited investor as
that term is defined in Rule 501(a) of Regulation D or (ii) a qualified institutional investor as
defined in Rule 144A of the 1933 Act.
(d) Reliance on Exemptions. Such Buyer understands that the Securities are being
offered and sold to it in reliance on specific exemptions from the registration requirements of
United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Buyers compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Buyer set forth herein in order to determine
the availability of such exemptions and the eligibility of such Buyer to acquire the Securities.
(e) Information. Such Buyer and its advisors, if any, have been furnished with all
materials relating to the business, finances and operations of the Company and materials relating
to the offer and sale of the Securities which have been requested by such Buyer. Such Buyer and its
advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if
any, or its representatives shall modify, amend or affect such Buyers right to rely on the
Companys representations and warranties contained herein or any representations and warranties
contained in any other Transaction Document (as defined below) or any other document or instrument
executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby. Such Buyer understands that its investment in the Securities involves a high
degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the
Securities.
(f) No Governmental Review. Such Buyer understands that no United States federal or
state agency or any other government or governmental agency has passed on or made any
recommendation or endorsement of the Securities or the fairness or suitability of the investment
3
in the Securities nor have such authorities passed upon or endorsed the merits of the offering
of the Securities.
(g) Transfer or Resale. Such Buyer understands that except as provided in the
Registration Rights Agreement and Section 4(h) hereof: (i) the Securities have not been and are not
being registered under the 1933 Act or any state securities laws, and may not be offered for sale,
sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Buyer shall
have delivered to the Company (if requested by the Company) an opinion of counsel to such Buyer, in
a form reasonably acceptable to the Company, to the effect that such Securities to be sold,
assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such
registration, or (C) such Buyer provides the Company with reasonable assurance that such Securities
can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933
Act (or a successor rule thereto) (collectively, Rule 144); (ii) any sale of the Securities made
in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if
Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller
(or the Person (as defined below) through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the 1933 Act) may require compliance with some other exemption under
the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii) neither the
Company nor any other Person is under any obligation to register the Securities under the 1933 Act
or any state securities laws or to comply with the terms and conditions of any exemption
thereunder.
(h) Validity; Enforcement. This Agreement has been duly and validly authorized,
executed and delivered on behalf of such Buyer and constitutes the legal, valid and binding
obligations of such Buyer enforceable against such Buyer in accordance with its respective terms,
except as such enforceability may be limited by general principles of equity or to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to,
or affecting generally, the enforcement of applicable creditors rights and remedies.
(i) No Conflicts. The execution, delivery and performance by such Buyer of this
Agreement and the consummation by such Buyer of the transactions contemplated hereby and thereby
will not (i) result in a violation of the organizational documents of such Buyer, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii)
result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii)
above, for such conflicts, defaults, rights or violations which would not, individually or in the
aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to
perform its obligations hereunder.
(j) Residency. Such Buyer is a resident of that jurisdiction specified below its address on
the Schedule of Buyers.
(k) [Reserved]
4
(l) No International Sales. Such Buyer acknowledges, represents and agrees that no
action has been or will be taken in any jurisdiction outside the United States by the Company that
would permit an offering of the Securities, or possession or distribution of offering materials in
connection with the issue of the Securities in any jurisdiction outside the United States where
action for that purpose is required. Each Buyer outside the United States will comply with all
applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells
or delivers Securities or has in its possession or distributes any offering material, in all cases
at its own expense.
(m) Experience of Such Buyer. Such Buyer, either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such investment. Such Buyer is able to
bear the economic risk of an investment in the Securities and, at the present time, is able to
afford a complete loss of such investment.
(n) No Investment Advice. Such Buyer understands that nothing in this Agreement or
any other materials presented to the Buyer in connection with the purchase and sale of the
Securities constitutes legal, tax or investment advice. Such Buyer has consulted such legal, tax
and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of the Securities.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
The Company hereby represents and warrants to each of the Buyers that:
(a) Organization and Qualification; Subsidiaries. The Company is duly incorporated
and validly existing and in good standing under the laws of the State of Delaware, and has the
requisite power and authorization to own its properties and to carry on its business as described
in the Companys SEC Documents. The Company is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the
failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used
in this Agreement, Material Adverse Effect means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), or condition (financial
or otherwise) of the Company, (ii) the transactions contemplated hereby or in any of the other
Transaction Documents or (iii) the authority or ability of the Company to perform any of its
obligations under any of the Transaction Documents; , provided, however, that none of the
following shall constitute, or shall be considered in determining whether there has occurred, and
no event, circumstance, change or effect resulting from or arising out of any of the following
shall constitute, a Material Adverse Effect: (A) the announcement of the execution of this
Agreement; (B) changes in the national or world economy or financial markets as a whole or changes
in general economic conditions that affect the industries in which the Company conducts its
business, so long as such changes or conditions do not adversely affect the Company in a materially
disproportionate manner relative to other similarly situated participants in the industries or
markets in which they operate; (C) any change in applicable law, rule or regulation or GAAP or
interpretation thereof after the date hereof, so long as such changes do not adversely
5
affect the Company, in a materially disproportionate manner relative to other similarly
situated participants in the industries or markets in which they operate; (D) the failure, in and
of itself, of the Company to meet any published or internally prepared estimates of revenues,
earnings or other financial projections, performance measures or operating statistics; provided,
however, that the facts and circumstances underlying any such failure may, except as may be
provided in subsections (A), (B), (C), (E), and (F) of this definition, be considered in
determining whether a Material Adverse Effect has occurred; (E) a decline in the price, or a change
in the trading volume, of the Company Common Stock on the Principal Market (as defined below); and
(F) compliance with the terms of, and taking any action required by, this Agreement. The Company
has no significant subsidiaries (as such term is defined in Rule 1-02(w) of Regulation S-X
promulgated by the Commission) and does not own any beneficial interest, directly or indirectly, in
any corporation, partnership, joint venture or other business entity.
(b) Authorization; Enforcement; Validity. The Company has the requisite corporate
power and authority to enter into and perform its obligations under this Agreement and the other
Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof.
The execution and delivery of this Agreement and the other Transaction Documents by the Company and
the consummation by the Company of the transactions contemplated hereby and thereby (including,
without limitation, the issuance of the Common Shares, the issuance of the Warrants and the
reservation for issuance and issuance of the Warrant Shares issuable upon exercise of the Warrants)
have been duly authorized by the Companys board of directors and (other than the filing with the
SEC of a Form D with the SEC and any other filings as may be required by any state securities
agencies) no further filing, consent or authorization or action is required by the Company, its
board of directors or its stockholders or other governing body other than Required Approvals (as
defined below). This Agreement has been, and the other Transaction Documents will be prior to the
Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and
binding obligations of the Company, enforceable against the Company in accordance with its
respective terms, except as such enforceability may be limited by general principles of equity or
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally, the enforcement of applicable creditors rights and remedies as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and except as rights to indemnification and to contribution may be limited by federal or
state securities law. Transaction Documents means, collectively, this Agreement, the Warrants,
the Waiver Agreement, the Irrevocable Transfer Agent Instructions (as defined below) and each of
the other agreements and instruments entered into or delivered by any of the parties hereto in
connection with the transactions contemplated hereby and thereby, as may be amended from time to
time.
(c) Issuance of Securities. The issuance of the Common Shares and the Warrants are
duly authorized and, upon issuance in accordance with the terms of the Transaction Documents, will
be validly issued, fully paid and non-assessable and free from all preemptive or similar rights,
taxes, liens, charges and other encumbrances with respect to the issue thereof. As of the Closing,
the Company shall have reserved from its duly authorized capital stock not less than the maximum
number of shares of Common Stock issuable upon exercise of the Warrants (without taking into
account any limitations on the exercise of the Warrants set forth therein). The issuance of the
Warrant Shares is duly authorized, and upon exercise in accordance with the
6
Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and
non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other
encumbrances with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties
of the Buyers in this Agreement, the offer and issuance by the Company of the Securities is exempt
from registration under the 1933 Act.
(d) No Conflicts. Except as disclosed in the SEC Documents, the execution, delivery
and performance of the Transaction Documents by the Company and the consummation by the Company of
the transactions contemplated hereby and thereby (including, without limitation, the issuance of
the Common Shares, the Warrants and Warrant Shares and the reservation for issuance of the Warrant
Shares) will not (i) result in a violation of the Certificate of Incorporation (as defined below)
(including, without limitation, any certificates of designation contained therein) or other
organizational documents of the Company, any capital stock of the Company, or Bylaws, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any material agreement, indenture
or instrument to which the Company is a party, or (iii) subject to Required Approvals, result in a
violation of any law, rule, regulation, order, judgment or decree (including, without limitation,
federal and state securities laws and regulations and the rules and regulations of the OTC Bulletin
Board (the Principal Market)) applicable to the Company or by which any property or asset of the
Company is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such
violations that could not reasonably be expected to have a Material Adverse Effect.
(e) Consents. Except as disclosed in the SEC Documents, the Company is not required
to obtain any consent from, authorization or order of, or make any filing or registration with
(other than the filing with the SEC of a Form D with the SEC and any other filings as may be
required by any state securities agencies (collectively, the Required Approvals)), any court,
governmental agency or any regulatory or self-regulatory agency or any other Person in order for it
to execute, deliver or perform any of its obligations under, or contemplated, by the Transaction
Documents, in each case, in accordance with the terms hereof or thereof. All consents,
authorizations, orders, filings and registrations which the Company is required to obtain at or
prior to the Closing have been obtained or effected on or prior to the Closing Date, and the
Company is not aware of any facts or circumstances which might prevent the Company from obtaining
or effecting any of the registration, application or filings contemplated by the Transaction
Documents. The Company is not in violation of the requirements of the Principal Market and has no
knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of
the Common Stock in the foreseeable future.
(f) Acknowledgment Regarding Buyers Purchase of Securities. The Company acknowledges
and agrees that each Buyer is acting solely in the capacity of an arms length purchaser with
respect to the Transaction Documents and the transactions contemplated hereby and thereby. The
Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions
contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or
agents in connection with the Transaction Documents and the transactions
7
contemplated hereby and thereby is merely incidental to such Buyers purchase of the
Securities. The Company further represents to each Buyer that the Companys decision to enter into
the Transaction Documents has been based solely on the independent evaluation by the Company and
its representatives.
(g) No General Solicitation; Placement Agents Fees. Neither the Company, nor any of
its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D) in connection with the
offer or sale of the Securities. The Company shall be responsible for the payment of any placement
agents fees, financial advisory fees, or brokers commissions (other than for Persons engaged by
any Buyer or its investment advisor) relating to or arising out of the transactions contemplated
hereby. Other than Roth Capital Partners, LLC (the Placement Agent), the Company has not engaged
any placement agent or other agent in connection with the offer or sale of the Securities.
(h) No Integrated Offering. Neither the Company nor any of their affiliates, nor any
Person acting on their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of
the issuance of any of the Securities under the 1933 Act, whether through integration with prior
offerings or otherwise, or cause this offering of the Securities to require approval of
stockholders of the Company under any applicable stockholder approval provisions, including,
without limitation, under the rules and regulations of any exchange or automated quotation system
on which any of the securities of the Company are listed or designated for quotation. None of the
Company, its affiliates nor any Person acting on their behalf will take any action or steps that
would require registration of the issuance of any of the Securities under the 1933 Act or cause the
offering of any of the Securities to be integrated with other offerings of securities of the
Company.
(i) Dilutive Effect. The Company acknowledges that its obligation to issue the
Warrant Shares upon exercise of the Warrants in accordance with this Agreement and the Warrants is
absolute and unconditional, regardless of the dilutive effect that such issuance may have on the
ownership interests of other stockholders of the Company.
(j) Application of Takeover Protections; Rights Agreement. The Company and its board
of directors have taken all necessary action, if any, in order to render inapplicable any control
share acquisition, interested stockholder, business combination, poison pill (including, without
limitation, any distribution under a rights agreement) or other similar anti-takeover provision
under the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the
jurisdiction of its incorporation or otherwise which is or could become applicable to any Buyer as
a result of the transactions contemplated by this Agreement, including, without limitation, the
Companys issuance of the Securities and any Buyers ownership of the Securities. The Company and
its board of directors have taken all necessary action, if any, in order to render inapplicable any
stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of
shares of Common Stock or a change in control of the Company.
8
(k) SEC Documents; Financial Statements. During the two (2) years prior to the date
hereof, the Company has timely filed all reports, schedules, forms, statements and other documents
required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all
of the foregoing filed prior to the date hereof and all exhibits included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein being
hereinafter referred to as the SEC Documents). As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not
misleading. As of their respective dates, except as disclosed in the SEC Documents, the financial
statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC
with respect thereto as in effect as of the time of filing. Except as disclosed in the SEC
Documents, such financial statements have been prepared in accordance with generally accepted
accounting principles (GAAP), consistently applied, during the periods involved (except (i) as
may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case
of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial position of the
Company as of the dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments
which will not be material, either individually or in the aggregate). No other information provided
by or on behalf of the Company to any of the Buyers which is not included in the SEC Documents
(including, without limitation, information referred to in Section 2(e) of this Agreement) contains
any untrue statement of a material fact or omits to state any material fact necessary in order to
make the statements therein not misleading, in the light of the circumstance under which they are
or were made.
(l) Absence of Certain Changes; Solvency. Except as disclosed in the SEC Documents,
since the date of the Companys most recent audited financial statements contained in a Form 10-K,
there has been no material adverse change and no material adverse development in the business,
assets, liabilities, properties, operations (including results thereof), condition (financial or
otherwise) or prospects of the Company. Except as disclosed in the SEC Documents, since the date
of the Companys most recent audited financial statements contained in a Form 10-K, the Company has
not (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate,
outside of the ordinary course of business or (iii) made any material capital expenditures,
individually or in the aggregate. Except as disclosed in the SEC Documents, the Company has not
taken any steps to seek protection pursuant to any law or statute relating to bankruptcy,
insolvency, reorganization, receivership, liquidation or winding up, nor does the Company have any
knowledge or reason to believe that any of their respective creditors intend to initiate
involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead
a creditor to do so. Except as disclosed in the SEC Documents, the Company does not intend to
incur debts beyond its ability to pay such debts as they mature (taking into account the timing and
amounts of cash to be payable on or in respect of its debt). Except as disclosed in the SEC
Documents, the Company has no knowledge of any facts or circumstances which lead it to believe that
it will file for reorganization or liquidation
9
under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date.
(m) No Undisclosed Events, Liabilities, Developments or Circumstances. Except as
disclosed in the SEC Documents, no event, liability, development or circumstance has occurred or
exists, or is, to the Companys knowledge, reasonably expected to occur or exist, with respect to
the Company or any of their respective businesses, properties, liabilities, prospects, operations
(including results thereof) or condition (financial or otherwise) that (i) would be required to be
disclosed by the Company under applicable securities laws on a registration statement on Form S-1
filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which
has not been publicly announced, (ii) could have a material adverse effect on any Buyers
investment hereunder or (iii) could have a Material Adverse Effect.
(n) Conduct of Business; Regulatory Permits. The Company is not in violation of any
term of or in default under its Certificate of Incorporation, any certificate of designation,
preferences or rights of any other outstanding series of preferred stock of the Company or Bylaws.
Except as disclosed in the SEC Documents, the Company is not in violation of any judgment, decree
or order or any statute, ordinance, rule or regulation applicable to the Company, and the Company
will not conduct its business in violation of any of the foregoing, except in all cases for
possible violations which could not, individually or in the aggregate, have a Material Adverse
Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of
the rules, regulations or requirements of the Principal Market and has no knowledge of any facts or
circumstances that could reasonably lead to delisting or suspension of the Common Stock by the
Principal Market in the foreseeable future. Since June 9, 2009, (i) the Common Stock has been
listed or designated for quotation on the Principal Market, (ii) trading in the Common Stock has
not been suspended by the SEC or the Principal Market and (iii) the Company has received no
communication, written or oral, from the SEC or the Principal Market regarding the suspension or
delisting of the Common Stock from the Principal Market. The Company possess all certificates,
authorizations and permits issued by the appropriate regulatory authorities necessary to conduct
its respective businesses, except where the failure to possess such certificates, authorizations or
permits would not have, individually or in the aggregate, a Material Adverse Effect, and the
Company has not received any notice of proceedings relating to the revocation or modification of
any such certificate, authorization or permit.
(o) Foreign Corrupt Practices. Neither the Company nor, to the knowledge of the
Company, any director, officer, any agent, employee or other Person acting on behalf of the Company
has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or is in violation of any provision of
the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.
(p) Sarbanes-Oxley Act. Except as disclosed in the SEC Documents, the Company is in
material compliance with all applicable requirements of the Sarbanes-Oxley Act of 2002 that
10
are effective as of the date hereof, and all applicable rules and regulations promulgated by
the SEC thereunder that are effective as of the date hereof.
(q) Transactions With Affiliates. Except as disclosed in the SEC Documents or as set
forth on Schedule 3(q), none of the officers, directors or to the knowledge of the Company,
employees of the Company is presently a party to any transaction with the Company (other than for
ordinary course services as employees, officers or directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, or otherwise requiring payments to or from any such officer,
director or employee or, to the knowledge of the Company, any corporation, partnership, trust or
other Person in which any such officer, director, or employee has a substantial interest or is an
employee, officer, director, trustee or partner.
(r) Capitalization. Except as disclosed in the SEC Documents, the Company has not
issued any capital stock since its most recently filed periodic report under the 1934 Act, other
than pursuant to the exercise of employee stock options under the Companys stock option plans, the
issuance of shares of Common Stock to employees pursuant to the Companys employee stock purchase
plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of
the date of the most recently filed periodic report under the 1934 Act. Except as disclosed in the
SEC Documents or as set forth in Schedule 3(r)(i), no Person has any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents. Except as disclosed in the SEC Documents
or as set forth in Schedule 3(r)(ii), as a result of the purchase and sale of the
Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock, or contracts, commitments, understandings or
arrangements by which the Company is or may become bound to issue additional shares of Common Stock
or Common Stock Equivalents. Except as disclosed in the SEC Documents or as set forth in
Schedule 3(r)(iii), the issuance and sale of the Securities will not obligate the Company
to issue shares of Common Stock or other securities to any Person (other than the Buyers) and will
not result in a right of any holder of Company securities to adjust the exercise, conversion,
exchange or reset price under any of such securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and nonassessable, have been issued in
compliance with all federal and state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any stockholder, the Board of Directors or
others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Companys capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of
the Companys stockholders. Common Stock Equivalents means any securities of the Company which
would entitle the holder thereof to acquire at any time Common Stock, including, without
limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, Common Stock.
11
(s) Indebtedness and Other Contracts. Except as disclosed in the SEC Documents, the
Company (i) has no outstanding Indebtedness (as defined below), (ii) is not a party to any
contract, agreement or instrument, the violation of which, or default under which, by the other
party(ies) to such contract, agreement or instrument could reasonably be expected to result in a
Material Adverse Effect, (iii) is not in violation of any term of or in default under any contract,
agreement or instrument relating to any Indebtedness, except where such violations and defaults
would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is not a
party to any contract, agreement or instrument relating to any Indebtedness, the performance of
which, in the judgment of the Companys officers, has or is expected to have a Material Adverse
Effect. For purposes of this Agreement: (x) Indebtedness of any Person means, without duplication
(A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the
deferred purchase price of property or services (including, without limitation, capital leases in
accordance with generally accepted accounting principles) (other than trade payables entered into
in the ordinary course of business), (C) all reimbursement or payment obligations with respect to
letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by
notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in
connection with the acquisition of property, assets or businesses, (E) all indebtedness created or
arising under any conditional sale or other title retention agreement, or incurred as financing, in
either case with respect to any property or assets acquired with the proceeds of such indebtedness
(even though the rights and remedies of the seller or bank under such agreement in the event of
default are limited to repossession or sale of such property), (F) all monetary obligations under
any leasing or similar arrangement which, in connection with generally accepted accounting
principles, consistently applied for the periods covered thereby, is classified as a capital lease,
(G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the
holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any
mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or
assets (including accounts and contract rights) owned by any Person, even though the Person which
owns such assets or property has not assumed or become liable for the payment of such indebtedness,
and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds
referred to in clauses (A) through (G) above; (y) Contingent Obligation means, as to any Person,
any direct or indirect liability, contingent or otherwise, of that Person with respect to any
indebtedness, lease, dividend or other obligation of another Person if the primary purpose or
intent of the Person incurring such liability, or the primary effect thereof, is to provide
assurance to the obligee of such liability that such liability will be paid or discharged, or that
any agreements relating thereto will be complied with, or that the holders of such liability will
be protected (in whole or in part) against loss with respect thereto; and (z) Person means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization, any other entity and a government or any department or agency
thereof..
(t) Absence of Litigation. Except as disclosed in the SEC Documents, there is no
action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge
of the Company, threatened against or affecting the Company, the Common Stock or any of the
Companys officers or directors which is outside of the ordinary course of business or individually
or in the aggregate would have or reasonably expect to result in a Material Adverse Effect. There
has not been, and to the knowledge of the Company, there is not pending or
12
contemplated, any investigation by the SEC involving the Company or any current director or
officer of the Company. The SEC has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the 1933 Act or the 1934
Act.
(u) Insurance. The Company is insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as management of the Company
believes to be prudent and customary in the businesses in which the Company are engaged. The
Company has not been refused any insurance coverage sought or applied for, and the Company has no
reason to believe that it will be unable to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.
(v) Employee Relations. The Company is not a party to any collective bargaining
agreement or employs any member of a union. The Company believes that its relations with its
employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933
Act) or other key employee of the Company has notified the Company that such officer intends to
leave the Company or otherwise terminate such officers employment with the Company. No executive
officer or other key employee of the Company is, or is now expected to be, in violation of any
material term of any employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any restrictive
covenant, and the continued employment of each such executive officer or other key employee (as the
case may be) does not subject the Company to any liability with respect to any of the foregoing
matters. The Company is in compliance with all federal, state and local laws and regulations
respecting labor, employment and employment practices and benefits, terms and conditions of
employment and wages and hours, except where failure to be in compliance would not, either
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
(w) Title. Except as disclosed in the SEC Documents or as set forth on Schedule 3(w),
the Company has good and marketable title in fee simple to all real property, and have good and
marketable title to all personal property, owned by it which is material to the business of the
Company free and clear of all liens, charges, security interests, encumbrances, rights of first
refusal, preemptive rights or other restrictions (Liens), encumbrances and defects except such as
do not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company. Any real property and facilities held under
lease by the Company are held by it under valid, subsisting and enforceable leases with such
exceptions as are not material and do not interfere with the use made and proposed to be made of
such property and buildings by the Company.
(x) Intellectual Property Rights. The Company has or has adequate rights or licenses
to use all trademarks, trade names, service marks, service mark registrations, service names,
patents, patent rights, copyrights, original works, inventions, licenses, approvals, governmental
authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (Intellectual Property Rights) necessary to conduct its business as
described in the SEC Documents. None of the Companys Intellectual Property Rights have expired,
terminated or been abandoned, or are expected to expire, terminate or be abandoned,
13
within three years from the date of this Agreement, except as set forth in the SEC Documents
or except where such expiration, termination or abandonment would not, either individually or in
the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company has not
received a notice (written or otherwise) that any of the Intellectual Property Rights used by the
Company violates or infringes upon the rights of any Person. To the knowledge of the Company, all
such Intellectual Property Rights are enforceable. The Company has taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.
(y) Environmental Laws. The Company (i) is in material compliance with all
Environmental Laws (as defined below), (ii) has received all permits, licenses or other approvals
required of it under applicable Environmental Laws to conduct its business and (iii) is in
compliance with all terms and conditions of any such permit, license or approval where, in each of
the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect. The term Environmental Laws
means all federal, state, local or foreign laws relating to pollution or protection of human health
or the environment (including, without limitation, ambient air, surface water, groundwater, land
surface or subsurface strata), including, without limitation, laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, Hazardous Materials) into the environment, or
otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees,
demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations issued, entered, promulgated or approved thereunder.
(z) Tax Status. Except for matters that would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect, the Company has filed all
necessary federal, state and foreign income and franchise tax returns and has paid or accrued all
taxes shown as due thereon, and the Company has no knowledge of a tax deficiency which has been
asserted or threatened against the Company. The Company is not operated in such a manner as to
qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal
Revenue Code of 1986, as amended.
(aa) Internal Accounting and Disclosure Controls. Except as disclosed in the SEC
Documents, the Company maintains internal control over financial reporting (as such term is defined
in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including that (i) transactions are executed in accordance with
managements general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset and
liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in
accordance with managements general or specific authorization and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable
intervals and appropriate action is taken with respect to any difference. Except as disclosed in
the SEC Documents, the Company maintains disclosure controls and procedures (as such term is
defined in Rule 13a-15(e) under the 1934 Act) that are effective in
14
ensuring that information required to be disclosed by the Company in the reports that it files
or submits under the 1934 Act is recorded, processed, summarized and reported, within the time
periods specified in the rules and forms of the SEC, including, without limitation, controls and
procedures designed to ensure that information required to be disclosed by the Company in the
reports that it files or submits under the 1934 Act is accumulated and communicated to the
Companys management, including its principal executive officer or officers and its principal
financial officer or officers, as appropriate, to allow timely decisions regarding required
disclosure. The Company presented in its most recently filed periodic report under the 1934 Act
the conclusions of the certifying officers about the effectiveness of the disclosure controls and
procedures based on their evaluations as of the end of the period covered by the Companys most
recently filed periodic report under the 1934 Act (the Evaluation Date). Since the Evaluation
Date, there have been no changes in the Companys internal control over financial reporting (as
such term is defined in the 1934 Act) that has materially affected, or is reasonably likely to
materially affect, the Companys internal control over financial reporting.
(bb) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other
relationship between the Company and an unconsolidated or other off balance sheet entity that is
required to be disclosed by the Company in its 1934 Act filings and is not so disclosed or that
otherwise could be reasonably likely to have a Material Adverse Effect.
(cc) Investment Company Status. The Company is not, and upon consummation of the sale
of the Securities will not be, an investment company, as such term is defined in the Investment
Company Act of 1940, as amended.
(dd) Acknowledgement Regarding Buyers Trading Activity. It is understood and
acknowledged by the Company that (i) none of the Buyers have been asked by the Company to agree,
nor has any Buyer agreed with the Company, to desist from effecting any transactions in or with
respect to (including, without limitation, purchasing or selling, long and/or short) any securities
of the Company, or derivative securities based on securities issued by the Company or to hold any
of the Securities for any specified term; (ii) past or future open market or other transactions by
any Buyer, specifically including, without limitation, Short Sales or derivative transactions,
before or after the closing of this or future private placement transactions, may negatively impact
the market price of the Companys publicly-traded securities; (iii) any Buyer, and counterparties
in derivative transactions to which any such Buyer is a party, directly or indirectly, presently
may have a short position in the Common Stock which was established prior to such Buyers
knowledge of the transactions contemplated by the Transaction Documents; and (iv) each Buyer shall
not be deemed to have any affiliation with or control over any arms length counterparty in any
derivative transaction. The Company further understands and acknowledges that (a) one or more
Buyers may engage in hedging and/or trading activities at various times during the period that the
Securities are outstanding, including, without limitation, during the periods that the value and/or
number of the Warrant Shares deliverable with respect to the Securities are being determined and
(b) such hedging and/or trading activities, if any, can reduce the value of the existing
stockholders equity interest in the Company both at and after the time the hedging and/or trading
activities are being conducted. The Company acknowledges that such aforementioned hedging and/or
trading activities do not constitute a breach of this Agreement or any other Transaction Document
or any of the documents executed in connection herewith or therewith.
15
(ee) Manipulation of Price. The Company has not, and, to the knowledge of the Company,
no Person acting on its behalf has, directly or indirectly, (i) taken any action designed to cause
or to result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any
compensation for soliciting purchases of, any of the Securities (other than the Placement Agent),
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase
any other securities of the Company.
(ff) U.S. Real Property Holding Corporation. The Company is not nor has ever been, a
U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue
Code of 1986, as amended, and the Company shall so certify upon any Buyers request.
(gg) Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other
than income or similar taxes) which are required to be paid in connection with the issuance, sale
and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been
complied with.
(hh) Bank Holding Company Act. The Company is not subject to the Bank Holding Company
Act of 1956, as amended (the BHCA) and to regulation by the Board of Governors of the Federal
Reserve System (the Federal Reserve). Neither the Company nor any of its affiliates owns or
controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class
of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any
equity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company
nor any of its affiliates exercises a controlling influence over the management or policies of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
(ii) Shell Company Status. The Company is not, and has never been, an issuer
identified in, or subject to, Rule 144(i).
(jj) Public Utility Holding Act. The Company is not a holding company, or an
affiliate of a holding company, as such terms are defined in the Public Utility Holding Act of
2005.
(kk) Federal Power Act. The Company is not subject to regulation as a public
utility under the Federal Power Act, as amended.
(ll) FDA. Except as disclosed in the SEC Documents, as to each product subject to the
jurisdiction of the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug and
Cosmetic Act, as amended, and the regulations thereunder (FDCA) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a
"Pharmaceutical Product), such Pharmaceutical Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable
requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing
practices, good laboratory practices, good clinical practices,
16
product listing, quotas, labeling, advertising, record keeping and filing of reports, except
where the failure to be in compliance would not have a Material Adverse Effect. Except as
disclosed in the SEC Documents, there is no pending, completed or, to the Companys knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory
proceeding, charge, complaint, or investigation) against the Company, and the Company has not
received any notice, warning letter or other communication from the FDA or any other governmental
entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the
uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or
the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests
the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or
sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold
on any clinical investigation by the Company, (iv) enjoins production at any facility of the
Company, (v) enters or proposes to enter into a consent decree of permanent injunction with the
Company, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company,
and which, either individually or in the aggregate, would have a Material Adverse Effect. Except
as disclosed in the SEC Documents, the properties, business and operations of the Company have been
and are being conducted in all material respects in accordance with all applicable laws, rules and
regulations of the FDA. Except as disclosed in the SEC Documents, the Company has not been
informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the
FDA, to the Companys knowledge, expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.
(mm) Money Laundering. The Company is in compliance with, and has not previously
violated, the USA Patriot Act of 2001 and any other applicable U.S. and non-U.S. anti-money
laundering laws and regulations, including, but not limited to, the laws, regulations and Executive
Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, Blocking Property
and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism (66
Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.
(nn) Management. Except as disclosed in the SEC Documents, during the past five year
period, no current officer or director has been the subject of:
(i) a petition under bankruptcy laws or any other insolvency or moratorium law or the
appointment by a court of a receiver, fiscal agent or similar officer for such Person, or
any partnership in which such person was a general partner at, or any corporation or
business association of which such person was an executive officer at;
(ii) a conviction in a criminal proceeding or a named subject of a pending criminal
proceeding (excluding traffic violations that do not relate to driving while intoxicated or
driving under the influence);
17
(iii) any order, judgment or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining any such person
from, or otherwise limiting, the following activities:
(1) Acting as a futures commission merchant, introducing broker, commodity
trading advisor, commodity pool operator, floor broker, leverage transaction
merchant, any other person regulated by the United States Commodity Futures Trading
Commission or an associated person of any of the foregoing, or as an investment
adviser, underwriter, broker or dealer in securities, or as an affiliated person,
director or employee of any investment company, bank, savings and loan association
or insurance company, or engaging in or continuing any conduct or practice in
connection with such activity;
(2) Engaging in any type of business practice; or
(3) Engaging in any activity in connection with the purchase or sale of any
security or commodity or in connection with any violation of securities laws or
commodities laws;
(iv) any order, judgment or decree, not subsequently reversed, suspended or vacated, of
any authority barring, suspending or otherwise limiting for more than 60 days the right of
any such person to engage in any activity described in the preceding sub paragraph, or to be
associated with persons engaged in any such activity;
(v) a finding by a court of competent jurisdiction in a civil action or by the SEC or
other authority to have violated any securities law, regulation or decree and the judgment
in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or
(vi) a finding by a court of competent jurisdiction in a civil action or by the
Commodity Futures Trading Commission to have violated any federal commodities law, and the
judgment in such civil action or finding has not been subsequently reversed, suspended or
vacated.
(oo) No Additional Agreements. The Company does not have any agreement or
understanding with any Buyer with respect to the transactions contemplated by the Transaction
Documents other than as specified in the Transaction Documents.
(pp) Disclosure. The Company understands and confirms that each of the Buyers will
rely on the foregoing representations in effecting transactions in securities of the Company. All
disclosure provided to the Buyers regarding the Company, its business and the transactions
contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the
Company is true and correct and does not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. Each press release issued by the Company
during the twelve (12) months preceding the date of this Agreement did not at the time of release
contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the light of the
18
circumstances under which they are made, not misleading. No event or circumstance has
occurred or information exists with respect to the Company or its business, properties,
liabilities, prospects, operations (including results thereof) or conditions (financial or
otherwise), which, under applicable law, rule or regulation, requires public disclosure at or
before the date hereof or announcement by the Company but which has not been so publicly disclosed.
The Company acknowledges and agrees that no Buyer makes or has made any representations or
warranties with respect to the transactions contemplated hereby other than those specifically set
forth in Section 2.
(qq) Acknowledgement of Registration Rights and Piggyback Rights. The Company
acknowledges that each of the Buyers has registration rights pursuant to the Registration Rights
Agreement, and agrees that all the Securities purchased hereunder shall constitute Registrable
Securities under the terms of such agreement. The Company further acknowledges that (a) pursuant
to Article II of the Registration Rights Agreement, the Buyers may demand that the Company effect
the registration under the 1933 Act of all or a specified number of the Registrable Securities, and
(b) pursuant to Article III of the Registration Rights Agreement, if any time the Company proposes
to file a Registration Statement under the 1933 Act with respect to any offering of securities of
the Company, the Buyers shall have the opportunity to register any of its Registrable Securities of
the same class as those being registered by the Company.
4. COVENANTS.
(a) Best Efforts. Each Buyer shall use its reasonable best efforts to timely satisfy
each of the conditions to be satisfied by it as provided in Section 6 of this Agreement. The
Company shall use its reasonable best efforts to timely satisfy each of the conditions to be
satisfied by it as provided in Section 7 of this Agreement.
(b) Form D and Blue Sky. The Company shall file a Form D with respect to the
Securities as required under Regulation D. The Company shall, on or before the Closing Date, take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to, qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement
under applicable securities or Blue Sky laws of the states of the United States (or to obtain an
exemption from such qualification) if so required by such applicable state laws. Without limiting
any other obligation of the Company under this Agreement, the Company shall timely make all filings
and reports relating to the offer and sale of the Securities required under all applicable
securities laws (including, without limitation, all applicable federal securities laws and all
applicable Blue Sky laws), and the Company shall comply with all applicable federal, state and
local laws, statutes, rules, regulations and the like relating to the offering and sale of the
Securities to the Buyers.
(c) Reporting Status. Until the date on which the Buyers shall have sold all of the
Registrable Securities (the Reporting Period), the Company shall timely file all reports required
to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status
as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and
regulations thereunder would no longer require or otherwise permit such termination.
19
(d) Use of Proceeds. The Company shall use the proceeds from the sale of the
Securities solely as set forth on Schedule 4(d), and, without limitation of the foregoing, except
as set forth on Schedule 4(d), none of such proceeds shall be used, directly or indirectly, for (i)
the satisfaction of any debt of the Company (other than payment of trade payables incurred after
the date hereof in the ordinary course of business of the Company and consistent with prior
practices), (ii) the redemption of any securities of the Company or (iii) the settlement of any
outstanding litigation.
(e) Financial Information. The Company agrees to send the following to each Investor
(as defined in the Registration Rights Agreement) during the Reporting Period (i) unless the
following are filed with the SEC through EDGAR and are available to the public through the EDGAR
system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim reports or any consolidated
balance sheets, income statements, stockholders equity statements and/or cash flow statements for
any period other than annual, any Current Reports on Form 8-K and any registration statements
(other than on Form S-8) or amendments filed pursuant to the 1933 Act and (ii) copies of any
notices and other information made available or given to the stockholders of the Company generally,
contemporaneously with the making available or giving thereof to the stockholders. Notwithstanding
the foregoing, nothing in this Section 4(e) shall require the Company to disclose to any Investor
any redacted part of any filing in which the Company has requested confidential treatment by the
SEC.
(f) Listing. The Company shall promptly secure the listing or designation for
quotation (as the case may be) of all of the Registrable Securities upon each national securities
exchange and automated quotation system, if any, upon which the Common Stock is then listed or
designated for quotation (as the case may be) (subject to official notice of issuance) (but in no
event later than the Closing Date) and shall maintain such listing or designation for quotation (as
the case may be) of all Registrable Securities from time to time issuable under the terms of the
Transaction Documents on such national securities exchange or automated quotation system. The
Company further agrees, if the Company applies to have the Common Stock traded on any other
national securities exchange or automated quotation system, it will then include in such
application all of the Registrable Securities, and will take such other action as is necessary to
cause all of the Registrable Securities to be listed or quoted on such other exchange as promptly
as possible. The Company shall maintain the Common Stocks designation for quotation (as the case
may be) on the Principal Market, or, if applicable, listing on The NYSE Amex, The New York Stock
Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market
(as the case may be) (each, an Eligible Market), and shall take all action reasonably necessary
to continue the listing and trading of its Common Stock on an Eligible Market and will comply in
all respects with the Companys reporting, filing, and other obligations under the bylaws or rules
of such Eligible Market. The Company shall not take any action which could be reasonably expected
to result in the delisting or suspension of the Common Stock on an Eligible Market. The Company
shall pay all fees and expenses in connection with satisfying its obligations under this Section
4(d).
(g) Fees. The Company shall be responsible for the payment of any placement agents
fees, financial advisory fees, or brokers commissions (other than for Persons engaged by any
Buyer) relating to or arising out of the transactions contemplated hereby (including, without
20
limitation, any fees payable to the Placement Agent, who is the Companys sole placement agent
in connection with the transactions contemplated by this Agreement). The Company shall pay, and
hold each Buyer harmless against, any liability, loss or expense (including, without limitation,
reasonable attorneys fees and out-of-pocket expenses) arising in connection with any claim
relating to any such payment. Except as otherwise set forth in the Transaction Documents, each
party to this Agreement shall bear its own expenses in connection with the sale of the Securities
to the Buyers.
(h) Pledge of Securities. Notwithstanding anything to the contrary contained in this
Agreement, the Company acknowledges and agrees that the Securities may be pledged by a Buyer in
connection with a bona fide margin agreement or other loan or financing arrangement that is secured
by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or
assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities shall be
required to provide the Company with any notice thereof or otherwise make any delivery to the
Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees to
execute and deliver such documentation as a pledgee of the Securities may reasonably request in
connection with a pledge of the Securities to such pledgee by a Buyer.
(i) Disclosure of Transactions and Other Material Information. The Company shall, on
or before 9:30 a.m., New York time, (but in no event prior to 9:15 a.m., New York time) on the date
of this Agreement, issue a press release (the Press Release) reasonably acceptable to the Buyers
disclosing all the material terms of the transactions contemplated by the Transaction Documents. On
or before 9:30 a.m., New York time, (but in no event prior to 9:15 a.m., New York time) on the date
of this Agreement, the Company shall file a Current Report on Form 8-K describing all the material
terms of the transactions contemplated by the Transaction Documents in the form required by the
1934 Act and attaching all the material Transaction Documents (including, without limitation, this
Agreement, the form of Warrants and the Waiver Agreement) (including all attachments, the 8-K
Filing).
(j) [Reserved]
(k) Additional Issuance of Securities. The Company agrees that for the period
commencing on the date hereof and ending on the date immediately following the earlier to occur of
(i) the thirtieth (30th) Trading Day after the earlier of (x) the Applicable Date (as defined
below) and (y) the first date on which Rule 144 is available for the sale of any Securities and
(ii) the three (3) month anniversary of the Closing Date (the Restricted Period), the Company
shall not directly or indirectly issue, offer, sell, grant any option or right to purchase, or
otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to
purchase or other disposition of) any equity security or any equity-linked security (including,
without limitation, any equity security (as that term is defined under Rule 405 promulgated under
the 1933 Act), any Convertible Securities, or any preferred stock) (any such issuance, offer, sale,
grant, disposition or announcement (whether occurring during the Restricted Period or at any time
thereafter) is referred to as a Subsequent Placement), unless each purchaser (each a Subsequent
Purchaser) of securities in such Subsequent Placement (including, without limitation, any
securities issuable upon conversion, exercise or exchange thereof) (collectively, the Subsequent
Placement Securities) irrevocably agrees that during the Restricted Period it will not, directly
or indirectly, sell, offer to sell, contract or agree to sell, or
21
grant any option to purchase any Subsequent Placement Securities pursuant to an effective
registration statement or usable prospectus or in reliance on the Section 4(1) exemption under the
1933 Act (the foregoing restrictions are referred to as the Subsequent Transfer Restrictions).
For the avoidance of doubt, Subsequent Transfer Restrictions shall not include (A) any sale, offer
to sell, contract or agreement to sell any of the Subsequent Placement Securities directly or
indirectly to any Person in a private sale transaction in reliance on the 4(11/2) exemption under the
1933 Act, or (B) any sales, transfers, grants or gifts of any Subsequent Placement Securities to
(i) any spouse or lineal descendants, heirs, executors, administrators, testamentary trustees,
legatees or beneficiaries of such Subsequent Purchaser; (ii) any trust, charitable trust, or any
corporation, limited liability company, partnership or other entity, the stockholders, members,
general or limited partners or owners of which include only such Subsequent Purchaser or its
affiliates, or (iii) any affiliate of such Subsequent Purchaser (collectively, a Permitted
Transferee), so long as each such Permitted Transferee, prior to acquisition of any Subsequent
Placement Securities, agrees in writing with the Company to be bound by the Subsequent Transfer
Restrictions with respect to all Subsequent Placement Securities such Permitted Transferee
acquires. Notwithstanding the foregoing, this Section 4(k) shall not apply to the issuance of: (A)
shares of Common Stock or standard options to purchase Common Stock to directors, officers,
consultants or employees of the Company in their capacity as such pursuant to an Approved Share
Plan (as defined below), (B) shares of Common Stock issued upon the conversion or exercise of
Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an
Approved Share Plan that are covered by clause (A) above) issued prior to the date hereof,
provided, that, none of the terms or conditions of any such Convertible Securities (other than
standard options to purchase Common Stock issued pursuant to an Approved Share Plan that are
covered by clause (A) above) are otherwise materially changed (except pursuant to the terms
thereof) in any manner that adversely affects any of the Buyers, (C) the Warrant Shares, (D) any
securities issued in the Concurrent Offering or any securities issued upon the exercise or
conversion of any securities issued in connection therewith, including but not limited to any
securities issued in connection with the Waiver Agreement, dated as of the date hereof, between the
Company and the holders of the MHR Securities (as defined in the Warrants), (E) any equity
security, any equity linked security, any Convertible Securities, or any preferred stock issued or
issuable in connection with bona fide, arms length bank financings, corporate partnering or
intellectual property licensing transactions, equipment leases or acquisitions of all or any
portion of a business or its assets whether by merger, stock or asset purchase or any other bona
fide strategic transaction (each a Strategic Transaction) on terms approved by the Companys
board of directors, provided that (x) the primary purpose of such issuance is not to raise capital,
(y) the purchasers or acquirers of the securities in such issuance does not include an entity whose
primary business is investing in securities and (z) the number or amount of securities issued to
any Person by the Company shall not be disproportionate to such Persons actual participation in
such Strategic Transaction or ownership of such assets or securities to be acquired by the Company
in such Strategic Transaction, as applicable, (F) any equity security, equity linked security, any
Convertible Securities or preferred stock issued by the Company to all holders of Common Stock or
any other class of Company capital stock, pro rata (including without limitation, in connection
with a recapitalization, stock split, reverse stock split or rights offering), including any equity
security, equity linked security, Convertible Security or preferred stock issuable upon exercise or
conversion of such Convertible Securities, and (G) any equity security, any equity linked security,
any Convertible Securities, or any preferred stock to MHR or its
22
affiliates in connection with the waiver of any of MHRs anti-dilution rights in connection
with any Subsequent Placement, provided that the consideration being provided to MHR for such
waiver is on terms approved by the Companys board of directors as advised by independent member(s)
of the Board (each of the foregoing in clauses (A) through (G), collectively the Excluded
Securities). Approved Share Plan means any employee benefit plan which has been approved by the
board of directors of the Company prior to or subsequent to the date hereof pursuant to which
shares of Common Stock and standard options to purchase Common Stock may be issued to any employee,
officer, consultant or director for services provided to the Company in their capacity as such.
"Convertible Securities means any capital stock or other security of the Company that is at any
time and under any circumstances directly or indirectly convertible into, exercisable or
exchangeable for, or which otherwise entitles the holder thereof to acquire, any capital stock or
other security of the Company (including, without limitation, Common Stock). Applicable Date
means the first date on which the resale by the Buyers of all Registrable Securities is covered by
one or more effective Registration Statements (as defined in the Registration Rights Agreement)
(and each prospectus contained therein is available for use on such date).
(l) Reservation of Shares. So long as any of the Warrants remain outstanding, the
Company shall take all action necessary to at all times have authorized, and reserved for the
purpose of issuance, no less than the maximum number of shares of Common Stock issuable upon
exercise of all the Warrants (without regard to any limitations on the exercise of the Warrants set
forth therein).
(m) Conduct of Business. The business of the Company shall not be conducted in
violation of any law, ordinance or regulation of any governmental entity, except where such
violations would not result, either individually or in the aggregate, in a Material Adverse Effect.
(n) Passive Foreign Investment Company. The Company shall conduct its business in
such a manner as will ensure that the Company will not be deemed to constitute a passive foreign
investment company within the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as
amended.
(o) Closing Documents. Within a reasonable time after the Closing Date, the Company
agrees to deliver, or cause to be delivered, to each Buyer and [INSERT COUNSEL] executed copies of
the Transaction Documents, Securities and other document required to be delivered to any party
pursuant to Section 7 hereof.
(p) Delivery of Warrants After Closing. The Company shall deliver, or cause to be
delivered, the respective Warrants purchased by each Buyer to such Buyer within three (3) Trading
Days of the Closing Date.
(q) Shareholder Rights Plan. No claim will be made or enforced by the Company or, with
the consent of the Company, any other Person, that any Buyer is an Acquiring Person under any
control share acquisition, business combination, poison pill (including any distribution under a
rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Buyer could be deemed to trigger the provisions of any such plan or
arrangement, by virtue of receiving Securities under the Transaction Documents.
23
5. REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.
(a) Register. The Company shall maintain at its principal executive offices (or such
other office or agency of the Company as it may designate by notice to each holder of Securities),
a register for the Warrants in which the Company shall record the name and address of the Person in
whose name the Warrants have been issued (including the name and address of each transferee), the
number of Warrant Shares issuable upon exercise of the Warrants held by such Person. The Company
shall keep the register open and available for inspection during business hours, upon reasonable
request of any Buyer or its legal representatives.
(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to
its transfer agent and any subsequent transfer agent in a form acceptable to each of the Buyers
(the Irrevocable Transfer Agent Instructions) to issue certificates or credit shares to the
applicable balance accounts at The Depository Trust Company (DTC), registered in the name of each
Buyer or its respective nominee(s), for the Common Shares and the Warrant Shares in such amounts as
specified from time to time by each Buyer to the Company upon delivery of the Common Shares or the
exercise of the Warrants (as the case may be). The Company represents and warrants that no
instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section
5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the
Company to its transfer agent with respect to the Securities, and that the Securities shall
otherwise be freely transferable on the books and records of the Company, as applicable, to the
extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale,
assignment or transfer of the Securities in accordance with Section 2(g), the Company shall permit
the transfer and shall promptly instruct its transfer agent to issue one or more certificates or
credit shares to the applicable balance accounts at DTC in such name and in such denominations as
specified by such Buyer to effect such sale, transfer or assignment. In the event that such sale,
assignment or transfer involves Common Shares or Warrant Shares sold, assigned or transferred
pursuant to an effective registration statement or in compliance with Rule 144, the transfer agent
shall issue such shares to such Buyer, assignee or transferee (as the case may be) without any
restrictive legend in accordance with Section 5(d) below. The Company acknowledges that a breach by
it of its obligations hereunder will cause irreparable harm to each Buyer. Accordingly, the Company
acknowledges that the remedy at law for a breach of its obligations under this Section 5(b) will be
inadequate and agrees, in the event of a breach or threatened breach by the Company of the
provisions of this Section 5(b), that each Buyer shall be entitled, in addition to all other
available remedies, to an order and/or injunction restraining any breach and requiring immediate
issuance and transfer, without the necessity of showing economic loss and without any bond or other
security being required. The Company shall cause its counsel to issue such legal opinions as may be
requested from time to time in order to enable the sale of the Securities pursuant to the terms
hereof. Any fees (with respect to the transfer agent, counsel to the Company or otherwise)
associated with the issuance of such opinion or the removal of any legends on any of the Securities
shall be borne by the Company.
(c) Legends. Each Buyer understands that the Securities have been issued (or will be
issued in the case of the Warrant Shares) pursuant to an exemption from registration or
qualification under the 1933 Act and applicable state securities laws, and except as set forth
below, the Securities shall bear any legend as required by the blue sky laws of any state and a
24
restrictive legend in substantially the following form (and a stop-transfer order may be
placed against transfer of such stock certificates):
[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR
THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE] HAVE BEEN][THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE
ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF
REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE
SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE
FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
(d) Removal of Legends. Certificates evidencing Securities shall not be required to
contain the legend set forth in Section 5(c) above or any other legend (i) while a registration
statement (including a Registration Statement) covering the resale of such Securities is effective
under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the
transferor is not an affiliate of the Company), (iii) if such Securities are eligible to be sold,
assigned or transferred under Rule 144 (provided that a Buyer provides the Company with reasonable
assurances that such Securities are eligible for sale, assignment or transfer under Rule 144 which
shall not include an opinion of counsel), (iv) in connection with a sale, assignment or other
transfer (other than under Rule 144), provided that such Buyer provides the Company with an opinion
of counsel to such Buyer, in a generally acceptable form, to the effect that such sale, assignment
or transfer of the Securities may be made without registration under the applicable requirements of
the 1933 Act or (v) if such legend is not required under applicable requirements of the 1933 Act
(including, without limitation, controlling judicial interpretations and pronouncements issued by
the SEC). If a legend is not required pursuant to the foregoing, the Company shall no later than
three (3) Trading Days following the delivery by a Buyer to the Company or the transfer agent (with
notice to the Company) of a legended certificate representing such Securities (endorsed or with
stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the
reissuance and/or transfer, if applicable), together with any other deliveries from such Buyer as
may be required above in this Section 5(d), as directed by such Buyer, either: (A) provided that
the Companys transfer agent is participating in the DTC Fast Automated Securities Transfer Program
and such Securities are Common Shares or Warrant Shares, credit the aggregate number of shares of
Common Stock to which such Buyer shall be entitled to such Buyers or its designees balance
account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Companys
transfer agent is not participating in the DTC Fast Automated Securities Transfer Program, issue
and deliver (via
25
reputable overnight courier) to such Buyer, a certificate representing such Securities that is
free from all restrictive and other legends, registered in the name of such Buyer or its designee
(the date by which such credit is so required to be made to the balance account of such Buyers or
such Buyers nominee with DTC or such certificate is required to be delivered to such Buyer
pursuant to the foregoing is referred to herein as the Required Delivery Date).
(e) Failure to Timely Deliver; Buy-In. If the Company fails to (i) issue and deliver
(or cause to be delivered) to a Buyer by the Required Delivery Date a certificate representing the
Securities so delivered to the Company by such Buyer that is free from all restrictive and other
legends or (ii) credit the balance account of such Buyers or such Buyers nominee with DTC for
such number of shares of Common Shares or Warrant Shares so delivered to the Company, and if on or
after the Required Delivery Date such Buyer purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by such Buyer of shares of Common Stock
that such Buyer anticipated receiving from the Company without any restrictive legend, then, in
addition to all other remedies available to such Buyer, the Company shall, within three (3) Trading
Days after such Buyers request and in such Buyers sole discretion, either (i) pay cash to such
Buyer in an amount equal to such Buyers total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased (the Buy-In Price), at which point the Companys
obligation to deliver such certificate or credit such Buyers balance account shall terminate and
such shares shall be cancelled, or (ii) promptly honor its obligation to deliver to such Buyer a
certificate or certificates or credit such Buyers DTC account representing such number of shares
of Common Stock that would have been issued if the Company timely complied with its obligations
hereunder and pay cash to such Buyer in an amount equal to the excess (if any) of the Buy-In Price
over the product of (A) such number of shares of Common Shares or Warrant Shares (as the case may
be) that the Company was required to deliver to such Buyer by the Required Delivery Date times (B)
the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the Required
Delivery Date.
6. CONDITIONS TO THE COMPANYS OBLIGATION TO SELL.
(a) The obligation of the Company hereunder to issue and sell the Common Shares and the
related Warrants to each Buyer at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions, provided that these conditions are for the
Companys sole benefit and may be waived by the Company at any time in its sole discretion by
providing each Buyer with prior written notice thereof:
(i) Such Buyer shall have executed each of the other Transaction Documents to which it
is a party and delivered the same to the Company.
(ii) Such Buyer and each other Buyer shall have delivered to the Company the Purchase
Price for the Common Shares and the related Warrants being purchased by such Buyer at the
Closing by wire transfer of immediately available funds pursuant to the wire instructions
provided by the Company.
(iii) The representations and warranties of such Buyer shall be true and correct in all
material respects (except for those representations and warranties that are qualified by
materiality or Material Adverse Effect, which shall be true and correct in all respects)
26
as of the date when made and as of the Closing Date as though originally made at that
time (except for representations and warranties that speak as of a specific date, which
shall be true and correct as of such date), and such Buyer shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to
the Closing Date.
7. CONDITIONS TO EACH BUYERS OBLIGATION TO PURCHASE.
(a) The obligation of each Buyer hereunder to purchase the Common Shares and the related
Warrants at the Closing is subject to the satisfaction, at or before the Closing Date, of each of
the following conditions, provided that these conditions are for each Buyers sole benefit and may
be waived by such Buyer at any time in its sole discretion by providing the Company with prior
written notice thereof:
(i) The Company shall have duly executed and delivered to such Buyer (A) each of the
other Transaction Documents and (B) a copy of the irrevocable instructions to the Companys
transfer agent instructing the transfer agent to deliver the Common Shares (in the number as
is set forth across from such Buyers name in column (3) of the Schedule of Buyers) and the
related Warrants (for the number of Warrant Shares as is set forth across from such Buyers
name in column (4) of the Schedule of Buyers) (such Warrant certificate may be delivered
within three (3) Trading Days of the Closing Date) being purchased by such Buyer at the
Closing pursuant to this Agreement.
(ii) Such Buyer shall have received the opinion of Brown Rudnick LLP, the
Companys counsel, dated as of the Closing Date, in the form acceptable to such Buyer.
(iii) The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer
Agent Instructions, in the form acceptable to such Buyer, which instructions shall have been
delivered to and acknowledged in writing by the Companys transfer agent.
(iv) The Company shall have delivered to such Buyer a certificate evidencing the
formation and good standing of the Company issued by the Secretary of State of the State of
Delaware as of a date within ten (10) days of the Closing Date.
(v) The Company shall have delivered to such Buyer a certificate evidencing the
Companys qualification as a foreign corporation and good standing issued by the Secretary
of State of the State of New Jersey and the Secretary of State of the State of New York, as
of a date within ten (10) days of the Closing Date.
(vi) The Company shall have delivered to such Buyer a certificate, in the form
acceptable to such Buyer, executed by the Secretary of the Company and dated as of the
Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the
Companys board of directors in a form reasonably acceptable to such Buyer, (ii) the
Certificate of Incorporation and (iii) the Bylaws, each as in effect at the Closing.
27
(vii) Each and every representation and warranty of the Company shall be true and
correct in all material respects (except for those representations and warranties that are
qualified by materiality or Material Adverse Effect, which shall be true and correct in all
respects) as of the date when made and as of the Closing Date as though originally made at
that time (except for representations and warranties that speak as of a specific date) and
the Company shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required to be performed, satisfied or complied with by
the Company at or prior to the Closing Date. Such Buyer shall have received a certificate,
executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the
foregoing effect and as to such other matters as may be reasonably requested by such Buyer
in the form acceptable to such Buyer.
(viii) The Company shall have delivered to such Buyer a letter from the Companys
transfer agent certifying the number of shares of Common Stock outstanding on the Closing
Date immediately prior to the Closing.
(ix) The Common Stock (I) shall be designated for quotation or listed on the Principal
Market and (II) shall not have been suspended, as of the Closing Date, by the SEC or the
Principal Market from trading on the Principal Market nor shall suspension by the SEC or the
Principal Market have been threatened, as of the Closing Date, either (A) in writing by the
SEC or the Principal Market or (B) by falling below the minimum maintenance requirements of
the Principal Market.
(x) The Company shall have obtained all governmental, regulatory or third party
consents and approvals, if any, necessary for the sale of the Securities, including without
limitation, those required by the Principal Market.
(xi) No statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental authority
of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.
(xii) Since the date of execution of this Agreement, no event or series of events shall
have occurred that reasonably would have or result in a Material Adverse Effect.
(xiii) Such Buyer shall have received a letter on the letterhead of the Company, duly
executed by an appropriate officer of the Company, setting forth the wire instructions of
the Company.
(xiv) Such Buyer shall have received (A) a duly executed copy of the Securities
Purchase Agreement, by and between the Company and certain investors listed on the Schedule
of Buyers thereto (collectively, the Investors), dated as of the date hereof (the
Investor Agreement) with respect to an offering of
an aggregate of 4,300,438 shares of Common
Stock and related warrants (in the form of the Warrants) to purchase
3,010,307 shares of Common
Stock for an aggregate purchase price of $0.872 (the Investor Purchase Price), pursuant to
the terms hereof, (B) evidence reasonably satisfactory to such Buyer
28
of the closing of the transactions contemplated by the Investor Agreement shall have
occurred, (C) evidence reasonably satisfactory to such Buyer that the Company shall have
received the Investor Purchase Price from the Investors by one or more wire transfers of
U.S. dollars and immediately available funds and (D) a duly executed copy of the Waiver
Agreement (as defined in the MHR Agreement) (the foregoing transactions, collectively, the
Concurrent Offering).
(xv) The Company shall have delivered to such Buyer such other documents, instruments
or certificates relating to the transactions contemplated by this Agreement as such Buyer or
its counsel may reasonably request.
8. TERMINATION.
In
the event that the Closing shall not have occurred with respect to a
Buyer within five (5) Business
days of the date hereof, then such Buyer shall have the right to terminate its obligations under
this Agreement with respect to itself at any time on or after the close of business on such date
without liability of such Buyer to any other party; provided, however, (i) the right to terminate
this Agreement under this Section 8 shall not be available to such Buyer if the failure of the
transactions contemplated by this Agreement to have been consummated by such date is the result of
such Buyers breach of this Agreement and (ii) the abandonment of the sale and purchase of the
Common Shares and the Warrants shall be applicable only to such Buyer providing such written
notice. Nothing contained in this Section 8 shall be deemed to release any party from any liability
for any breach by such party of the terms and provisions of this Agreement or the other Transaction
Documents or to impair the right of any party to compel specific performance by any other party of
its obligations under this Agreement or the other Transaction Documents.
9. MISCELLANEOUS.
(a) Governing Law; Jurisdiction; Jury Trial. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by the
internal laws of the State of New York, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding
is improper. Each party hereby irrevocably waives personal service of process and consents to
process being served in any such suit, action or proceeding by mailing a copy thereof to such party
at the address for such notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL
FOR THE
29
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT
OR ANY TRANSACTION CONTEMPLATED HEREBY.
(b) Counterparts. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party. In the
event that any signature is delivered by facsimile transmission or by an e-mail which contains a
portable document format (.pdf) file of an executed signature page, such signature page shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such signature page were an original thereof.
(c) Headings; Gender. The headings of this Agreement are for convenience of reference
and shall not form part of, or affect the interpretation of, this Agreement. Unless the context
clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms including, includes, include
and words of like import shall be construed broadly as if followed by the words without
limitation. The terms herein, hereunder, hereof and words of like import refer to this
entire Agreement instead of just the provision in which they are found.
(d) Severability. If any provision of this Agreement is prohibited by law or otherwise
determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that
would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Agreement so long
as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits
that would otherwise be conferred upon the parties. The parties will endeavor in good faith
negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid
provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or
unenforceable provision(s).
(e) Entire Agreement; Amendments. This Agreement, the other Transaction Documents and
the schedules and exhibits attached hereto and thereto and the instruments referenced herein and
therein supersede all other prior oral or written agreements between the Buyers, the Company, their
affiliates and Persons acting on their behalf solely with respect to the matters contained herein
and therein, and this Agreement, the other Transaction Documents, the schedules and exhibits
attached hereto and thereto and the instruments referenced herein and therein contain the entire
understanding of the parties solely with respect to the matters covered herein and therein;
provided, however, nothing contained in this Agreement or any other Transaction Document shall (or
shall be deemed to) (i) have any effect on any agreements any Buyer has entered into with the
Company prior to the date hereof with respect to any prior investment made by such Buyer in the
Company or (ii) waive, alter, modify or amend in any respect any obligations of the Company, or any
rights of or benefits to any Buyer or any other Person, in any agreement entered into prior to the
date hereof between or among the Company
30
and any Buyer and all such agreements shall continue in full force and effect. Except as
specifically set forth herein or therein, neither the Company nor any Buyer makes any
representation, warranty, covenant or undertaking with respect to such matters. For clarification
purposes, the Recitals are part of this Agreement. No provision of this Agreement may be amended or
waived other than by an instrument in writing signed by the Company and the holders of at least 67%
of the Common Shares initially issued hereunder on the Closing Date, and any amendment or to, or
waiver of any provision of, this Agreement made in conformity with the provisions of this Section
9(d) shall be binding on all Buyers and holders of Securities, as applicable, provided that any
party may give a waiver in writing as to itself. No such amendment or waiver (unless given pursuant
to the foregoing proviso in the case of a waiver) shall be effective to the extent that it applies
to less than all of the Buyers and holders of Securities. The Company has not, directly or
indirectly, made any agreements with any Buyers relating to the terms or conditions of the
transactions contemplated by the Transaction Documents except as set forth in the Transaction
Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this
Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any
financing to the Company, or otherwise. As a material inducement for each Buyer to enter into this
Agreement, the Company expressly acknowledges and agrees that (i) no due diligence or other
investigation conducted by a Buyer, any of its advisors or any of its representatives shall affect
such Buyers right to rely on, or shall modify or qualify in any manner or be an exception to any
of, the Companys representations and warranties contained in this Agreement or any other
Transaction Document and (ii) unless a provision of this Agreement or any other Transaction
Document is expressly preceded by the phrase except as disclosed in the SEC Documents, nothing
contained in any of the SEC Documents shall affect such Buyers right to rely on, or shall modify
or qualify in any manner or be an exception to any of, the Companys representations and warranties
contained in this Agreement or any other Transaction Document. The Company further agrees not to
amend the Investor Agreement or the terms of the warrants issued to the Investors without the prior
written consent of the holders of at least 67% of the shares of Common Stock initially issued
hereunder on the Closing Date.
(f) Notices. Any notices, consents, waivers or other communications required or
permitted to be given under the terms of this Agreement must be in writing and will be deemed to
have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by
facsimile or electronic mail (provided confirmation of transmission is mechanically or
electronically generated and kept on file by the sending party); or (iii) one (1) Business Day
after deposit with an overnight courier service with next day delivery specified, in each case,
properly addressed to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:
If to the Company:
Emisphere Technologies, Inc.
240 Cedar Knolls Rd
Suite 200
Cedar Knolls, New Jersey 07927
Telephone: (973) 532-8000
31
Facsimile: (973) 532-8115
Attention: Chief Financial Officer
Email: mgarone@emisphere.com
With a copy (for informational purposes only) to:
Brown Rudnick LLP
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 856-8200
Facsimile: (617) 856-8201
Attention: Timothy C. Maguire, Esq.
Email: tmaguire@brownrudnick.com
If to the Transfer Agent:
The Bank of New York Mellon Shareowner Services
111 Founders Plaza, Suite 1100
East Harford, Connecticut 06108
Telephone: (860) 282-3513
Facsimile: (860) 528-6472
Attention: John Boryczki
Email:
If to a Buyer, to its address and facsimile number set forth on the Schedule of Buyers, with copies
to such Buyers representatives as set forth on the Schedule of Buyers.
or to such other address and/or facsimile number and/or to the attention of such other Person as
the recipient party has specified by written notice given to each other party five (5) days prior
to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the senders facsimile machine containing the time, date, recipient facsimile number and an
image of the first page of such transmission or (C) provided by an overnight courier service shall
be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight
courier service in accordance with clause (i), (ii) or (iii) above, respectively.
(g) Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns, including, as contemplated
below, any assignee of any of the Securities. The Company shall not assign this Agreement or any
rights or obligations hereunder without the prior written consent of the holders of at least a
majority of the aggregate number of Registrable Securities issued and issuable under the
Transaction Documents, including, without limitation, by way of a Fundamental Transaction (as
defined in the Warrants) (unless the Company is in compliance with the applicable provisions
governing Fundamental Transactions set forth in the Warrants). A Buyer may assign some or all of
its rights hereunder in connection with any transfer of any of its Securities without the consent
of the Company, in which event such assignee shall be deemed to be a Buyer hereunder with respect
to such assigned rights.
32
(h) No Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees
referred to in Section 9(k).
(i) Survival. The representations, warranties, agreements and covenants shall survive
the Closing for the applicable statute of limitations. Each Buyer shall be responsible only for its
own representations, warranties, agreements and covenants hereunder.
(j) Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as any other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.
(k) Indemnification. In consideration of each Buyers execution and delivery of the
Transaction Documents and acquiring the Securities thereunder and in addition to all of the
Companys other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless each Buyer and each holder of any Securities and all of their
stockholders, partners, members, officers, directors, employees and direct or indirect investors
and any of the foregoing Persons agents or other representatives (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title), each Person who controls or is controlled by such Buyer (within the meaning of
Section 15 of the 1933 Act and Section 20 of the 1934 Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title) of such controlling or controlled persons (including, without limitation, those retained in
connection with the transactions contemplated by this Agreement) (collectively, the Indemnitees)
from and against any and all actions, causes of action, suits, claims, contingencies, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is
sought), and including all judgments, amounts paid in settlements, court costs and reasonable
attorneys fees and disbursements and costs of investigation (the Indemnified Liabilities),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any
misrepresentation or breach of any representation or warranty made by the Company in any of the
Transaction Documents, (b) any breach of any covenant, agreement or obligation of the Company
contained in any of the Transaction Documents or (c) any cause of action, suit or claim brought or
made against such Indemnitee by a third party (including for these purposes a derivative action
brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery,
performance or enforcement of any of the Transaction Documents or the transactions contemplated by
the Transaction Documents, (ii) any disclosure properly made by such Buyer pursuant to Section
4(g), or (iii) the status of such Buyer or holder of the Securities as an investor in the Company
pursuant to the transactions contemplated by the Transaction Documents. To the extent that the
foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
which is permissible under applicable law. If any action shall be brought against any Indemnitee
in respect of which
33
indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Indemnitee; provided, however that any failure to
give such notice within any particular time period shall not adversely affect any Indemnitees
rights to indemnification except to the extent that the Company can show that the failure to give
such notice on a timely basis materially and adversely affected the Companys ability to defend the
claim. Any Indemnitee shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel shall be at the
expense of such Indemnitee except to the extent that (i) the employment thereof has been
specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in
the reasonable opinion of counsel, a material conflict on any material issue between the position
of the Company and the position of such Indemnitee, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will
not be liable to any Indemnitee under this Agreement (y) for any settlement by a Indemnitee
effected without the Companys prior written consent, which shall not be unreasonably withheld or
delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is
attributable to any Indemnitees breach of any of the representations, warranties, covenants or
agreements made by such Indemnitees in this Agreement or in the other Transaction Documents.
(l) No Strict Construction. The language used in this Agreement will be deemed to be
the language chosen by the parties to express their mutual intent, and no rules of strict
construction will be applied against any party.
(m) Remedies. Each Buyer and each holder of any Securities shall have all rights and
remedies set forth in the Transaction Documents and all rights and remedies which such holders have
been granted at any time under any other agreement or contract and all of the rights which such
holders have under any law. Any Person having any rights under any provision of this Agreement
shall be entitled to enforce such rights specifically (without posting a bond or other security),
to recover damages by reason of any breach of any provision of this Agreement and to exercise all
other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to
perform, observe, or discharge any or all of its obligations under the Transaction Documents, any
remedy at law may prove to be inadequate relief to the Buyers. The Company therefore agrees that
the Buyers shall be entitled to seek specific performance and/or temporary, preliminary and
permanent injunctive or other equitable relief from any court of competent jurisdiction in any such
case without the necessity of proving actual damages and without posting a bond or other security.
(n) Withdrawal Right. Notwithstanding anything to the contrary contained in (and
without limiting any similar provisions of) the Transaction Documents, whenever any Buyer exercises
a right, election, demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then such Buyer may rescind or
withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights.
34
(o) Payment Set Aside; Currency. To the extent that the Company makes a payment or
payments to any Buyer hereunder or pursuant to any of the other Transaction Documents or any of the
Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or
the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other
Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the
obligation or part thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement or setoff had not
occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement
and the other Transaction Documents are in United States Dollars (U.S. Dollars), and all amounts
owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All
amounts denominated in other currencies (if any) shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. Exchange Rate means, in
relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement,
the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation.
(p) Judgment Currency.
(i) If for the purpose of obtaining or enforcing judgment against the Company in any
court in any jurisdiction it becomes necessary to convert into any other currency (such
other currency being hereinafter in this Section 9(p) referred to as the Judgment
Currency) an amount due in U.S. Dollars under this Agreement or any other Transaction
Document, the conversion shall be made at the Exchange Rate prevailing on the Trading Day
immediately preceding: (1) the date actual payment of the amount due, in the case of any
proceeding in the courts of New York or in the courts of any other jurisdiction that will
give effect to such conversion being made on such date or (2) the date on which the foreign
court determines, in the case of any proceeding in the courts of any other jurisdiction (the
date as of which such conversion is made pursuant to this Section 9(p)(i) being hereinafter
referred to as the Judgment Conversion Date).
(ii) If in the case of any proceeding in the court of any jurisdiction referred to in
Section 9(p)(i) above, there is a change in the Exchange Rate prevailing between the
Judgment Conversion Date and the date of actual payment of the amount due, the applicable
party shall pay such adjusted amount as may be necessary to ensure that the amount paid in
the Judgment Currency, when converted at the Exchange Rate prevailing on the date of
payment, will produce the amount of U.S. Dollars which could have been purchased with the
amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange
Rate prevailing on the Judgment Conversion Date.
(iii) Any amount due from the Company under this provision shall be due as a separate
debt and shall not be affected by judgment being obtained for any other amounts due under or
in respect of this Agreement or any other Transaction Document.
35
(q) Independent Nature of Buyers Obligations and Rights. The obligations of each
Buyer under the Transaction Documents are several and not joint with the obligations of any other
Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any
other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to
constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute, a
partnership, an association, a joint venture or any other kind of group or entity, or create a
presumption that the Buyers are in any way acting in concert or as a group or entity with respect
to such obligations or the transactions contemplated by the Transaction Documents or any matters,
and the Company acknowledges that the Buyers are not acting in concert or as a group, and the
Company shall not assert any such claim, with respect to such obligations or the transactions
contemplated by the Transaction Documents. Each Buyer shall be entitled to independently protect
and enforce its rights, including, without limitation, the rights arising out of this Agreement or
out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be
joined as an additional party in any proceeding for such purpose. The use of a single agreement to
effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of
the Company, not the action or decision of any Buyer, and was done solely for the convenience of
the Company and not because it was required or requested to do so by any Buyer. It is expressly
understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Buyer, solely, and not between the Company and the Buyers
collectively and not between and among the Buyers.
[signature pages follow]
36
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
COMPANY:
EMISPHERE TECHNOLOGIES, INC.
|
|
|
By: |
/s/ Michael R. Garone
|
|
|
|
Name: |
Michael R. Garone |
|
|
|
Title: |
Chief Financial Officer |
|
|
IN WITNESS WHEREOF, each Buyer and the Company have caused their respective signature page to
this Agreement to be duly executed as of the date first written above.
|
|
|
|
|
|
BUYERS:
MHR FUND MANAGEMENT LLC
|
|
|
By: |
/s/ Hal Goldstein
|
|
|
|
Name: |
Hal Goldstein |
|
|
|
Title: |
Authorized Signatory |
|
|
SCHEDULE OF BUYERS
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(5) |
|
(6) |
|
|
|
|
Number of |
|
|
|
|
|
Legal Representatives |
|
|
|
|
Common |
|
Number of |
|
|
|
Address and Facsimile |
Buyer |
|
Address and Facsimile Number |
|
Shares |
|
Warrant Shares |
|
Purchase Price |
|
Number |
MHR Fund Management
LLC
|
|
40 West 57th Street
24th Floor
New York, NY 10019
|
|
4,300,438
|
|
3,010,307
|
|
$3,749,083
|
|
Dechert LLP
1095 Avenue of the
Americas New York, NY 10036-6797 Attn: Derek M. Winokur, Esq. Fax: (212) 698-3599 |
|
|
Attn: Hal Goldstein
|
|
|
|
|
|
|
|
|
|
Fax: (212) 262-9356
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit A
Form of Warrant
[See Exhibit 4.3 to Form 8-K]
Exhibit 10.3
WAIVER AGREEMENT
This
Waiver Agreement (the Agreement) dated as of June 30, 2011 among Emisphere
Technologies, Inc., a Delaware corporation (the Company), and each of the investors
identified on the signature pages hereto (collectively, MHR).
WHEREAS, concurrently herewith the Company has entered into two Securities Purchase Agreements
with those certain investors listed on the Schedule of Buyers thereto (collectively, the
Securities Purchase Agreements) pursuant to which the Company has agreed to issue and
sell to the investors (the Investors) thereto and the Investors have agreed to purchase, in each
case subject to the conditions therein, an aggregate of 4,300,438 shares (the Shares) of
its common stock, par value $0.01 per share (the Common Stock), and warrants to purchase
3,010,307 shares of Common Stock (the Warrants, and together with the Shares, the
Securities) in a private placement (the Private Placement).
WHEREAS, as a result of prior transactions and agreements between MHR and the Company, the
issuance of the Securities in connection with the Private Placement would trigger certain
anti-dilution adjustments provided to MHR pursuant to the 11% Senior Secured Convertible Notes,
dated as of September 26, 2005, as amended (the Notes) and Warrant Nos. A-12, A-13, A-14
and A-15, each dated as of September 21, 2006, issued by Company and Warrant Nos. A-34, A-35, A-36
and A-37, each dated June 8, 2010, issued by the Company (the Existing Warrants) .
WHEREAS, the provisions of the Registration Rights Agreements between the Company and MHR,
dated as of September 30, 2005 (the Registration Rights Agreement) restrict the ability
of the Company to grant registration rights.
WHEREAS, in exchange for the consideration provided herein, MHR agrees to, in connection with
the Private Placement to the Investors, waive its Adjustment and Registration Right Restriction (as
defined below).
NOW, THEREFORE, in consideration of the terms and conditions contained herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto, intending to be legally bound, hereby agree as follows:
A. This Agreement will become effective upon the Closing (as such term is defined in the
Securities Purchase Agreements) (the Effective Date). If a Closing does not occur or if
the Securities Purchase Agreements are terminated in accordance with their terms and provisions
prior to the occurrence of the Closing this Agreement will become void ab initio, without any
liability of any of the parties hereto under this Agreement.
B. In consideration for MHRs waiver of its Adjustment and Registration Right Restriction, the
Company shall: (1) issue to MHR Warrants to purchase 795,000 shares of Common Stock on the same
terms and conditions as the Warrants issued in the Private Placement to MHR; and (2) reimburse MHR
for up to a maximum of $25,000 of MHRs reasonable and documented fees and expenses incurred for
legal services in connection with the
Private Placement, the Securities Purchase Agreements and this Agreement, against delivery of
such documentation of expenses as may be reasonably requested by the Company (which such
documentation shall not include descriptions of time entries and related information).
C. Each of the undersigned hereby waives, solely to the extent such provisions would be
triggered or otherwise implicated in connection with the sale and issuance of the Securities
pursuant to the Private Placement or upon any issuance by the Company of shares of Common Stock
upon exercise of such Warrants, the following rights:
|
1. |
|
the application of any anti-dilution adjustments to the rate of
conversion or conversion price of the Notes as set forth in Sections 3(d)(iv)
and 3(d)(vi) of the Notes; and |
|
|
2. |
|
the application of any anti-dilution adjustments to the rate of
exchange or exercise price of the Existing Warrants as set forth in Sections
7(e)(iii) and 7(e)(iv) of the Existing Warrants. |
|
|
|
|
(such anti-dilution adjustments, the Adjustment). |
D. Each of the undersigned hereby waives, solely to the extent such provisions would be
implicated in connection with the registration rights being granted by the Company to the Investors
concurrently with the consummation of the Private Placement, the application of the restriction on
the grant of registration rights as set forth in Section 10.1 of the Registration Rights Agreement
(the Registration Right Restriction).
E. Except as expressly provided herein, the execution, delivery and effectiveness of this
Waiver Agreement shall not operate as a waiver of any right, adjustment, restriction, power or
remedy of the undersigned or any one of them under any agreement or document, including but not
limited to the Notes, the Existing Warrants or the Registration Rights Agreement. The Company
acknowledges that nothing in this waiver shall be construed as a waiver of MHRs rights with
respect to any future issuance, sale, conversion or exercise of securities of the Company (except
for the issuance of Common Stock upon exercise of the Warrants) or any other transaction or upon
any other event.
F. This Agreement shall in all respects be governed by, and construed and enforced in
accordance with, the laws of the State of New York, without giving effect to any choice or conflict
of law provision or rule that would cause the application of laws of any jurisdiction other than
those of the State of New York.
G. This Agreement may be executed in multiple counterparts each of which shall be deemed an
original, but all of which will constitute one and the same instrument. This Agreement may be
executed and delivered by facsimile or .pdf transmission.
[Signature Page Follows]
IN WITNESS WHEREOF, the parties have caused this agreement to be duly executed as of the date
first indicated above.
|
|
|
|
|
|
|
|
|
COMPANY |
|
|
|
|
|
|
|
|
|
|
|
EMISPHERE TECHNOLOGIES, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Michael R. Garone |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Michael R. Garone |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
Interim Chief Executive Officer and Chief Financial Officer |
|
|
|
|
|
|
|
|
|
[Signature Page to Waiver Agreement]
|
|
|
|
|
|
|
|
|
INVESTORS |
|
|
|
|
|
|
|
|
|
|
|
MHR CAPITAL PARTNERS (100) LP |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
Authorized Signatory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MHR INSTITUTIONAL PARTNERS II LP |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
Authorized Signatory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MHR INSTITUTIONAL PARTNERS IIA LP |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
Authorized Signatory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MHR CAPITAL PARTNERS MASTER ACCOUNT LP |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Hal Goldstein |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
Authorized Signatory |
|
|
|
|
|
|
|
|
|
[Signature Page to Waiver Agreement]
Exhibit 99.1
For further information contact:
Michael R. Garone, Interim CEO and CFO
973-532-8005 or mgarone@emisphere.com
EMISPHERE TECHNOLOGIES ANNOUNCES AGREEMENTS TO RAISE $7.5 MILLION
IN PRIVATE PLACEMENT TRANSACTIONS
CEDAR
KNOLLS, NJ, June 30, 2011 Emisphere Technologies,
Inc. (the Company)(OTCQB: EMIS) today announced
that it has entered into a securities
purchase agreement with certain institutional investors pursuant to which the Company has agreed to
sell an aggregate of approximately 4.3 million shares of its common
stock and warrants to purchase a total of approximately 3.0 million
shares of its common stock for total gross proceeds of approximately $3.75 million. Each unit, consisting
of one share of common stock and a warrant to purchase 0.7 shares of common stock, will be sold at
a purchase price of $0.872.
The warrants to purchase additional shares will be exercisable at an exercise price of $1.09 per
share beginning immediately after issuance and will expire five (5) years from the date they are
first exercisable. The Company has agreed to provide certain registration rights under the
Securities Act of 1933, as amended, to the investors identified above in connection with their
purchased securities. The Company will be required to file a registration statement within 20 days
of the closing date and will use its reasonable best efforts to have such registration statement
declared effective as soon as practicable, but in no event later than 60 days of the closing date
(90 days in the event the SEC reviews the registration statement).
The Company also announced today that, in connection with the above private placement, it has
entered into a separate securities purchase agreement with MHR Fund Management LLC (together with
its affiliates, MHR) pursuant to which the Company has
agreed to sell an aggregate of approximately 4.3 million shares of
its common stock and warrants to purchase a total of approximately 3.0 million shares of its common stock
for total gross proceeds of approximately $3.75 million. Each unit, consisting of one share of common stock and a
warrant to purchase 0.7 shares of common stock, will be sold at a purchase price of $0.872.
The warrants to purchase additional shares will be exercisable at an exercise price of $1.09 per
share beginning immediately after issuance and will expire five (5) years from the date they are
first exercisable.
The Company expects to receive total net proceeds from both transactions of approximately $7.25
million after deducting fees and expenses and excluding the proceeds, if any, from the exercise of
the warrants that will be issued in the transactions. Proceeds from these transactions will be used
to fund the Companys operations, (including investments in new product development and
commercialization) and to meet the Companys obligations as they may arise.
In connection with the transactions described above, the Company entered into a Waiver Agreement
with MHR, pursuant to which MHR waived certain anti-dilution adjustment rights under its 11% senior
secured notes and certain warrants issued by the Company to MHR that would otherwise have been
triggered by the private placement described above. As consideration for such waiver, the Company
will issue to MHR a warrant to purchase 795,000 shares of common stock and agreed to reimburse MHR
for its legal fees up to a maximum reimbursement of $25,000. The terms of such warrant are
identical to the warrants issued to MHR in the transaction described above.
The Company was advised and represented in these transactions by an independent committee of the
Board of Directors. Roth Capital Partners served as the exclusive placement agent for the offering.
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of
therapeutic molecules or nutritional supplements using its Eligen® Technology. These
molecules and compounds could be currently available or in development. Such molecules are usually
delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow
on-set of action or variable absorption. The Eligen® Technology can be applied to the
oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation,
intra-vaginal or transdermal. The companys website is: www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to
matters that are not historical facts (including without limitation those regarding the timing or
potential outcomes of research collaborations or clinical trials, any market that might develop for
any of Emispheres product candidates, the sufficiency of Emispheres cash and other capital
resources and its ability to obtain additional financing to meet its capital needs) are
forward-looking statements that involve risks and uncertainties, including, but not limited to, the
likelihood that future research will prove successful, the likelihood that any product in the
research pipeline will receive regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize products using Emispheres
drug delivery technology, Emispheres ability to fund such efforts with or without partners, and
other risks and uncertainties detailed in Emispheres filings with the Securities and Exchange
Commission, including those factors discussed under the caption Risk Factors in Emispheres
Annual Report on Form 10-K for the fiscal year ended December 31, 2010 (file no. 000-17758) filed
on March 31, 2011 and Emispheres Quarterly Report on Form 10-Q for the quarter ended March 31,
2011, filed on May 10, 2011.
# # #